{"logo_image": "api/images/earnings/05-11-2020.png", "companies": [{"symbol": "MAR", "name": "Marriott International, Inc.", "next_earnings_utc": 1589192100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 10, "next_earnings_revenue_consensus": 4031840400.0, "next_earnings_eps_num_analysts": 18, "next_earnings_eps_consensus": 0.78235, "eps_up_revisions": 0, "eps_down_revisions": 14, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 28, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 3, "analysts_hold": 20, "analysts_underperform": 1, "webpage": "marriott.com", "year_founded": 1927, "street_address": "10400 Fernwood Road", "city": "Bethesda", "state": "MD", "zipcode": "20817", "country": "United States", "phone_number": "301-380-3000", "short_description": "Marriott International, Inc. operates, franchises, and licenses hotel, residential, and timeshare properties worldwide.", "long_description": "Marriott International, Inc. operates, franchises, and licenses hotel, residential, and timeshare properties worldwide. The company operates through North American Full-Service, North American Limited-Service, and Asia Pacific segments. It operates its properties under the JW Marriott, The Ritz-Carlton, Ritz-Carlton Reserve, W Hotels, The Luxury Collection, St. Regis, EDITION, Bulgari, Marriott Hotels, Sheraton, Delta Hotels, Marriott Executive Apartments, Marriott Vacation Club, Westin, Renaissance, Le Meridien, Autograph Collection, Gaylord Hotels, Tribute Portfolio, Design Hotels, Courtyard, Residence Inn, Fairfield by Marriott, SpringHill Suites, Four Points, TownePlace Suites, Aloft, AC Hotels by Marriott, Protea Hotels, Element, and Moxy brand names. As of February 3, 2020, it operated approximately 7,300 properties under 30 hotel brands in 134 countries and territories. Marriott International, Inc. was founded in 1927 and is headquartered in Bethesda, Maryland.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 28262360173, "total_enterprise": 39989360173, "number_of_employees": 174000, "outstanding_shares": 324221179, "eps": 3.826269, "diluted_eps": 3.8, "earnings_from_cont_operations": 1273000000, "gross_profit": 4057000000, "cash": 225000000, "total_debt": 11952000000, "total_revenue": 5373000000, "cash_from_operations": 1685000000, "net_income": 1273000000, "ebitda": 2521000000, "year_low_stock_price": 46.56, "year_high_stock_price": 153.39, "image_position": [128, 0, 128, 128]}, {"symbol": "ZBH", "name": "Zimmer Biomet Holdings, Inc.", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 20, "next_earnings_revenue_consensus": 1792284020.0, "next_earnings_eps_num_analysts": 22, "next_earnings_eps_consensus": 1.46989, "eps_up_revisions": 0, "eps_down_revisions": 20, "revenue_up_revisions": 0, "revenue_down_revisions": 19, "total_analysts": 30, "analysts_sell": 1, "analysts_buy": 15, "analysts_outperform": 5, "analysts_hold": 8, "analysts_underperform": 1, "webpage": "zimmerbiomet.com", "year_founded": 1927, "street_address": "345 East Main Street", "city": "Warsaw", "state": "IN", "zipcode": "46580", "country": "United States", "phone_number": "574 267 6131", "short_description": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.", "long_description": "Zimmer Biomet Holdings, Inc., together with its subsidiaries, designs, manufactures, and markets musculoskeletal healthcare products and solutions in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in four segments: Spine, less Asia Pacific; Office Based Technologies; Craniomaxillofacial and Thoracic; and Dental. The company provides orthopaedic reconstructive products, such as knee and hip replacement products; S.E.T. products, including surgical, sports medicine, biologics, foot and ankle, extremities, and trauma products; spine products comprising medical devices and surgical instruments; and face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest. It also offers dental products that include dental reconstructive implants, and dental prosthetic and regenerative products; and bone cement and office based technology products. The company's products and solutions are used to treat patients suffering from disorders of, or injuries to, bones, joints, or supporting soft tissues. It serves orthopedic surgeons, neurosurgeons, oral surgeons, dentists, hospitals, stocking distributors, healthcare dealers, and other specialists, as well as agents, healthcare purchasing organizations, or buying groups. The company was formerly known as Zimmer Holdings, Inc. and changed its name to Zimmer Biomet Holdings, Inc. in June 2015. Zimmer Biomet Holdings, Inc. was founded in 1927 and is headquartered in Warsaw, Indiana.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 25186219776, "total_enterprise": 33074119776, "number_of_employees": 19900, "outstanding_shares": 206681600, "eps": 5.517308, "diluted_eps": 5.47, "earnings_from_cont_operations": 1131500000, "gross_profit": 5729600000, "cash": 617900000, "total_debt": 8501100000, "total_revenue": 7982200000, "cash_from_operations": 1585800000, "net_income": 1131600000, "ebitda": 2361300000, "year_low_stock_price": 74.37, "year_high_stock_price": 161.11, "image_position": [256, 0, 128, 128]}, {"symbol": "PROS", "name": "ProSight Global, Inc.", "next_earnings_utc": 1589228400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 193180000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.28, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "prosightspecialty.com", "year_founded": 2009, "street_address": "412 Mount Kemble Avenue", "city": "Morristown", "state": "NJ", "zipcode": "07960", "country": "United States", "phone_number": "973-532-1900", "short_description": "ProSight Global, Inc., together with its subsidiaries, operates as an entrepreneurial specialty insurance company in the United States.", "long_description": "ProSight Global, Inc., together with its subsidiaries, operates as an entrepreneurial specialty insurance company in the United States. The company underwrites insurance coverages in the lines of commercial auto, general liability, workers' compensation, commercial multiple peril, and other. It serves customers in construction, consumer service, marine and energy, media and entertainment, professional service, real estate, sports, and transportation industries. ProSight Global, Inc. was founded in 2009 and is headquartered in Morristown, New Jersey.", "industry_name": "Insurance", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 423262754, "total_enterprise": 570671754, "number_of_employees": 396, "outstanding_shares": 43058266, "eps": 0.946343, "diluted_eps": 0.940955, "earnings_from_cont_operations": 45494000, "gross_profit": 192263000, "cash": 61157000, "total_debt": 164693000, "total_revenue": 878059000, "cash_from_operations": 253296000, "net_income": 38890000, "ebitda": 72163000, "year_low_stock_price": 7.26, "year_high_stock_price": 21.0, "image_position": [384, 0, 128, 128]}, {"symbol": "EC", "name": "Ecopetrol S.A.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 3803680866.180458, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.13039, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 15, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 2, "analysts_hold": 6, "analysts_underperform": 1, "webpage": "ecopetrol.com.co", "year_founded": 1948, "street_address": "Carrera 13 No. 36 - 24", "city": "Bogot\u00c3\u00a1", "state": null, "zipcode": null, "country": "Colombia", "phone_number": "57 1 234 4000", "short_description": "Ecopetrol S.A. operates as an integrated oil and gas company.", "long_description": "Ecopetrol S.A. operates as an integrated oil and gas company. The company operates through Exploration and Production; Transport and Logistics; and Refining, Petrochemical and Biofuels segments. It engages in the exploration, production, and sale of oil and gas. It also transports and distributes hydrocarbons and derivative products. As of December 31, 2019, the company had approximately 9,106 kilometers of crude oil and multi-purpose pipelines. In addition, the company manufactures and commercializes polypropylene resins, compounds, and masterbatches; and offers refined and petrochemical products, and biofuels, as well as industrial service sales to customers. It has operations in Colombia, the United States, Asia, Central America and the Caribbean, Europe, South America, and internationally. Ecopetrol S.A. has a strategic alliance with Occidental Petroleum Corporation. The company was formerly known as Empresa Colombiana de Petroleos and changed its name to Ecopetrol S.A. in June 2003. Ecopetrol S.A. was founded in 1948 and is based in Bogota, Colombia.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 21553063486, "total_enterprise": 30153714872, "number_of_employees": 15157, "outstanding_shares": 41116694690, "eps": 0.0981423298517007, "diluted_eps": 0.0981423298517007, "earnings_from_cont_operations": 4416242577, "gross_profit": 8023953531, "cash": 2649220744, "total_debt": 11644428576, "total_revenue": 21573972715, "cash_from_operations": 8438675660, "net_income": 4035288224, "ebitda": 9133849691, "year_low_stock_price": 6.28, "year_high_stock_price": 20.95, "image_position": [512, 0, 128, 128]}, {"symbol": "ET", "name": "Energy Transfer LP", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 14395373010.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.32027, "eps_up_revisions": 0, "eps_down_revisions": 6, "revenue_up_revisions": 5, "revenue_down_revisions": 1, "total_analysts": 20, "analysts_sell": 0, "analysts_buy": 10, "analysts_outperform": 4, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "energytransfer.com", "year_founded": 2002, "street_address": "8111 Westchester Drive", "city": "Dallas", "state": "TX", "zipcode": "75225", "country": "United States", "phone_number": "214-981-0700", "short_description": "Energy Transfer LP provides energy-related services.", "long_description": "Energy Transfer LP provides energy-related services. The company owns and operates approximately 9,400 miles of natural gas transportation pipelines and three natural gas storage facilities in Texas; and 12,500 miles of interstate natural gas pipelines. It sells natural gas to electric utilities, independent power plants, local distribution companies, industrial end-users, and other marketing companies. The company also owns and operates natural gas gathering and natural gas liquid (NGL) pipelines, processing plants, and treating and conditioning facilities in Texas, New Mexico, West Virginia, Pennsylvania, Ohio, Oklahoma, Kansas, and Louisiana; natural gas gathering, oil pipeline, and oil stabilization facilities in South Texas; and a natural gas gathering system in Ohio, as well as transports and supplies water to natural gas producers in Pennsylvania. In addition, it owns approximately 4,515 miles of NGL pipelines; NGL and propane fractionation facilities; NGL storage facilities with working storage capacity of approximately 50 million barrels (MMBbls); and other NGL storage assets and terminals with an aggregate storage capacity of approximately 13 MMBbls. Further, the company sells gasoline, middle distillates, and motor fuel at retail, as well as crude oil, NGLs, and refined products; operates convenience stores; and distributes motor fuels and other petroleum products. Additionally, it provides natural gas compression services; carbon dioxide and hydrogen sulfide removal, natural gas cooling, dehydration, and British thermal unit management services; and manages coal and natural resources properties, as well as sells standing timber, leases coal-related infrastructure facilities, collects oil and gas royalties, and generates electrical power. The company was formerly known as Energy Transfer Equity, L.P. and changed its name to Energy Transfer LP in October 2018. Energy Transfer LP was founded in 2002 and is headquartered in Dallas, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 20550819138, "total_enterprise": 85031819138, "number_of_employees": 12812, "outstanding_shares": 2689897793, "eps": 1.365296, "diluted_eps": 1.359948, "earnings_from_cont_operations": 4899000000, "gross_profit": 11352000000, "cash": 291000000, "total_debt": 52019000000, "total_revenue": 54213000000, "cash_from_operations": 8003000000, "net_income": 3588000000, "ebitda": 10498000000, "year_low_stock_price": 3.75, "year_high_stock_price": 15.27, "image_position": [640, 0, 128, 27]}, {"symbol": "GTX", "name": "Garrett Motion Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 663913330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.03667, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 5, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "garrettmotion.com", "year_founded": 2018, "street_address": "La Pi\u00c3\u00a8ce 16", "city": "Rolle", "state": null, "zipcode": "1180", "country": "Switzerland", "phone_number": "41 21 695 30 00", "short_description": "Garrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide.", "long_description": "Garrett Motion Inc. designs, manufactures, and sells turbocharger and electric boosting technologies for light and commercial vehicle original equipment manufacturers and the aftermarket worldwide. The company offers light vehicle gasoline and diesel, and commercial vehicle turbochargers. Its integrated vehicle health management tools detect intermittent faults and anomalies to provide understanding of the real-time health of a vehicle system. The company offers its products through distribution networks. Garrett Motion Inc. was incorporated in 2018 and is headquartered in Rolle, Switzerland.", "industry_name": "Auto Components", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 457208488, "total_enterprise": 1719208488, "number_of_employees": 6200, "outstanding_shares": 75571651, "eps": 4.195549, "diluted_eps": 4.12, "earnings_from_cont_operations": 313000000, "gross_profit": 713000000, "cash": 187000000, "total_debt": 1449000000, "total_revenue": 3248000000, "cash_from_operations": 242000000, "net_income": 313000000, "ebitda": 529000000, "year_low_stock_price": 2.5, "year_high_stock_price": 18.66, "image_position": [768, 0, 128, 128]}, {"symbol": "ETR", "name": "Entergy Corporation", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 2592246750.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 0.95003, "eps_up_revisions": 1, "eps_down_revisions": 3, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 18, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 4, "analysts_hold": 8, "analysts_underperform": 0, "webpage": "entergy.com", "year_founded": 1949, "street_address": "639 Loyola Avenue", "city": "New Orleans", "state": "LA", "zipcode": "70113", "country": "United States", "phone_number": "504-576-4000", "short_description": "Entergy Corporation, together with its subsidiaries, engages in the production and distribution of electricity in the United States.", "long_description": "Entergy Corporation, together with its subsidiaries, engages in the production and distribution of electricity in the United States. The company generates electricity through gas/oil, nuclear, coal, hydro, and solar power sources. It operates in two segments, Utility and Entergy Wholesale Commodities. The company's Utility segment generates, transmits, distributes, and sells electric power in portions of Arkansas, Mississippi, Texas, and Louisiana, including the City of New Orleans; and distributes natural gas. Its Entergy Wholesale Commodities segment engages in the ownership, operation, and decommissioning of nuclear power plants located in the northern United States; sale of electric power to wholesale customers; provision of services to other nuclear power plant owners; and owning interests in non-nuclear power plants that sell electric power to wholesale customers. This segment sells energy to retail power providers, utilities, electric power co-operatives, power trading organizations, and other power generation companies. The company's power plants have approximately 30,000 megawatts (MW) of electric generating capacity, including approximately 9,000 MW of nuclear power. The company delivers electricity to 2.9 million utility customers in Arkansas, Louisiana, Mississippi, and Texas. Entergy Corporation was founded in 1949 and is based in New Orleans, Louisiana.", "industry_name": "Electric Utilities", "sector_name": "Utilities", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 19079490726, "total_enterprise": 39027386726, "number_of_employees": 13635, "outstanding_shares": 200815606, "eps": 6.358874, "diluted_eps": 6.299999, "earnings_from_cont_operations": 1241226000, "gross_profit": 4269867000, "cash": 425722000, "total_debt": 20119208000, "total_revenue": 10878673000, "cash_from_operations": 2816627000, "net_income": 1241226000, "ebitda": 3553035000, "year_low_stock_price": 75.2, "year_high_stock_price": 135.55, "image_position": [896, 0, 128, 50]}, {"symbol": "TME", "name": "Tencent Music Entertainment Group", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 12, "next_earnings_revenue_consensus": 887588066.492921, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 0.08820173276044235, "eps_up_revisions": 0, "eps_down_revisions": 7, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 19, "analysts_sell": 0, "analysts_buy": 10, "analysts_outperform": 4, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "tencentmusic.com", "year_founded": 2012, "street_address": "Matsunichi Building", "city": "Shenzhen", "state": null, "zipcode": "518057", "country": "China", "phone_number": "86 755 8601 3388", "short_description": "Tencent Music Entertainment Group operates online music entertainment platforms that provides music streaming, online karaoke, and live streaming services in the People\u2019s Republic of China.", "long_description": "Tencent Music Entertainment Group operates online music entertainment platforms that provides music streaming, online karaoke, and live streaming services in the People\u2019s Republic of China. It offers QQ Music, Kugou Music, and Kuwo Music that enable users to discover and listen to music in personalized ways; and WeSing, which enables users to have fun by singing and interacting with friends, sharing their singing performances with friends, and discovering songs that others have sung. The company also operates Kugou Live and Kuwo Live that provides an interactive online stage for performers and users to showcase their talent and engage with those interested in their performance. In addition, it sells music-related merchandise, including Kugou M1 headsets, smart speakers, WeSing karaoke microphones, and Hi-Fi systems; and offers online music event ticketing services, as well as services to smart device and automobile makers to build and operate music services on devices and vehicles. The company was formerly known as China Music Corporation. The company was incorporated in 2012 and is headquartered in Shenzhen, China. Tencent Music Entertainment Group is a subsidiary of Tencent Holdings Limited.", "industry_name": "Entertainment", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 18503188648, "total_enterprise": 15309835304, "number_of_employees": 3610, "outstanding_shares": 1677532969, "eps": 0.349484266613049, "diluted_eps": 0.341811457869566, "earnings_from_cont_operations": 571170058, "gross_profit": 1245601689, "cash": 3227103649, "total_debt": 21111893, "total_revenue": 3652788350, "cash_from_operations": 890433584, "net_income": 571888150, "ebitda": 645277112, "year_low_stock_price": 9.22, "year_high_stock_price": 16.77, "image_position": [1024, 0, 128, 128]}, {"symbol": "SPG", "name": "Simon Property Group, Inc.", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 1334889830.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 1.61246, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 19, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 2, "analysts_hold": 13, "analysts_underperform": 0, "webpage": "simon.com", "year_founded": null, "street_address": null, "city": null, "state": null, "zipcode": null, "country": null, "phone_number": null, "short_description": null, "long_description": null, "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 17732201494, "total_enterprise": 42389200494, "number_of_employees": 4000, "outstanding_shares": 305622225, "eps": 6.813593, "diluted_eps": 6.81, "earnings_from_cont_operations": 2423188000, "gross_profit": 4655045000, "cash": 669373000, "total_debt": 24680039000, "total_revenue": 5676689000, "cash_from_operations": 3807831000, "net_income": 2101584000, "ebitda": 4174514000, "year_low_stock_price": 42.25, "year_high_stock_price": 177.93, "image_position": [1152, 0, 128, 128]}, {"symbol": "AEE", "name": "Ameren Corporation", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 1560933000.0, "next_earnings_eps_num_analysts": 12, "next_earnings_eps_consensus": 0.70756, "eps_up_revisions": 0, "eps_down_revisions": 5, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 15, "analysts_sell": 0, "analysts_buy": 7, "analysts_outperform": 3, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "ameren.com", "year_founded": 1881, "street_address": "1901 Chouteau Avenue", "city": "St. Louis", "state": "MO", "zipcode": "63103", "country": "United States", "phone_number": "314-621-3222", "short_description": "Ameren Corporation, together with its subsidiaries, operates as a public utility holding company in the United States.", "long_description": "Ameren Corporation, together with its subsidiaries, operates as a public utility holding company in the United States. It operates through four segments: Ameren Missouri, Ameren Illinois Electric Distribution, Ameren Illinois Natural Gas, and Ameren Transmission. The company engages in the rate-regulated electric generation, transmission, and distribution activities; and rate-regulated natural gas distribution and transmission businesses. It primarily generates electricity through coal, nuclear, and natural gas, as well as renewable sources, such as hydroelectric, methane gas, and solar. The company serves residential, commercial, and industrial customers. As of March 25, 2020, it served approximately 1.2 million electric customers and approximately 132,000 natural gas customers in central and eastern Missouri. The company was founded in 1881 and is headquartered in St. Louis, Missouri.", "industry_name": "Multi-Utilities", "sector_name": "Utilities", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 17483801747, "total_enterprise": 27442801747, "number_of_employees": 9323, "outstanding_shares": 246737253, "eps": 3.371335, "diluted_eps": 3.35, "earnings_from_cont_operations": 834000000, "gross_profit": 2743000000, "cash": 16000000, "total_debt": 9833000000, "total_revenue": 5646000000, "cash_from_operations": 2170000000, "net_income": 828000000, "ebitda": 2360000000, "year_low_stock_price": 58.74, "year_high_stock_price": 87.66, "image_position": [1280, 0, 128, 125]}, {"symbol": "DDOG", "name": "Datadog, Inc.", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 14, "next_earnings_revenue_consensus": 117731570.0, "next_earnings_eps_num_analysts": 16, "next_earnings_eps_consensus": -0.01501, "eps_up_revisions": 12, "eps_down_revisions": 1, "revenue_up_revisions": 12, "revenue_down_revisions": 0, "total_analysts": 16, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 4, "analysts_hold": 8, "analysts_underperform": 0, "webpage": "datadoghq.com", "year_founded": 2010, "street_address": "620, 8th Avenue", "city": "New York", "state": "NY", "zipcode": "10018", "country": "United States", "phone_number": "866 329 4466", "short_description": "Datadog, Inc. provides monitoring and analytics platform for developers, information technology operations teams, and business users in the cloud in North America and internationally.", "long_description": "Datadog, Inc. provides monitoring and analytics platform for developers, information technology operations teams, and business users in the cloud in North America and internationally. The company's SaaS platform integrates and automates infrastructure monitoring, application performance monitoring, and log management to provide real-time observability of customers technology stack. Its platform also provides user experience and network performance monitoring, and various shared features, such as sophisticated dashboards, advanced analytics, collaboration tools, and alerting capabilities. The company was founded in 2010 and is headquartered in New York, New York.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 15461210554, "total_enterprise": 14747665554, "number_of_employees": 1403, "outstanding_shares": 298882864, "eps": -0.119465, "diluted_eps": -0.12, "earnings_from_cont_operations": -16710000, "gross_profit": 273831000, "cash": 773971000, "total_debt": 60426000, "total_revenue": 362780000, "cash_from_operations": 24234000, "net_income": -16710000, "ebitda": -8522000, "year_low_stock_price": 27.55, "year_high_stock_price": 52.24, "image_position": [1408, 0, 128, 128]}, {"symbol": "NOG", "name": "Northern Oil and Gas, Inc.", "next_earnings_utc": 1589196600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 137906500.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.03333, "eps_up_revisions": 0, "eps_down_revisions": 4, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "northernoil.com", "year_founded": null, "street_address": "601 Carlson Parkway", "city": "Minnetonka", "state": "MN", "zipcode": "55305", "country": "United States", "phone_number": "952 476 9800", "short_description": "Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States.", "long_description": "Northern Oil and Gas, Inc., an independent energy company, engages in the acquisition, exploration, exploitation, development, and production of crude oil and natural gas properties in the United States. The company primarily holds interests in the Bakken and Three Forks formations in the Williston Basin of North Dakota and Montana. As of December 31, 2019, it owned working interests in 6,156 gross producing wells; and had proved reserves of 163.3 million barrels of oil equivalent. The company is based in Minnetonka, Minnesota.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 306588695, "total_enterprise": 1408683695, "number_of_employees": 24, "outstanding_shares": 405379737, "eps": -0.199819, "diluted_eps": -0.199999, "earnings_from_cont_operations": -76318000, "gross_profit": 424569000, "cash": 16068000, "total_debt": 1118161000, "total_revenue": 543468000, "cash_from_operations": 339750000, "net_income": -76318000, "ebitda": 268232000, "year_low_stock_price": 0.5, "year_high_stock_price": 2.45, "image_position": [1468, 0, 60, 60]}, {"symbol": "CAH", "name": "Cardinal Health, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 12, "next_earnings_revenue_consensus": 37042481880.0, "next_earnings_eps_num_analysts": 15, "next_earnings_eps_consensus": 1.44809, "eps_up_revisions": 4, "eps_down_revisions": 3, "revenue_up_revisions": 3, "revenue_down_revisions": 3, "total_analysts": 20, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 15, "analysts_underperform": 0, "webpage": "cardinalhealth.com", "year_founded": 1979, "street_address": "7000 Cardinal Place", "city": "Dublin", "state": "OH", "zipcode": "43017", "country": "United States", "phone_number": "614-757-5000", "short_description": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally.", "long_description": "Cardinal Health, Inc. operates as an integrated healthcare services and products company in the United States and internationally. It provides customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories, and physician offices. The company operates through two segments, Pharmaceutical and Medical. The Pharmaceutical segment distributes branded and generic pharmaceutical, specialty pharmaceutical, and over-the-counter healthcare and consumer products. It also provides services to pharmaceutical manufacturers and healthcare providers for specialty pharmaceutical products; operates nuclear pharmacies and radiopharmaceutical manufacturing facilities; and offers pharmacy management services to hospitals, as well as medication therapy management and patient outcomes services to hospitals, other healthcare providers, and payers. In addition, this segment repackages generic pharmaceuticals and over-the-counter healthcare products. The Medical segment manufactures, sources, and distributes Cardinal Health branded medical, surgical, and laboratory products. It also provides incontinence, wound care, enteral feeding, urology, operating room supply, electrode and needle, syringe, and sharps disposal products. In addition, this segment distributes a range of national brand products, including medical, surgical, and laboratory products; and provides supply chain services and solutions to hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare providers. Cardinal Health, Inc. was founded in 1979 and is headquartered in Dublin, Ohio.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 14554162626, "total_enterprise": 21258162626, "number_of_employees": 49500, "outstanding_shares": 291783533, "eps": -14.229729, "diluted_eps": -14.229729, "earnings_from_cont_operations": -4210000000, "gross_profit": 6830000000, "cash": 1659000000, "total_debt": 8360000000, "total_revenue": 149657000000, "cash_from_operations": 2030000000, "net_income": -4212000000, "ebitda": 2728000000, "year_low_stock_price": 39.05, "year_high_stock_price": 60.69, "image_position": [1596, 0, 128, 128]}, {"symbol": "IFF", "name": "International Flavors & Fragrances Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 10, "next_earnings_revenue_consensus": 1313368420.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 1.58505, "eps_up_revisions": 1, "eps_down_revisions": 6, "revenue_up_revisions": 1, "revenue_down_revisions": 5, "total_analysts": 16, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 2, "analysts_hold": 7, "analysts_underperform": 3, "webpage": "iff.com", "year_founded": 1833, "street_address": "521 West 57th Street", "city": "New York", "state": "NY", "zipcode": "10019", "country": "United States", "phone_number": "212 765 5500", "short_description": "International Flavors & Fragrances Inc., together with its subsidiaries, manufactures flavors and fragrances for use in various consumer products.", "long_description": "International Flavors & Fragrances Inc., together with its subsidiaries, manufactures flavors and fragrances for use in various consumer products. It operates through two segments, Taste and Scent. The Taste segment offers flavor compounds primarily to the food and beverage industries for use in consumer products, such as prepared foods, beverages, dairy, food, and sweet products. This segment also creates and manufactures a naturals-focused suite of flavor compounds, functional foods, and specialty fine ingredients to small, local, and regional customers. The Scent segment provides fragrance compounds, which include fine fragrances comprising perfumes and colognes, as well as consumer fragrances for personal care, household products, and beauty care; fragrance ingredients comprising synthetic and natural ingredients that could be combined with other materials to create fragrance and consumer compounds; and cosmetic active ingredients consisting of active and functional ingredients, botanicals, and delivery systems to support its customers' cosmetic and personal care product lines. This segment serves perfume and toiletries manufacturers in the cosmetics industry; and manufacturers of soaps, detergents, fabric care, household cleaners, and air fresheners in the household products industry. The company has operations in Europe, Africa, the Middle East, Greater Asia, North America, and Latin America. International Flavors & Fragrances Inc. was founded in 1833 and is headquartered in New York, New York.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 14368273333, "total_enterprise": 18550700333, "number_of_employees": 13668, "outstanding_shares": 106851144, "eps": 4.04387, "diluted_eps": 4.0, "earnings_from_cont_operations": 460268000, "gross_profit": 2120242000, "cash": 606823000, "total_debt": 4677963000, "total_revenue": 5140084000, "cash_from_operations": 698965000, "net_income": 455873000, "ebitda": 1110905000, "year_low_stock_price": 92.14, "year_high_stock_price": 152.95, "image_position": [1724, 0, 128, 128]}, {"symbol": "AMCR", "name": "Amcor plc", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 3257345250.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.18363, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 2, "analysts_underperform": 1, "webpage": "amcor.com", "year_founded": null, "street_address": "Thurgauerstrasse 34", "city": "Zurich", "state": null, "zipcode": "8050", "country": "Switzerland", "phone_number": "41 44 316 1717", "short_description": "Amcor plc develops, manufactures, and sells various packaging products for food, beverage, pharmaceutical, medical, home and personal care, and other consumer goods end markets worldwide.", "long_description": "Amcor plc develops, manufactures, and sells various packaging products for food, beverage, pharmaceutical, medical, home and personal care, and other consumer goods end markets worldwide. It operates through two segments, Flexible Packaging and Rigid Packaging. The company provides flexible packaging products, rigid containers, specialty cartons, and closures. The company is headquartered in Z\u00c3\u00bcrich, Switzerland.", "industry_name": "Containers and Packaging", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 13697821723, "total_enterprise": 19438738246, "number_of_employees": 50000, "outstanding_shares": 1567571347, "eps": 0.314652, "diluted_eps": 0.31252, "earnings_from_cont_operations": 458100000, "gross_profit": 2118500000, "cash": 673900000, "total_debt": 6786400000, "total_revenue": 11096400000, "cash_from_operations": 883400000, "net_income": 444800000, "ebitda": 1487000000, "year_low_stock_price": 5.8, "year_high_stock_price": 11.77, "image_position": [1852, 0, 128, 128]}, {"symbol": "ECPG", "name": "Encore Capital Group, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 326444170.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.94143, "eps_up_revisions": 2, "eps_down_revisions": 3, "revenue_up_revisions": 3, "revenue_down_revisions": 2, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "encorecapital.com", "year_founded": 1998, "street_address": "350 Camino De La Reina", "city": "San Diego", "state": "CA", "zipcode": "92108", "country": "United States", "phone_number": "877-445-4581", "short_description": "Encore Capital Group, Inc., a specialty finance company, together with its subsidiaries, provides debt recovery solutions and other related services for consumers across a range of financial assets worldwide.", "long_description": "Encore Capital Group, Inc., a specialty finance company, together with its subsidiaries, provides debt recovery solutions and other related services for consumers across a range of financial assets worldwide. The company purchases portfolios of defaulted consumer receivables at deep discounts to face value, as well as manages them by working with individuals as they repay their obligations and works toward financial recovery. It is also involved in the early stage collections, business process outsourcing, contingent collections, trace services, and litigation activities; and the management of non-performing loans, as well as provides portfolio management services to credit originator for non-performing loans. Encore Capital Group, Inc. was founded in 1998 and is headquartered in San Diego, California.", "industry_name": "Consumer Finance", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 969828741, "total_enterprise": 4394406741, "number_of_employees": 7300, "outstanding_shares": 31234420, "eps": 5.378692, "diluted_eps": 5.33, "earnings_from_cont_operations": 168909000, "gross_profit": 1405789000, "cash": 194795000, "total_debt": 3616160000, "total_revenue": 1405789000, "cash_from_operations": 244733000, "net_income": 167869000, "ebitda": 498092000, "year_low_stock_price": 15.27, "year_high_stock_price": 40.16, "image_position": [1980, 0, 128, 128]}, {"symbol": "CABO", "name": "Cable One, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 317199670.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 9.95, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "cableone.biz", "year_founded": 1980, "street_address": "210 East Earll Drive", "city": "Phoenix", "state": "AZ", "zipcode": "85012", "country": "United States", "phone_number": "602-364-6000", "short_description": "Cable One, Inc. provides data, video, and voice services in the United States.", "long_description": "Cable One, Inc. provides data, video, and voice services in the United States. The company offers residential data services, a service to enhance Wi-Fi signal throughout the home. It also provides residential video services, such as local networks; local community programming that includes governmental and public access; and other channels, which comprise weather, shopping, and religious channels, as well as digital video services, including national and regional cable networks, music channels, and an interactive electronic programming guide with parental controls. In addition, the company offers premium channels; and advanced video services, such as whole-home DVRs and high-definition set-top boxes, as well as TV Everywhere product, which enables its video customers to stream various channels and shows to mobile devices and computers. Further, it provides residential voice and international calling by the minute services. Additionally, the company offers data, voice, and video products to business customers, including small to mid-markets, enterprises, and wholesale and carrier customers. As of February 27, 2020, it served approximately 900,000 residential and business customers in 21 states through its Sparklight and Clearwave brands. Cable One, Inc. was incorporated in 1980 and is headquartered in Phoenix, Arizona.", "industry_name": "Media", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 10559946878, "total_enterprise": 12286726878, "number_of_employees": 2751, "outstanding_shares": 5725131, "eps": 31.446084, "diluted_eps": 31.12, "earnings_from_cont_operations": 178582000, "gross_profit": 779445000, "cash": 125271000, "total_debt": 1852051000, "total_revenue": 1167997000, "cash_from_operations": 491741000, "net_income": 178582000, "ebitda": 543915000, "year_low_stock_price": 1031.39, "year_high_stock_price": 1976.23, "image_position": [2108, 0, 128, 21]}, {"symbol": "MYL", "name": "Mylan N.V.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 12, "next_earnings_revenue_consensus": 2646152760.0, "next_earnings_eps_num_analysts": 14, "next_earnings_eps_consensus": 0.86527, "eps_up_revisions": 1, "eps_down_revisions": 6, "revenue_up_revisions": 4, "revenue_down_revisions": 3, "total_analysts": 20, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 5, "analysts_hold": 10, "analysts_underperform": 0, "webpage": "mylan.com", "year_founded": 1961, "street_address": "Building 4", "city": "Hatfield", "state": null, "zipcode": "AL10 9UL", "country": "United Kingdom", "phone_number": "44 1707 853 000", "short_description": "Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally.", "long_description": "Mylan N.V., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic, branded-generic, brand-name, and over-the-counter (OTC) pharmaceutical products in North America, Europe, and internationally. It offers active pharmaceutical ingredients and finished dosage forms; and antiretroviral medicines to treat HIV/AIDS. The company also provides prescription products, such as EpiPen Auto-Injector; Perforomist Inhalation Solution; Dymista; Creon; and Influvac, as well as YUPELRI, an inhalation solution for the maintenance treatment of patients with chronic obstructive pulmonary diseases. In addition, it markets OTC products, including Cold-EEZE, MidNite, Vivarin, Brufen, CB12, and EndWarts. The company offers its products to therapeutic areas, such as cardiovascular, CNS and anesthesia, dermatology, diabetes and metabolism, gastroenterology, immunology, infectious disease, oncology, respiratory and allergy, and women's health. Its customers include retail pharmacies, wholesalers and distributors, payers, and insurers and governments, as well as institutions, such as hospitals. Mylan N.V. has collaboration and license agreements with Pfizer Inc.; Momenta Pharmaceuticals, Inc.; Theravance Biopharma, Inc.; Biocon Ltd.; and Fujifilm Kyowa Kirin Biologics Co. Ltd. The company was founded in 1961 and is based in Hatfield, the United Kingdom.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 9069233210, "total_enterprise": 21429833210, "number_of_employees": 35000, "outstanding_shares": 516177189, "eps": 0.032577, "diluted_eps": 0.03, "earnings_from_cont_operations": 16800000, "gross_profit": 4551900000, "cash": 563700000, "total_debt": 12924300000, "total_revenue": 11500500000, "cash_from_operations": 1803700000, "net_income": 16800000, "ebitda": 3372200000, "year_low_stock_price": 12.75, "year_high_stock_price": 23.19, "image_position": [2236, 0, 128, 37]}, {"symbol": "LOGI", "name": "Logitech International S.A.", "next_earnings_utc": 1589158800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 661635290.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.36066, "eps_up_revisions": 1, "eps_down_revisions": 4, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "logitech.com", "year_founded": 1981, "street_address": "Daniel Borel Innovation Center", "city": "Lausanne", "state": null, "zipcode": "1015", "country": "Switzerland", "phone_number": "41 21 863 55 11", "short_description": "Logitech International S.A., through its subsidiaries, designs, manufactures, and markets products that allow people to connect through music, gaming, video, computing, and other digital platforms worldwide.", "long_description": "Logitech International S.A., through its subsidiaries, designs, manufactures, and markets products that allow people to connect through music, gaming, video, computing, and other digital platforms worldwide. The company offers portable wireless Bluetooth and Wi-Fi speakers, PC speakers, PC headsets, in-ear headphones, and wireless audio wearables; gaming mice, keyboards, headsets, mousepads, and steering wheels and flight sticks; and audio and video, and other products that connect small and medium sized user groups. It also provides keyboards and covers for tablets and smartphones, as well as other accessories for mobile devices; pointing devices, such as PC and Mac-related mice, touchpads, and presenters; corded and cordless keyboards, living room keyboards, and keyboard-and-mouse combos; PC-based Webcams; and remote control and home automation products. The company sells its products through direct sales to retailers and e-tailers, as well as indirect sales through distributors. Its channel network includes consumer electronics distributors, retailers, mass merchandisers, specialty electronics stores, computer and telecommunications stores, value-added resellers, and online merchants. The company was founded in 1981 and is headquartered in Lausanne, Switzerland.", "industry_name": "Technology Hardware, Storage and Peripherals", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 8457168109, "total_enterprise": 7835863719, "number_of_employees": 6600, "outstanding_shares": 167305147, "eps": 1.669679, "diluted_eps": 1.630205, "earnings_from_cont_operations": 277924000, "gross_profit": 1092278000, "cash": 656046000, "total_debt": 33048000, "total_revenue": 2890911000, "cash_from_operations": 355892000, "net_income": 277924000, "ebitda": 358687000, "year_low_stock_price": 31.37, "year_high_stock_price": 51.48, "image_position": [2364, 0, 128, 128]}, {"symbol": "TXG", "name": "10x Genomics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 71750000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.13235, "eps_up_revisions": 2, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "10xgenomics.com", "year_founded": 2012, "street_address": "6230 Stoneridge Mall Road", "city": "Pleasanton", "state": "CA", "zipcode": "94588", "country": "United States", "phone_number": "925 401 7300", "short_description": "10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific.", "long_description": "10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. Its company offers chromium instruments, enzymes, microfluidic chips, slides, reagents, and other consumable products. The company's single cell solution runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell ATAC for measuring epigenetics, including the physical organization of DNA; single cell CNV for measuring cellular heterogeneity through DNA changes, such as copy number variation; and visium spatial gene expression solution that measures the spatial gene expression patterns across a tissue sample. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10X Genomics, Inc. in November 2014. 10x Genomics, Inc. was founded in 2012 and is headquartered in Pleasanton, California.", "industry_name": "Life Sciences Tools and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 8155119733, "total_enterprise": 7760672733, "number_of_employees": 584, "outstanding_shares": 98301829, "eps": -0.799434, "diluted_eps": -0.799434, "earnings_from_cont_operations": -31251000, "gross_profit": 214060000, "cash": 424166000, "total_debt": 29719000, "total_revenue": 245893000, "cash_from_operations": 34627000, "net_income": -31251000, "ebitda": 7195000, "year_low_stock_price": 45.11, "year_high_stock_price": 108.36, "image_position": [2492, 0, 128, 128]}, {"symbol": "ACEL", "name": "Accel Entertainment, Inc.", "next_earnings_utc": 1589196600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 95444000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.015, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "accelentertainment.com", "year_founded": 2009, "street_address": "20W267 101st Street", "city": "Lemont", "state": "IL", "zipcode": "60439", "country": "United States", "phone_number": "630-280-6144", "short_description": "Accel Entertainment Gaming, LLC owns and operates video gaming stores.", "long_description": "Accel Entertainment Gaming, LLC owns and operates video gaming stores. It installs gaming terminals in the United States. The company was founded in 2009 and is based in Lemont, Illinois.\r\n", "industry_name": null, "sector_name": null, "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 734070537, "total_enterprise": 947359537, "number_of_employees": 730, "outstanding_shares": 81563393, "eps": -0.09481, "diluted_eps": -0.09481, "earnings_from_cont_operations": -5864000, "gross_profit": 152386000, "cash": 136403000, "total_debt": 349692000, "total_revenue": 424385000, "cash_from_operations": 45565000, "net_income": -5864000, "ebitda": 64355000, "year_low_stock_price": 5.22, "year_high_stock_price": 13.35, "image_position": [2620, 0, 128, 128]}, {"symbol": "G", "name": "Genpact Limited", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 894393220.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 0.45154, "eps_up_revisions": 1, "eps_down_revisions": 6, "revenue_up_revisions": 1, "revenue_down_revisions": 4, "total_analysts": 12, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "genpact.com", "year_founded": 1997, "street_address": "Victoria Place", "city": "Hamilton", "state": null, "zipcode": "HM 10", "country": "Bermuda", "phone_number": "441-294-8000", "short_description": "Genpact Limited provides business process outsourcing and information technology (IT) services North and Latin America, India, rest of Asia, and Europe.", "long_description": "Genpact Limited provides business process outsourcing and information technology (IT) services North and Latin America, India, rest of Asia, and Europe. It operates in three segments: Banking, Capital Markets and Insurance; Consumer Goods, Retail, Life Sciences and Healthcare; and High Tech, Manufacturing and Services. The company's finance and accounting services include accounts payable, such as document management, invoice processing, approval and resolution management, and travel and expense processing; invoice-to-cash services, including customer master data management, credit and contract management, fulfillment, billing, collections, and dispute management services; record to report services comprising accounting, treasury, tax, product cost accounting, and closing and reporting services; enterprise performance management consisting of budgeting, forecasting, and business performance reporting; and enterprise risk and compliance services, including operational risks and controls. It also provides transformation services; core industry operation services; and sourcing, procurement, and supply chain services, such as direct and indirect strategic sourcing, category management, spend analytics, procurement operations, master data management, and other procurement and supply chain advisory services. The company's IT services comprise end-user computing support, infrastructure management, application production support, and database management services, as well as business intelligence and data, enterprise resource planning, quality assurance, technology integration, and business intelligence reporting services. It serves banking, capital markets, insurance, consumer goods, retail, life sciences, healthcare, high tech, and manufacturing and services industries. Genpact Limited was founded in 1997 and is based in Hamilton, Bermuda.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 6782570477, "total_enterprise": 8147224477, "number_of_employees": 96500, "outstanding_shares": 190201079, "eps": 1.604008, "diluted_eps": 1.56, "earnings_from_cont_operations": 304881000, "gross_profit": 1225855000, "cash": 468880000, "total_debt": 1833534000, "total_revenue": 3520543000, "cash_from_operations": 427888000, "net_income": 304881000, "ebitda": 520883000, "year_low_stock_price": 19.41, "year_high_stock_price": 45.2, "image_position": [2748, 0, 128, 128]}, {"symbol": "EGRX", "name": "Eagle Pharmaceuticals, Inc.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 51101500.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.5675, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "eagleus.com", "year_founded": 2007, "street_address": "50 Tice Boulevard", "city": "Woodcliff Lake", "state": "NJ", "zipcode": "07677", "country": "United States", "phone_number": "201 326 5300", "short_description": "Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States.", "long_description": "Eagle Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin's lymphoma. Its product candidates also includes EP-4104, a dantrolene sodium for exertional heat stroke, as well as to treat organophosphate exposure; EP-5101 (PEMFEXY) for lung cancer and mesothelioma; EGL-5385-C-1701 (fulvestrant) for breast cancer; and Vasopressin injection, which is indicated to enhance blood pressure in adults with vasodilatory shock. The company has a strategic collaboration with Tyme Technologies, Inc. to advance oral SM-88 for the treatment of patients with cancer. Eagle Pharmaceuticals, Inc. was founded in 2007 and is headquartered in Woodcliff Lake, New Jersey.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 752955192, "total_enterprise": 685838192, "number_of_employees": 108, "outstanding_shares": 13685118, "eps": 1.040603, "diluted_eps": 1.009999, "earnings_from_cont_operations": 14313000, "gross_profit": 134995000, "cash": 109775000, "total_debt": 42658000, "total_revenue": 195892000, "cash_from_operations": 55986000, "net_income": 14313000, "ebitda": 25307000, "year_low_stock_price": 33.8, "year_high_stock_price": 64.94, "image_position": [2828, 0, 80, 80]}, {"symbol": "CZR", "name": "Caesars Entertainment Corporation", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 1887200000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.165, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "caesars.com", "year_founded": 1937, "street_address": "One Caesars Palace Drive", "city": "Las Vegas", "state": "NV", "zipcode": "89109", "country": "United States", "phone_number": "702-407-6000", "short_description": "Caesars Entertainment Corporation, through its subsidiaries, provides casino-entertainment and hospitality services in the United States and internationally.", "long_description": "Caesars Entertainment Corporation, through its subsidiaries, provides casino-entertainment and hospitality services in the United States and internationally. The company operates 38,000 slot machines and 2,700 table games, as well as other games comprising keno, poker, and race and sports books; and approximately 220 buffets, restaurants, bars, nightclubs, and lounges located throughout its casinos, as well as banquets and room service. As of December 31, 2019, it had 49 casinos, including 36 casinos in the United States and 13 casinos internationally with approximately 3 million square feet of gaming space, and 40,000 hotel rooms. The company also provides various retail and entertainment offerings in its casinos; and operates various entertainment venues, including the Colosseum at Caesars Palace and Zappos Theater at Planet Hollywood, as well as The LINQ promenade, an open-air dining, entertainment, and retail development. In addition, it operates an online gaming business that provides real money games; and owns the World Series of Poker tournaments and brand. The company was formerly known as Harrah's Entertainment Inc. and changed its name to Caesars Entertainment Corporation in November 2010. Caesars Entertainment Corporation was founded in 1937 and is headquartered in Las Vegas, Nevada.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 6618006642, "total_enterprise": 25200006642, "number_of_employees": 64000, "outstanding_shares": 682268726, "eps": -1.767751, "diluted_eps": -1.77, "earnings_from_cont_operations": -1198000000, "gross_profit": 4420000000, "cash": 1755000000, "total_debt": 20257000000, "total_revenue": 8530000000, "cash_from_operations": 1007000000, "net_income": -1195000000, "ebitda": 2116000000, "year_low_stock_price": 3.22, "year_high_stock_price": 14.74, "image_position": [2956, 0, 128, 128]}, {"symbol": "AFG", "name": "American Financial Group, Inc.", "next_earnings_utc": 1589230800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 1327000000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 1.8475, "eps_up_revisions": 0, "eps_down_revisions": 4, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 1, "webpage": "afginc.com", "year_founded": 1872, "street_address": "301 East Fourth Street", "city": "Cincinnati", "state": "OH", "zipcode": "45202", "country": "United States", "phone_number": "513-579-2121", "short_description": "American Financial Group, Inc., an insurance holding company, provides property and casualty insurance products in the United States.", "long_description": "American Financial Group, Inc., an insurance holding company, provides property and casualty insurance products in the United States. The company operates through three segments: Property and Casualty Insurance, Annuity, and Other. It offers property and transportation insurance products, such as physical damage and liability coverage for buses, trucks, inland and ocean marine, agricultural-related products, and other commercial property coverages; specialty casualty insurance, including primarily excess and surplus, general liability, executive and professional liability, umbrella and excess liability, and specialty coverage in targeted markets, as well as customized programs for small to mid-sized businesses and workers' compensation insurance; and specialty financial insurance products comprising risk management insurance programs for lending and leasing institutions, surety and fidelity products, and trade credit insurance. The company sells its property and casualty insurance products through independent insurance agents and brokers, as well as through employee agents. It also provides traditional fixed, fixed-indexed, and variable-indexed annuities to the retail, financial institutions, registered investment advisor, and education markets. In addition, the company engages in the commercial real estate operations in Cincinnati, Whitefield, New Hampshire, Chesapeake Bay, Charleston, and Palm Beach. American Financial Group, Inc. was founded in 1872 and is headquartered in Cincinnati, Ohio.", "industry_name": "Insurance", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 5907221268, "total_enterprise": 6347221268, "number_of_employees": 7700, "outstanding_shares": 89857336, "eps": 9.977753, "diluted_eps": 9.85, "earnings_from_cont_operations": 869000000, "gross_profit": 1675000000, "cash": 2477000000, "total_debt": 2754000000, "total_revenue": 8017000000, "cash_from_operations": 2456000000, "net_income": 897000000, "ebitda": 1545000000, "year_low_stock_price": 44.01, "year_high_stock_price": 115.03, "image_position": [3084, 0, 128, 128]}, {"symbol": "GFL", "name": "GFL Environmental Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 636839205.0010289, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": -0.3015873015873016, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 11, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 6, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "gflenv.com", "year_founded": 2007, "street_address": "100 New Park Place", "city": "Vaughan", "state": "ON", "zipcode": "L4K 0H9", "country": "Canada", "phone_number": "905 326 0101", "short_description": "GFL Environmental Inc. operates as a diversified environmental services company in North America.", "long_description": "GFL Environmental Inc. operates as a diversified environmental services company in North America. The company offers non-hazardous solid waste management, infrastructure and soil remediation, and liquid waste management services. Its solid waste management business line includes the collection, transportation, transfer, recycling, and disposal of non-hazardous solid waste for municipal, residential, and commercial and industrial customers. The company's infrastructure and soil remediation business line provides remediation of contaminated soils, as well as complementary services, including civil, demolition, and excavation and shoring services. Its liquid waste management business collects, transports, processes, recycles, and/or disposes a range of liquid wastes from commercial and industrial customers. The company was founded in 2007 and is headquartered in Vaughan, Canada.", "industry_name": "Commercial Services and Supplies", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 5651221728, "total_enterprise": 10866765092, "number_of_employees": 11500, "outstanding_shares": 326420755, "eps": -0.0947669985906707, "diluted_eps": -0.0947669985906707, "earnings_from_cont_operations": -347829402, "gross_profit": 238855132, "cash": 442665712, "total_debt": 6036293695, "total_revenue": 2577494628, "cash_from_operations": 193301450, "net_income": -347829402, "ebitda": 581795008, "year_low_stock_price": 11.92, "year_high_stock_price": 18.22, "image_position": [3212, 0, 128, 128]}, {"symbol": "XLRN", "name": "Acceleron Pharma Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 5483750.0, "next_earnings_eps_num_analysts": 9, "next_earnings_eps_consensus": -0.86873, "eps_up_revisions": 4, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 13, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 6, "analysts_hold": 2, "analysts_underperform": 1, "webpage": "acceleronpharma.com", "year_founded": 2003, "street_address": "128 Sidney Street", "city": "Cambridge", "state": "MA", "zipcode": "02139", "country": "United States", "phone_number": "617-649-9200", "short_description": "Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases.", "long_description": "Acceleron Pharma Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics to treat serious and rare diseases. Its therapeutic candidates include luspatercept, which completed Phase III clinical trials for the treatment of myelodysplastic syndromes, beta-thalassemia, and myelofibrosis; Phase II clinical trials for the treatment of patients with transfusion-dependent beta-thalassemia. The company is also developing and sotatercept for the treatment of patients with pulmonary hypertension. In addition, the company is developing ACE-083, a neuromuscular candidate that is in Phase II clinical trials for the treatment of patients with facioscapulohumeral dystrophy and Charcot-Marie-Tooth disease; and ACE-2494, which is in Phase I clinical trials for the treatment of systemic muscle disorders. It has a collaboration, license, and option agreement with Celgene Corporation; and collaboration and license agreement with Fulcrum Therapeutics, Inc. to identify small molecules designed to modulate specific pathways associated with a targeted indication within the pulmonary disease space. The company was formerly known as Phoenix Pharma, Inc. Acceleron Pharma Inc. was founded in 2003 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 5448116349, "total_enterprise": 5043131349, "number_of_employees": 237, "outstanding_shares": 53523100, "eps": -2.380378, "diluted_eps": -2.380378, "earnings_from_cont_operations": -124858000, "gross_profit": 15830000, "cash": 431369000, "total_debt": 26384000, "total_revenue": 73993000, "cash_from_operations": -93804000, "net_income": -124858000, "ebitda": -132504000, "year_low_stock_price": 37.01, "year_high_stock_price": 105.22, "image_position": [3340, 0, 128, 128]}, {"symbol": "RETA", "name": "Reata Pharmaceuticals, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 1279000.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": -1.98571, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 7, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "reatapharma.com", "year_founded": 2002, "street_address": "5320 Legacy Drive", "city": "Plano", "state": "TX", "zipcode": "75024", "country": "United States", "phone_number": "972 865 2219", "short_description": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation.", "long_description": "Reata Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops novel therapeutics for patients with serious or life-threatening diseases by targeting molecular pathways that regulate cellular metabolism and inflammation. The company is developing Phase III clinical trial programs, including bardoxolone methyl (bardoxolone) for the treatment of patients with chronic kidney disease(CKD) caused by Alport syndrome, as well as for a form of pulmonary arterial hypertension associated with connective tissue disease; omaveloxolone that is Phase II clinical trial to treat Friedreich's ataxia; and conduct phase 2 study for various form of CKD, such as IgA nephropathy, type 1 diabetic, and focal segmental glomerulosclerosis. It is also developing RTA 901, which completed Phase 1 clinical trials for the treatment of neurological diseases, such as diabetic neuropathy; and RORgT Inhibitors that are in the preclinical development phase for the potential treatment of a range of autoimmune, inflammatory, and fibrotic diseases. In addition, the company offers bardoxolone for the treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD), as well as initiated phase 3 Falcon trial for the treatment of ADPKD. Further, it has a strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize bardoxolone for renal, cardiovascular, diabetes, and various other related metabolic indications in Japan, China, Hong Kong, Macao, South Korea, Taiwan, Thailand, Singapore, the Philippines, Malaysia, Indonesia, Brunei, Vietnam, Laos, Myanmar, and Cambodia; and AbbVie Inc. to jointly research, develop, and commercialize all second- and later-generation Nrf2 activators for all indications other than renal, cardiovascular, and metabolic indications. The company was formerly known as Reata Discovery, Inc. and changed its name to Reata Pharmaceuticals, Inc. in May 2005. Reata Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Plano, Texas.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 5392026018, "total_enterprise": 4892857018, "number_of_employees": 220, "outstanding_shares": 33236923, "eps": -9.540608, "diluted_eps": -9.540608, "earnings_from_cont_operations": -290170000, "gross_profit": -225990000, "cash": 664324000, "total_debt": 165155000, "total_revenue": 26517000, "cash_from_operations": -251151000, "net_income": -290170000, "ebitda": -284288000, "year_low_stock_price": 70.0, "year_high_stock_price": 257.97, "image_position": [3468, 0, 128, 128]}, {"symbol": "IRET", "name": "Investors Real Estate Trust", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 45124000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.52333, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "iretapartments.com", "year_founded": 1970, "street_address": "1400 31st Avenue SW", "city": "Minot", "state": "ND", "zipcode": "58702", "country": "United States", "phone_number": "701-837-4738", "short_description": "IRET is a real estate company focused on the ownership, management, acquisition, redevelopment, and development of apartment communities.", "long_description": "IRET is a real estate company focused on the ownership, management, acquisition, redevelopment, and development of apartment communities. As of December 31, 2019, IRET owned interests in 69 apartment communities consisting of 11,953 homes. IRET's common shares and Series C preferred shares are publicly traded on the New York Stock Exchange (NYSE symbols: IRET and IRET-PC, respectively).", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 757180210, "total_enterprise": 1563874210, "number_of_employees": 377, "outstanding_shares": 12149875, "eps": 6.117847, "diluted_eps": 6.003413, "earnings_from_cont_operations": 84822000, "gross_profit": 101254000, "cash": 26579000, "total_debt": 656408000, "total_revenue": 185755000, "cash_from_operations": 69624000, "net_income": 79206000, "ebitda": 87941000, "year_low_stock_price": 43.58, "year_high_stock_price": 85.24, "image_position": [3568, 0, 100, 90]}, {"symbol": "CLR", "name": "Continental Resources, Inc.", "next_earnings_utc": 1589169600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 843573990.0, "next_earnings_eps_num_analysts": 24, "next_earnings_eps_consensus": -0.03951, "eps_up_revisions": 0, "eps_down_revisions": 21, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 32, "analysts_sell": 3, "analysts_buy": 5, "analysts_outperform": 2, "analysts_hold": 21, "analysts_underperform": 1, "webpage": "clr.com", "year_founded": 1967, "street_address": "20 North Broadway", "city": "Oklahoma City", "state": "OK", "zipcode": "73102", "country": "United States", "phone_number": "405 234 9000", "short_description": "Continental Resources, Inc. explores for, develops, and produces crude oil and natural gas properties primarily in the north, south, and east regions of the United States.", "long_description": "Continental Resources, Inc. explores for, develops, and produces crude oil and natural gas properties primarily in the north, south, and east regions of the United States. The company sells its crude oil and natural gas production to energy marketing companies, crude oil refining companies, and natural gas gathering and processing companies. As of December 31, 2019, its proved reserves were 1,619 million barrels of crude oil equivalent (MMBoe) with estimated proved developed reserves of 707 MMBoe. Continental Resources, Inc. was founded in 1967 and is based in Oklahoma City, Oklahoma.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 5554316516, "total_enterprise": 11217242516, "number_of_employees": 1260, "outstanding_shares": 368079292, "eps": 2.092374, "diluted_eps": 2.08, "earnings_from_cont_operations": 774473000, "gross_profit": 3521348000, "cash": 39400000, "total_debt": 5335642000, "total_revenue": 4224876000, "cash_from_operations": 3115688000, "net_income": 775641000, "ebitda": 3362783000, "year_low_stock_price": 6.9, "year_high_stock_price": 43.77, "image_position": [3696, 0, 128, 64]}, {"symbol": "UAA", "name": "Under Armour, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 21, "next_earnings_revenue_consensus": 939217880.0, "next_earnings_eps_num_analysts": 21, "next_earnings_eps_consensus": -0.18742, "eps_up_revisions": 0, "eps_down_revisions": 17, "revenue_up_revisions": 0, "revenue_down_revisions": 17, "total_analysts": 34, "analysts_sell": 3, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 25, "analysts_underperform": 1, "webpage": "underarmour.com", "year_founded": 1996, "street_address": "1020 Hull Street", "city": "Baltimore", "state": "MD", "zipcode": "21230", "country": "United States", "phone_number": "410 454 6428", "short_description": "Under Armour, Inc., together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America.", "long_description": "Under Armour, Inc., together with its subsidiaries, develops, markets, and distributes branded performance apparel, footwear, and accessories for men, women, and youth primarily in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. The company offers its apparel in compression, fitted, and loose types to be worn in hot and cold. It also provides various footwear products for running, basketball, cleated sports, training, and outdoor. In addition, the company offers accessories, which include gloves, bags, and headwear; and digital fitness subscriptions, as well as digital advertising through MapMyFitness, MyFitnessPal, and Endomondo platforms. It primarily offers its products under the HEATGEAR, COLDGEAR, RUSH or RECOVER, UA Logo, UNDER ARMOUR, UA, ARMOUR, PROTECT THIS HOUSE, I WILL, ARMOURBOX, ARMOUR BRA, and ARMOUR FLEECE, as well as MyFitnessPal, MapMyFitness, and UNDER ARMOUR CONNECTED FITNESS brands. The company sells its products through wholesale channels, including national and regional sporting goods chains, independent and specialty retailers, department store chains, institutional athletic departments, and leagues and teams, as well as independent distributors; and directly to consumers through a network of 388 brand and factory house stores, as well as through e-commerce websites. Under Armour, Inc. was founded in 1996 and is headquartered in Baltimore, Maryland.", "industry_name": "Textiles, Apparel and Luxury Goods", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 4271942478, "total_enterprise": 4783092478, "number_of_employees": 11700, "outstanding_shares": 451921415, "eps": 0.204316, "diluted_eps": 0.202826, "earnings_from_cont_operations": 92139000, "gross_profit": 2470533000, "cash": 788072000, "total_debt": 1299222000, "total_revenue": 5267132000, "cash_from_operations": 509031000, "net_income": 92139000, "ebitda": 428695000, "year_low_stock_price": 7.39, "year_high_stock_price": 27.72, "image_position": [3824, 0, 128, 128]}, {"symbol": "CHH", "name": "Choice Hotels International, Inc.", "next_earnings_utc": 1589199000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 202868000.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.65953, "eps_up_revisions": 0, "eps_down_revisions": 7, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 14, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 9, "analysts_underperform": 2, "webpage": "choicehotels.com", "year_founded": 1939, "street_address": "1 Choice Hotels Circle", "city": "Rockville", "state": "MD", "zipcode": "20850", "country": "United States", "phone_number": "301-592-5000", "short_description": "Choice Hotels International, Inc., together with its subsidiaries, operates as a hotel franchisor worldwide.", "long_description": "Choice Hotels International, Inc., together with its subsidiaries, operates as a hotel franchisor worldwide. It operates through Hotel Franchising and Corporate & Other segments. The company franchises lodging properties under the brand names of Comfort Inn, Comfort Suites, Quality, Clarion, Clarion Pointe, Sleep Inn, Econo Lodge, Rodeway Inn, MainStay Suites, Suburban Extended Stay Hotel, WoodSpring Suites, Cambria Hotels, V8 Hotel Koln @Motorworld, Quality Hotel Ostrava, Hotel Aquarius Venice, and Ascend Hotel Collection. It also develops and markets cloud-based technology products to the hotel industry. As of February 12, 2020, the company had approximately 7,000 hotels with 575,000 rooms in approximately 40 countries and territories. Choice Hotels International, Inc. has a strategic agreement with AM Resorts, LLC to improve its loyalty program. The company was founded in 1939 and is based in Rockville, Maryland.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 4127599367, "total_enterprise": 4976815367, "number_of_employees": 1807, "outstanding_shares": 55846291, "eps": 4.001698, "diluted_eps": 3.979521, "earnings_from_cont_operations": 222878000, "gross_profit": 521233000, "cash": 33766000, "total_debt": 882982000, "total_revenue": 1114820000, "cash_from_operations": 270556000, "net_income": 222878000, "ebitda": 361494000, "year_low_stock_price": 46.25, "year_high_stock_price": 109.26, "image_position": [3952, 0, 128, 128]}, {"symbol": "ATEC", "name": "Alphatec Holdings, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 29740250.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.205, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "atecspine.com", "year_founded": 1990, "street_address": "5818 El Camino Real", "city": "Carlsbad", "state": "CA", "zipcode": "92008", "country": "United States", "phone_number": "760-431-9286", "short_description": "Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders.", "long_description": "Alphatec Holdings, Inc., a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders. The company offers SafeOp Neural InformatiX System, an Alpha InformatiX product platform designed to reduce the risk of intraoperative nerve injury; squadron lateral retractor designed to meet the surgeon's needs and to maximize patient outcomes; LLICO access system, a minimally invasive posterior thoracolumbar access system; Invictus Spinal Fixation System, a comprehensive thoracolumbar fixation system to treat a range of pathologies; and Invictus MIS SingleStep designed to improve surgical efficiency without compromising accuracy. It also provides Arsenal spinal fixation system intended for posterior, non-cervical fixation in skeletally mature patients for treating degenerative disc disease, spondylolisthesis, fracture or dislocation, spinal stenosis, curvatures, tumor, pseud arthrosis, and failed previous fusion; zodiac degenerative spinal fixation system, a comprehensive spinal system used to address degenerative spinal conditions and deformity correction; OsseoScrew system to restore the integrity of the spinal column; trestle luxe anterior cervical plate system; and solanas posterior cervico/thoracic fixation system and avalon occipital plate. In addition, the company offers IdentiTi Porous Ti and Transcend Lateral Interbody Implants; Battalion PC; Novel SD; Solus Anterior Lumbar Interbody Fusion System. Further, it is developing EOS imaging products. Additionally, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 309480493, "total_enterprise": 342146493, "number_of_employees": 227, "outstanding_shares": 63418134, "eps": -1.091281, "diluted_eps": -1.091281, "earnings_from_cont_operations": -56902000, "gross_profit": 77594000, "cash": 47113000, "total_debt": 56176000, "total_revenue": 113427000, "cash_from_operations": -33121000, "net_income": -57002000, "ebitda": -30800000, "year_low_stock_price": 2.19, "year_high_stock_price": 7.93, "image_position": [4080, 0, 128, 128]}, {"symbol": "TERP", "name": "TerraForm Power, Inc.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 264923330.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.05002, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "terraformpower.com", "year_founded": 2014, "street_address": "200 Liberty Street", "city": "New York", "state": "NY", "zipcode": "10281", "country": "United States", "phone_number": "646-992-2400", "short_description": "TerraForm Power, Inc., together with its subsidiaries, acquires, owns, and operates solar and wind power generation assets.", "long_description": "TerraForm Power, Inc., together with its subsidiaries, acquires, owns, and operates solar and wind power generation assets. The company operates through three segments: Solar, Wind, and Regulated Solar and Wind. As of December 31, 2019, its portfolio consisted of solar and wind projects located in the United States, Canada, Spain, Chile, Portugal, the United Kingdom, and Uruguay with a combined nameplate capacity of 4,100 megawatts. The company was formerly known as SunEdison Yieldco, Inc. and changed its name to TerraForm Power, Inc. in May 2014. TerraForm Power, Inc. was founded in 2014 and is headquartered in New York, New York.", "industry_name": "Independent Power and Renewable Electricity Producers", "sector_name": "Utilities", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 4156665653, "total_enterprise": 11073034653, "number_of_employees": 174, "outstanding_shares": 226521289, "eps": -0.697146, "diluted_eps": -0.697146, "earnings_from_cont_operations": -206585000, "gross_profit": 671644000, "cash": 237480000, "total_debt": 6526414000, "total_revenue": 941240000, "cash_from_operations": 328444000, "net_income": -148684000, "ebitda": 602551000, "year_low_stock_price": 11.4, "year_high_stock_price": 21.58, "image_position": [4208, 0, 128, 128]}, {"symbol": "JCOM", "name": "J2 Global, Inc.", "next_earnings_utc": 1589232300, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 12, "next_earnings_revenue_consensus": 331360420.0, "next_earnings_eps_num_analysts": 13, "next_earnings_eps_consensus": 1.39863, "eps_up_revisions": 0, "eps_down_revisions": 5, "revenue_up_revisions": 4, "revenue_down_revisions": 2, "total_analysts": 14, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 4, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "j2global.com", "year_founded": 1995, "street_address": "700 South Flower Street", "city": "Los Angeles", "state": "CA", "zipcode": "90017", "country": "United States", "phone_number": "323 860 9200", "short_description": "J2 Global, Inc., together with its subsidiaries, provides Internet services worldwide.", "long_description": "J2 Global, Inc., together with its subsidiaries, provides Internet services worldwide. The company operates through three segments: Fax and Martech; Voice, Backup, Security, and Consumer Privacy and Protection; and Digital Media. It offers cloud services, which includes online fax services under the eFax, sFax, MyFax, eFax Plus, eFax Pro, eFax Secure, eFax Corporate, and eFax Developer brands; on-demand voice, cloud phone, and unified communications services under the eVoice, Line2, and Onebox names; online backup and disaster recovery, sync storage, veeam services, and synchronization and sharing solutions under the KeepItSafe, LiveDrive, LiveVault, OffsiteDataSync, and SugarSync names; email security, web security, and endpoint protection services under the VIPRE and Excel Micro brands; email marketing and delivery services under the Campaigner and SMTP names; virtual private network services under the IPVanish and Encrypt.me; IP licensing services; and customer support services. The company also operates a portfolio of Web properties and applications, including IGN, Mashable, PC Mag, Humble Bundle, Speedtest, Offers, Black Friday, AskMen, MedPageToday, Everyday Health, What to Expect, and others that offer technology products, gaming and lifestyle products and services, news and commentary related products, speed testing for Internet and network connections, online deals and discounts for consumers, interactive tools and mobile applications, and tools and information for healthcare professionals, as well as professional networking tools, targeted emails, and white papers for IT professionals. It serves sole proprietors, small to medium-sized businesses and enterprises, and government organizations. The company was formerly known as j2 Global Communications, Inc. and changed its name to j2 Global, Inc. in December 2011. J2 Global, Inc. was founded in 1995 and is headquartered in Los Angeles, California.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3976446580, "total_enterprise": 4982632580, "number_of_employees": 3090, "outstanding_shares": 48730963, "eps": 4.518819, "diluted_eps": 4.39, "earnings_from_cont_operations": 218806000, "gross_profit": 1134731000, "cash": 575615000, "total_debt": 1581801000, "total_revenue": 1372054000, "cash_from_operations": 412539000, "net_income": 218806000, "ebitda": 515430000, "year_low_stock_price": 58.0, "year_high_stock_price": 104.57, "image_position": [4336, 0, 128, 128]}, {"symbol": "COTY", "name": "Coty Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 1517649040.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.12332, "eps_up_revisions": 0, "eps_down_revisions": 12, "revenue_up_revisions": 0, "revenue_down_revisions": 9, "total_analysts": 16, "analysts_sell": 1, "analysts_buy": 1, "analysts_outperform": 3, "analysts_hold": 11, "analysts_underperform": 0, "webpage": "coty.com", "year_founded": 1904, "street_address": "350 Fifth Avenue", "city": "New York", "state": "NY", "zipcode": "10118", "country": "United States", "phone_number": "212-389-7300", "short_description": "Coty Inc., together with its subsidiaries, manufactures, markets, distributes, and sells beauty products worldwide.", "long_description": "Coty Inc., together with its subsidiaries, manufactures, markets, distributes, and sells beauty products worldwide. The company operates in three segments: Luxury, Consumer Beauty, and Professional Beauty. The Luxury segment offers prestige fragrances, and skincare and cosmetics products through various retailers, including perfumeries, department stores, and e-retailers and duty-free shops under the Alexander McQueen, Balenciaga, Burberry, Bottega Veneta, Calvin Klein, Cavalli, Chloe, Davidoff, Escada, Gucci, Hugo Boss, Jil Sander, Joop!, Lacoste, Lancaster, Marc Jacobs, Miu Miu, philosophy, Stella McCartney, and Tiffany & Co. brands. The Consumer Beauty segment offers color cosmetics, retail hair coloring and styling products, mass fragrance, and body care and mass skin care products primarily through hypermarkets, supermarkets, drug stores, pharmacies, mid-tier department stores, traditional food and drug retailers, and e-commerce retailers. It provides its products under the Adidas, Beckham, Beyonce, Biocolor, Bozzano, Bourjois, Bruno Banani, Clairol, CoverGirl, Enrique, Jovan, Nautica, Max Factor, Mexx, Monange, Paixao, Rimmel, Risque, Sally Hansen, Stetson, Wella, Younique, and 007 James Bond brands. The Professional Beauty segment offers hair and nail care products to nail and hair salons, nail and hair professionals, and professional stores through direct sales forces and e-commerce platforms under the Clairol Professional, ghd, Kadus Professional, Londa Professional, Nioxin, O P I, Sassoon Professional, Sebastian, System Professional, and Wella Professionals brands. The company also sells its products to third-party distributors. It sells its products to approximately 150 countries. The company was founded in 1904 and is based in New York, New York. Coty Inc. operates as a subsidiary of Cottage Holdco B.V.", "industry_name": "Personal Products", "sector_name": "Consumer Staples", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 3954864368, "total_enterprise": 11761964368, "number_of_employees": 19000, "outstanding_shares": 760550840, "eps": -3.688623, "diluted_eps": -3.688623, "earnings_from_cont_operations": -2763600000, "gross_profit": 5255000000, "cash": 288800000, "total_debt": 7987300000, "total_revenue": 8393800000, "cash_from_operations": 863900000, "net_income": -2780300000, "ebitda": 1358300000, "year_low_stock_price": 3.02, "year_high_stock_price": 14.14, "image_position": [4464, 0, 128, 128]}, {"symbol": "GWPH", "name": "GW Pharmaceuticals plc", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 14, "next_earnings_revenue_consensus": 105943747.9949658, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.06041, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 4, "revenue_down_revisions": 4, "total_analysts": 17, "analysts_sell": 0, "analysts_buy": 11, "analysts_outperform": 6, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "gwpharm.com", "year_founded": 1998, "street_address": "Sovereign House", "city": "Cambridge", "state": null, "zipcode": "CB24 9BZ", "country": "United Kingdom", "phone_number": "44 1223 266 800", "short_description": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant.", "long_description": "GW Pharmaceuticals plc, a biopharmaceutical company, focuses on discovering, developing, and commercializing cannabinoid prescription medicines using botanical extracts derived from the Cannabis plant. Its lead product is Epidiolex, an oral medicine for the treatment of refractory childhood epilepsies, as well as for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, tuberous sclerosis complex, and infantile spasms. The company also develops and markets Sativex, an oromucosal spray for the treatment of spasticity due to multiple sclerosis. In addition, it develops various product candidates for the treatment of glioblastoma, neonatal hypoxic-ischemic encephalopathy, and schizophrenia. Further, the company has license and development agreements with Almirall S.A.; Bayer HealthCare AG; Ipsen Biopharm Ltd; and Neopharm Group. It primarily operates in Europe, the United Kingdom, the United States, Canada, and Asia. GW Pharmaceuticals plc was founded in 1998 and is based in Cambridge, the United Kingdom.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3365799804, "total_enterprise": 2872043804, "number_of_employees": 901, "outstanding_shares": 31044086, "eps": -0.291264, "diluted_eps": -0.291264, "earnings_from_cont_operations": -9019000, "gross_profit": 243863000, "cash": 536933000, "total_debt": 43177000, "total_revenue": 311332000, "cash_from_operations": -123469000, "net_income": -9019000, "ebitda": -109185000, "year_low_stock_price": 67.98, "year_high_stock_price": 188.76, "image_position": [4592, 0, 128, 90]}, {"symbol": "CCXI", "name": "ChemoCentryx, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 9001330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.29671, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "chemocentryx.com", "year_founded": 1996, "street_address": "850 Maude Avenue", "city": "Mountain View", "state": "CA", "zipcode": "94043", "country": "United States", "phone_number": "650 210 2900", "short_description": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States.", "long_description": "ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. Its lead drug candidate is Avacopan, an orally-administered complement inhibitor of the complement C5a receptor (C5aR), which is in Phase III development for the treatment of anti-neutrophil cytoplasmic auto-antibody-associated vasculitis; and Phase IIb clinical trial, the AURORA trial for the treatment of patients with moderate-to-severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. In addition, the company is developing CCX140, an inhibitor of the chemokine receptor known as CCR2, which has completed a Phase II clinical trial in diabetic nephropathy and is being developed for patients with focal segmental glomerulosclerosis; CCX507, a second generation CCR9 inhibitor, which has completed Phase I clinical trial; and CCX872, a potent and selective inhibitor of CCR2, which is in phase Ib clinical trial for the treatment of patients with stage 3 and 4 pancreatic cancer. ChemoCentryx, Inc. was founded in 1996 and is headquartered in Mountain View, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3360902831, "total_enterprise": 3209971831, "number_of_employees": 82, "outstanding_shares": 61792661, "eps": -0.975228, "diluted_eps": -0.979999, "earnings_from_cont_operations": -55489000, "gross_profit": -34148000, "cash": 172786000, "total_debt": 21855000, "total_revenue": 36128000, "cash_from_operations": -70123000, "net_income": -55489000, "ebitda": -57753000, "year_low_stock_price": 6.16, "year_high_stock_price": 55.53, "image_position": [4720, 0, 128, 128]}, {"symbol": "MNLO", "name": "Menlo Therapeutics Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 1806000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.6, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "menlotherapeutics.com", "year_founded": 2003, "street_address": "520 U.S. Highway 22", "city": "Bridgewater", "state": "NJ", "zipcode": "08807", "country": "United States", "phone_number": "800-775-7936", "short_description": "Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology.", "long_description": "Menlo Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapeutics for dermatology. It offers AMZEEQ, a topical minocycline used for the treatment of inflammatory lesions of non-nodular moderate-to-severe acne vulgaris in patients 9 years of age and older. The company is also developing FMX103, which is in Phase III clinical trials for the treatment of moderate-to-severe papulopustular rosacea in adults; and FCD105, a topical combination foam that is in Phase II clinical trials for the treatment of moderate-to-severe acne vulgaris. In addition, it is developing Serlopitant, a once-daily oral NK1 receptor antagonist, used as a treatment option for pruritus associated with prurigo nodularis. The company was founded in 2003 and is headquartered in Bridgewater, New Jersey.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 119145000, "total_enterprise": 81508000, "number_of_employees": 81, "outstanding_shares": 61100000, "eps": -1.661279, "diluted_eps": -1.661279, "earnings_from_cont_operations": -95178000, "gross_profit": 443000, "cash": 72107000, "total_debt": 34470000, "total_revenue": 443000, "cash_from_operations": -73394000, "net_income": -95178000, "ebitda": -95523000, "year_low_stock_price": 1.0, "year_high_stock_price": 7.48, "image_position": [4848, 0, 128, 128]}, {"symbol": "BLUE", "name": "bluebird bio, Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 16, "next_earnings_revenue_consensus": 8003500.0, "next_earnings_eps_num_analysts": 18, "next_earnings_eps_consensus": -4.04778, "eps_up_revisions": 2, "eps_down_revisions": 11, "revenue_up_revisions": 1, "revenue_down_revisions": 10, "total_analysts": 23, "analysts_sell": 0, "analysts_buy": 12, "analysts_outperform": 5, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "bluebirdbio.com", "year_founded": 1992, "street_address": "60 Binney Street", "city": "Cambridge", "state": "MA", "zipcode": "02142", "country": "United States", "phone_number": "339-499-9300", "short_description": "bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer.", "long_description": "bluebird bio, Inc., a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent \u00c3\u0178-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder. The company\u00e2\u20ac\u2122s product candidates in oncology include bb2121 and bb21217, which are chimeric antigen receptor T (CAR T) cell product candidates for the treatment of multiple myeloma. It has a strategic collaboration with Celgene Corporation to discover, develop, and commercialize disease-altering gene therapies in oncology; and Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize various immune cell therapies for cancer. The company also has collaborations with Medigene AG to discover T cell receptor (TCR) product candidates in the field of cancer; Gritstone Oncology, Inc. to discover TCR product candidates in the field of cancer; TC BioPharm Limited to research and develop gamma delta CAR T cells directed at hematologic and solid tumor targets; and Novo Nordisk A/S to develop in vivo genome editing treatments for genetic diseases. The company was formerly known as Genetix Pharmaceuticals, Inc., and changed its name to bluebird bio, Inc. in September 2010. bluebird bio, Inc. was founded in 1992 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3298188984, "total_enterprise": 2382715984, "number_of_employees": 1090, "outstanding_shares": 55637466, "eps": -14.306825, "diluted_eps": -14.306825, "earnings_from_cont_operations": -789608000, "gross_profit": -540717000, "cash": 1106460000, "total_debt": 190987000, "total_revenue": 44674000, "cash_from_operations": -564384000, "net_income": -789608000, "ebitda": -798441000, "year_low_stock_price": 38.95, "year_high_stock_price": 143.98, "image_position": [4928, 0, 80, 80]}, {"symbol": "GO", "name": "Grocery Outlet Holding Corp.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 748133980.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.32072, "eps_up_revisions": 7, "eps_down_revisions": 0, "revenue_up_revisions": 5, "revenue_down_revisions": 0, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "groceryoutlet.com", "year_founded": 1946, "street_address": "5650 Hollis Street", "city": "EmeryVille", "state": "CA", "zipcode": "94608", "country": "United States", "phone_number": "510 845 1999", "short_description": "Grocery Outlet Holding Corp. owns and operates a chain of grocery stores in the United States.", "long_description": "Grocery Outlet Holding Corp. owns and operates a chain of grocery stores in the United States. The company offers products in various categories, such as dairy and deli, produce, and fresh meat and seafood products, as well as grocery, frozen, beer and wine, general merchandise, and health and beauty care products; and natural, organic, specialty, and healthy products. As of December 28, 2019, it had 347 stores, including 342 independent operated stores in California, Washington, Oregon, Pennsylvania, Idaho, and Nevada. The company was founded in 1946 and is headquartered in Emeryville, California.", "industry_name": "Food and Staples Retailing", "sector_name": "Consumer Staples", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3304141992, "total_enterprise": 4530029992, "number_of_employees": 765, "outstanding_shares": 90006592, "eps": 0.195068, "diluted_eps": 0.19, "earnings_from_cont_operations": 15419000, "gross_profit": 787102000, "cash": 28101000, "total_debt": 1253989000, "total_revenue": 2559617000, "cash_from_operations": 132835000, "net_income": 15419000, "ebitda": 118486000, "year_low_stock_price": 27.75, "year_high_stock_price": 47.57, "image_position": [5056, 0, 128, 128]}, {"symbol": "AN", "name": "AutoNation, Inc.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 4579078920.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.715, "eps_up_revisions": 0, "eps_down_revisions": 6, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 12, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 8, "analysts_underperform": 0, "webpage": "autonation.com", "year_founded": 1991, "street_address": "200 SW 1st Avenue", "city": "Fort Lauderdale", "state": "FL", "zipcode": "33301", "country": "United States", "phone_number": "954-769-6000", "short_description": "AutoNation, Inc., through its subsidiaries, operates as an automotive retailer in the United States.", "long_description": "AutoNation, Inc., through its subsidiaries, operates as an automotive retailer in the United States. The company operates through three segments: Domestic, Import, and Premium Luxury. It offers a range of automotive products and services, including new and used vehicles; and parts and services, such as automotive repair and maintenance, and wholesale parts and collision services. The company also provides automotive finance and insurance products comprising vehicle services and other protection products, as well as arranges finance for vehicle purchases through third-party finance sources. As of December 31, 2019, it owned and operated 317 new vehicle franchises from 231 stores located primarily in metropolitan markets in the Sunbelt region. It also owned and operated 81 AutoNation-branded collision centers, 5 AutoNation USA stores, 4 automotive auction operations, and 17 parts distribution centers. The company was founded in 1991 and is headquartered in Fort Lauderdale, Florida.", "industry_name": "Specialty Retail", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 3428660540, "total_enterprise": 9412560540, "number_of_employees": 25000, "outstanding_shares": 89474440, "eps": 4.99445, "diluted_eps": 4.97116, "earnings_from_cont_operations": 450800000, "gross_profit": 3523000000, "cash": 42000000, "total_debt": 6025900000, "total_revenue": 21335700000, "cash_from_operations": 769200000, "net_income": 450000000, "ebitda": 963000000, "year_low_stock_price": 20.59, "year_high_stock_price": 53.19, "image_position": [5184, 0, 128, 128]}, {"symbol": "HALO", "name": "Halozyme Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 42962220.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": -0.03864, "eps_up_revisions": 3, "eps_down_revisions": 4, "revenue_up_revisions": 2, "revenue_down_revisions": 3, "total_analysts": 12, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 5, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "halozyme.com", "year_founded": 1998, "street_address": "11388 Sorrento Valley Road", "city": "San Diego", "state": "CA", "zipcode": "92121", "country": "United States", "phone_number": "858 794 8889", "short_description": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally.", "long_description": "Halozyme Therapeutics, Inc. operates as a biopharma technology platform company in the United States, Switzerland, and internationally. The company's products are based on the ENHANZE drug delivery technology, a patented recombinant human hyaluronidase enzyme (rHuPH20) that enables the subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. Its proprietary product include Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous fluid administration for achieving hydration; to enhance the dispersion and absorption of other injected drugs in subcutaneous urography; and to improve resorption of radiopaque agents. The company is also developing Perjeta for breast cancer; RITUXAN HYCELA and MabThera SC for the treatment of non-Hodgkin lymphoma and chronic lymphocytic leukemia (CLL); RITUXAN SC for patients with CLL; and HYQVIA for the treatment of immunodeficiency disorders. In addition, it is developing Tecentriq for non-small cell lung cancer; OCREVUS for multiple sclerosis; DARZALEX for the treatment of patients with amyloidosis, smoldering myeloma, and multiple myeloma; nivolumab for the treatment of solid tumors; ALXN1210 and ALXN1810 subcutaneous formulations; ARGX-113, a human neonatal Fc receptor; ARGX-117 to treat autoimmune diseases; and BMS-986179, an anti-CD-73 antibody. The company has collaborations with F. Hoffmann-La Roche, Ltd.; Hoffmann-La Roche, Inc.; Baxalta US Inc.; Baxalta GmbH; Pfizer Inc.; Janssen Biotech, Inc.; AbbVie, Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; Alexion Pharma Holding; ARGENX BVBA; and National Institute of Allergy and Infectious Diseases. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3254834156, "total_enterprise": 3242628156, "number_of_employees": 132, "outstanding_shares": 137858287, "eps": -0.500523, "diluted_eps": -0.500523, "earnings_from_cont_operations": -72240000, "gross_profit": 26843000, "cash": 421262000, "total_debt": 409056000, "total_revenue": 195992000, "cash_from_operations": -85423000, "net_income": -72240000, "ebitda": -36941000, "year_low_stock_price": 12.71, "year_high_stock_price": 24.49, "image_position": [5312, 0, 128, 49]}, {"symbol": "ORA", "name": "Ormat Technologies, Inc.", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 186905120.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.51401, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 6, "analysts_underperform": 1, "webpage": "ormat.com", "year_founded": 1965, "street_address": "6140 Plumas Street", "city": "Reno", "state": "NV", "zipcode": "89519", "country": "United States", "phone_number": "775-356-9029", "short_description": "Ormat Technologies, Inc. engages in the geothermal and recovered energy power business in the United States, Indonesia, Kenya, Turkey, Chile, Guatemala, New Zealand, and internationally.", "long_description": "Ormat Technologies, Inc. engages in the geothermal and recovered energy power business in the United States, Indonesia, Kenya, Turkey, Chile, Guatemala, New Zealand, and internationally. The company operates through three segments: Electricity, Product, and Other. The Electricity segment develops, builds, owns, and operates geothermal and recovered energy-based power plants; and sells electricity. The Product segment designs, manufactures, and sells equipment for geothermal, recovered energy-based electricity generation, and remote power units, such as fossil fuel powered turbo-generators and heavy duty direct-current generators. This segment also provides services relating to the engineering, procurement, construction, operation, and maintenance of geothermal, solar photovoltaic, and recovered energy-based power plants. The Product segment serves contractors; developers, owners, and operators of geothermal power plants; and owners and operators of interstate natural gas pipelines, gas processing plants, and cement plants, as well as companies in other energy-intensive industrial processes. The Other segment offers energy storage, demand response, and energy management related services. Ormat Technologies, Inc. was founded in 1965 and is based in Reno, Nevada.", "industry_name": "Independent Power and Renewable Electricity Producers", "sector_name": "Utilities", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 3219843448, "total_enterprise": 4549922448, "number_of_employees": 1408, "outstanding_shares": 51035718, "eps": 1.731869, "diluted_eps": 1.72, "earnings_from_cont_operations": 93543000, "gross_profit": 269323000, "cash": 71173000, "total_debt": 1269012000, "total_revenue": 746044000, "cash_from_operations": 236493000, "net_income": 88095000, "ebitda": 345266000, "year_low_stock_price": 55.22, "year_high_stock_price": 87.07, "image_position": [5440, 0, 128, 78]}, {"symbol": "SKT", "name": "Tanger Factory Outlet Centers, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.17078, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 6, "analysts_sell": 2, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 3, "webpage": "tangeroutlets.com", "year_founded": 1981, "street_address": "3200 Northline Avenue", "city": "Greensboro", "state": "NC", "zipcode": "27408", "country": "United States", "phone_number": "336-292-3010", "short_description": "Tanger Factory Outlet Centers, Inc. (NYSE: SKT), is a publicly-traded REIT headquartered in Greensboro, North Carolina that presently operates and owns, or has an ownership interest in, a portfolio of 39 upscale outlet shopping centers.", "long_description": "Tanger Factory Outlet Centers, Inc. (NYSE: SKT), is a publicly-traded REIT headquartered in Greensboro, North Carolina that presently operates and owns, or has an ownership interest in, a portfolio of 39 upscale outlet shopping centers. Tanger's operating properties are located in 20 states and in Canada, totaling approximately 14.3 million square feet, leased to over 2,800 stores which are operated by more than 510 different brand name companies. The Company has more than 39 years of experience in the outlet industry. Tanger Outlet Centers continue to attract more than 181 million visitors annually. Tanger is furnishing a Form 8-K with the Securities and Exchange Commission that includes a supplemental information package for the quarter and year ended December 31, 2019.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 611513925, "total_enterprise": 2279178925, "number_of_employees": 461, "outstanding_shares": 93076701, "eps": 0.932236, "diluted_eps": 0.93, "earnings_from_cont_operations": 92728000, "gross_profit": 354475000, "cash": 17690000, "total_debt": 1662452000, "total_revenue": 486187000, "cash_from_operations": 220452000, "net_income": 87855000, "ebitda": 265510000, "year_low_stock_price": 4.05, "year_high_stock_price": 18.82, "image_position": [5568, 0, 128, 128]}, {"symbol": "IIVI", "name": "II-VI Incorporated", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 13, "next_earnings_revenue_consensus": 575659000.0, "next_earnings_eps_num_analysts": 14, "next_earnings_eps_consensus": 0.14331, "eps_up_revisions": 0, "eps_down_revisions": 13, "revenue_up_revisions": 0, "revenue_down_revisions": 13, "total_analysts": 15, "analysts_sell": 0, "analysts_buy": 7, "analysts_outperform": 4, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "ii-vi.com", "year_founded": 1971, "street_address": "375 Saxonburg Boulevard", "city": "Saxonburg", "state": "PA", "zipcode": "16056", "country": "United States", "phone_number": "724 352 4455", "short_description": "II-VI Incorporated develops, manufactures, and markets engineered materials, and optoelectronic components and devices worldwide.", "long_description": "II-VI Incorporated develops, manufactures, and markets engineered materials, and optoelectronic components and devices worldwide. The company operates through three segments: II-VI Laser Solutions, II-VI Photonics, and II-VI Performance Products. The II-VI Laser Solutions segment offers optical and electro-optical components and materials used in high-power CO2 lasers; fiber-delivered beam delivery systems, and processing tools and direct diode lasers for industrial lasers; and compound semiconductor epitaxial and gallium arsenide wafers. The II-VI Photonics segment provides crystal materials, optics, microchip lasers, and optoelectronic modules for use in optical communication networks and other consumer, life sciences, and commercial applications. It also offers pump lasers, optical isolators, and optical amplifiers and micro-optics for optical amplifiers for terrestrial and submarine applications; and direct-diode laser modules, subsystems, and systems, as well as super-hard materials processing laser systems. The II-VI Performance Products segment provides infrared optical components and optical assemblies for aerospace and defense, medical, and commercial laser imaging applications; and silicon carbide engineered materials for thermoelectric devices and subsystems for silicon carbide applications. The company serves OEMs, laser end-users, system integrators of high-power lasers, manufacturers of equipment and devices for the industrial, optical communications, aerospace and defense, semiconductor, medical and life science markets, consumers, the U.S. government prime contractors, various U.S. government agencies, and thermoelectric integrators. II-VI Incorporated has a strategic partnership agreement with LITE-ON Technology Corporation to partner in the volume manufacturing and commercialization of packaged semiconductor lasers for mass-market light detection and ranging. The company was founded in 1971 and is headquartered in Saxonburg, Pennsylvania.", "industry_name": "Electronic Equipment, Instruments and Components", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 3262666757, "total_enterprise": 5329859757, "number_of_employees": 12487, "outstanding_shares": 91059636, "eps": -1.007023, "diluted_eps": -1.007023, "earnings_from_cont_operations": -71545000, "gross_profit": 625116000, "cash": 376840000, "total_debt": 2444033000, "total_revenue": 1711964000, "cash_from_operations": 146529000, "net_income": -71545000, "ebitda": 278262000, "year_low_stock_price": 19.0, "year_high_stock_price": 42.95, "image_position": [5648, 0, 80, 80]}, {"symbol": "HHC", "name": "The Howard Hughes Corporation", "next_earnings_utc": 1589228700, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 236138000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.221, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "howardhughes.com", "year_founded": 2010, "street_address": "13355 Noel Road", "city": "Dallas", "state": "TX", "zipcode": "75240", "country": "United States", "phone_number": "214-741-7744", "short_description": "The Howard Hughes Corporation owns, manages, and develops commercial, residential, and hospitality operating properties in the United States.", "long_description": "The Howard Hughes Corporation owns, manages, and develops commercial, residential, and hospitality operating properties in the United States. It operates through three segments: Operating Assets, Master Planned Communities, and Strategic Developments. The Operating Assets segment owns 15 retail, 28 office, 8 multi-family, and 4 hospitality properties, as well as 10 other operating assets and investments primarily located and around The Woodlands, Texas; Columbia, Maryland; New York, New York; Las Vegas, Nevada; and Honolulu, Hawai\u00e2\u20ac\u02dci. The Master Planned Communities segment develops and sells residential and commercial land. This segment sells residential land designated for detached and attached single family homes ranging from entry-level to luxury homes; and commercial land parcels designated for retail, office, hospitality, and high density residential projects, as well as services and other for-profit activities, and parcels designated for use by government, schools, and other not-for-profit entities. As of December 31, 2018, this segment had 10,543 remaining saleable acres of land. The Strategic Development segment comprises residential condominium and commercial property projects. This segment consist of 29 development or redevelopment projects. The company was founded in 2010 and is headquartered in Dallas, Texas.", "industry_name": "Real Estate Management and Development", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 3012510462, "total_enterprise": 6941391462, "number_of_employees": 1500, "outstanding_shares": 55063251, "eps": 1.714484, "diluted_eps": 1.71, "earnings_from_cont_operations": 74295000, "gross_profit": 487332000, "cash": 422857000, "total_debt": 4207018000, "total_revenue": 1300539000, "cash_from_operations": 207732000, "net_income": 73956000, "ebitda": 317357000, "year_low_stock_price": 35.1, "year_high_stock_price": 135.42, "image_position": [5776, 0, 128, 128]}, {"symbol": "KOS", "name": "Kosmos Energy Ltd.", "next_earnings_utc": 1589176800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 218600000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.145, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 14, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 2, "analysts_hold": 8, "analysts_underperform": 1, "webpage": "kosmosenergy.com", "year_founded": 2003, "street_address": "8176 Park Lane", "city": "Dallas", "state": "TX", "zipcode": "75231", "country": "United States", "phone_number": "214 445 9600", "short_description": "Kosmos Energy Ltd., a deepwater independent oil and gas exploration and production company, focuses along the Atlantic Margins.", "long_description": "Kosmos Energy Ltd., a deepwater independent oil and gas exploration and production company, focuses along the Atlantic Margins. The company's primary assets include production offshore Ghana, Equatorial Guinea, and U.S. Gulf of Mexico, as well as a gas development offshore Mauritania and Senegal. It also maintains an exploration program balanced between proven basin infrastructure-led exploration, emerging basins, and frontier basins. The company was founded in 2003 and is headquartered in Dallas, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 603734584, "total_enterprise": 2410674584, "number_of_employees": 360, "outstanding_shares": 405190996, "eps": -0.138967, "diluted_eps": -0.14, "earnings_from_cont_operations": -55777000, "gross_profit": 1049522000, "cash": 224502000, "total_debt": 2031442000, "total_revenue": 1499381000, "cash_from_operations": 628150000, "net_income": -55777000, "ebitda": 674385000, "year_low_stock_price": 0.501, "year_high_stock_price": 7.55, "image_position": [5904, 0, 128, 128]}, {"symbol": "ICPT", "name": "Intercept Pharmaceuticals, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 19, "next_earnings_revenue_consensus": 69665740.0, "next_earnings_eps_num_analysts": 11, "next_earnings_eps_consensus": -2.87364, "eps_up_revisions": 1, "eps_down_revisions": 5, "revenue_up_revisions": 4, "revenue_down_revisions": 5, "total_analysts": 24, "analysts_sell": 0, "analysts_buy": 13, "analysts_outperform": 7, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "interceptpharma.com", "year_founded": 2002, "street_address": "10 Hudson Yards", "city": "New York", "state": "NY", "zipcode": "10001", "country": "United States", "phone_number": "646 747 1000", "short_description": "Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.", "long_description": "Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. Its lead products candidate is the Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid in adults. The company is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis (NASH); and several other product candidates in various stages of clinical and preclinical development. It has a license agreement with Sumitomo Dainippon Pharma Co. Ltd. for the research, development, and commercialization of OCA as a therapeutic for the treatment of PBC and NASH in Japan and China; and Aralez Pharmaceuticals Canada Inc to develop and commercialize bezafibrate in the United States. The company markets its products through an internal commercial organization, a contract sales organization, and third-party distributors. Intercept Pharmaceuticals, Inc. was founded in 2002 and is headquartered in New York, New York.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2892402336, "total_enterprise": 2787536336, "number_of_employees": 583, "outstanding_shares": 32943079, "eps": -10.889018, "diluted_eps": -10.889018, "earnings_from_cont_operations": -344681000, "gross_profit": 247790000, "cash": 652622000, "total_debt": 547756000, "total_revenue": 252002000, "cash_from_operations": -236613000, "net_income": -344681000, "ebitda": -308764000, "year_low_stock_price": 47.57, "year_high_stock_price": 125.0, "image_position": [6032, 0, 128, 128]}, {"symbol": "MIME", "name": "Mimecast Limited", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": 15, "next_earnings_revenue_consensus": 112387120.0, "next_earnings_eps_num_analysts": 16, "next_earnings_eps_consensus": 0.12321, "eps_up_revisions": 7, "eps_down_revisions": 9, "revenue_up_revisions": 5, "revenue_down_revisions": 8, "total_analysts": 18, "analysts_sell": 0, "analysts_buy": 10, "analysts_outperform": 5, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "mimecast.com", "year_founded": 2003, "street_address": "1 Finsbury Avenue", "city": "London", "state": null, "zipcode": "EC2M 2PF", "country": "United Kingdom", "phone_number": "44 20 7847 8700", "short_description": "Mimecast Limited, an email and data security company, provides cloud security and risk management services for corporate information and email.", "long_description": "Mimecast Limited, an email and data security company, provides cloud security and risk management services for corporate information and email. The company offers Mimecast Email Security services, including targeted threat protection services, such as URL Protect that addresses the threat from emails containing malicious links; Attachment Protect that reduces threat from weaponized or malware-laden attachments used in spear-phishing and other attacks; Impersonation Protect that gives protection from malware-less social engineering attacks; and Internal Email Protect, which allows customers to monitor, detect, and remediate security threats that originate from within their internal email systems. Its Mimecast Email Security services also comprise Secure Messaging for sharing sensitive information with external contacts through email; Large File Send that enables employees to create security and compliance risks when they turn to file sharing services; and Data Leak Prevention, which prevents the inadvertent or malicious loss of sensitive corporate data. In addition, the company offers Mimecast Business Continuity, which protects email and data against the threat of downtime as a result of system failure, natural disasters, planned maintenance, system upgrades, and migrations; and Mimecast Enterprise Information Archiving that offers cloud archive consolidation of inbound, outbound and internal email, files, and instant messaging in an archive, as well as incorporates legacy data from additional archives into the same searchable store. Further, it provides Service Bundles, a unified service managed from a single administration console; and Mimecast Mobile and Desktop Apps for mobile, PC, and Mac users to get self-service access to security features. The company sells its services through direct sales and channel partners. Mimecast Limited was founded in 2003 and is headquartered in London, the United Kingdom.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2558759988, "total_enterprise": 2609884988, "number_of_employees": 1495, "outstanding_shares": 62515514, "eps": -0.10813, "diluted_eps": -0.119656, "earnings_from_cont_operations": -6655000, "gross_profit": 300181000, "cash": 189863000, "total_debt": 240988000, "total_revenue": 404939000, "cash_from_operations": 83818000, "net_income": -6655000, "ebitda": 32420000, "year_low_stock_price": 25.14, "year_high_stock_price": 54.4, "image_position": [6160, 0, 128, 128]}, {"symbol": "BHF", "name": "Brighthouse Financial, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 2011085000.0, "next_earnings_eps_num_analysts": 12, "next_earnings_eps_consensus": 1.73911, "eps_up_revisions": 0, "eps_down_revisions": 8, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 13, "analysts_sell": 2, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 8, "analysts_underperform": 1, "webpage": "brighthousefinancial.com", "year_founded": 2016, "street_address": "11225 North Community House Road", "city": "Charlotte", "state": "NC", "zipcode": "28277", "country": "United States", "phone_number": "980-365-7100", "short_description": "Brighthouse Financial, Inc. provides annuity and life insurance products in the United States.", "long_description": "Brighthouse Financial, Inc. provides annuity and life insurance products in the United States. It operates through three segments: Annuities, Life, and Run-off. The Annuities segment offers variable, fixed, index-linked, and income annuities for contract holders\u2019 needs for protected wealth accumulation on a tax-deferred basis, wealth transfer, and income security. The Life segment consist of term, universal, whole, and variable life products for policyholders\u2019 needs for financial security and protected wealth transfer. The Run-off segment provides structured settlements, pension risk transfer contracts, certain company-owned life insurance policies, funding agreements, and universal life with secondary guarantees. The company was founded in 2016 and is headquartered in Charlotte, North Carolina.", "industry_name": "Insurance", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2827683280, "total_enterprise": 9101683280, "number_of_employees": 1330, "outstanding_shares": 98422669, "eps": -6.763924, "diluted_eps": -6.763924, "earnings_from_cont_operations": -735000000, "gross_profit": 1405000000, "cash": 6613000000, "total_debt": 9086000000, "total_revenue": 6520000000, "cash_from_operations": 1828000000, "net_income": -740000000, "ebitda": -877000000, "year_low_stock_price": 12.05, "year_high_stock_price": 48.25, "image_position": [6288, 0, 128, 30]}, {"symbol": "KWR", "name": "Quaker Chemical Corporation", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 362757750.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 1.002, "eps_up_revisions": 0, "eps_down_revisions": 5, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "quakerchem.com", "year_founded": 1918, "street_address": "One Quaker Park", "city": "Conshohocken", "state": "PA", "zipcode": "19428-2380", "country": "United States", "phone_number": "610 832 4000", "short_description": "Quaker Chemical Corporation, doing business as Quaker Houghton, engages in the development, production, and marketing of various formulated specialty chemical products for various industrial and manufacturing applications.", "long_description": "Quaker Chemical Corporation, doing business as Quaker Houghton, engages in the development, production, and marketing of various formulated specialty chemical products for various industrial and manufacturing applications. The company operates through four segments: Americas; Europe, Middle East and Africa (EMEA); Asia/Pacific; and Global Specialty Businesses. Its principal products include metal removal fluids, cleaning fluids, corrosion inhibitors, metal drawing and forming fluids, die cast mold releases, heat treatment and quenchants, metal forging fluids, hydraulic fluids, specialty greases, offshore sub-sea energy control fluids, rolling lubricants, rod and wire drawing fluids, and surface treatment chemicals. The company also offers operating equipment; and chemical management services. It serves metalworking, metals, and industrial end markets, including steel, aluminum, aerospace, defense, transportation-original equipment manufacturer, transportation-components, offshore sub-sea energy, architectural aluminum, construction, tube and pipe, can and container, mining, specialty coatings, and specialty greases. The company was formerly known as Quaker Chemical Products Corporation and changed its name to Quaker Chemical Corporation in August 1962. Quaker Chemical Corporation was founded in 1918 and is headquartered in Conshohocken, Pennsylvania.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2717731686, "total_enterprise": 3559445686, "number_of_employees": 4500, "outstanding_shares": 17732818, "eps": 2.084494, "diluted_eps": 2.08, "earnings_from_cont_operations": 31884000, "gross_profit": 404331000, "cash": 123524000, "total_debt": 963634000, "total_revenue": 1133503000, "cash_from_operations": 82374000, "net_income": 31622000, "ebitda": 161877000, "year_low_stock_price": 108.14, "year_high_stock_price": 209.05, "image_position": [6416, 0, 128, 36]}, {"symbol": "DIOD", "name": "Diodes Incorporated", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 286239000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.48667, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "diodes.com", "year_founded": 1959, "street_address": "4949 Hedgcoxe Road", "city": "Plano", "state": "TX", "zipcode": "75024", "country": "United States", "phone_number": "972 987 3900", "short_description": "Diodes Incorporated, together with its subsidiaries, designs, manufactures, and supplies application-specific standard products in the discrete, logic, and analog and mixed-signal semiconductor markets in Asia, North America, and Europe.", "long_description": "Diodes Incorporated, together with its subsidiaries, designs, manufactures, and supplies application-specific standard products in the discrete, logic, and analog and mixed-signal semiconductor markets in Asia, North America, and Europe. It primarily focuses on low pin count semiconductor devices with one or more active or passive components. The company offers discrete semiconductor products, such as performance Schottky rectifiers and diodes; Zener and performance Zener diodes, including tight tolerance and low operating current type; standard, fast, super-fast, and ultra-fast recovery rectifiers; bridge rectifiers; switching diodes; small signal bipolar and pre-biased transistors; MOSFETs; thyristor surge protection devices; and transient voltage suppressors. It also provides analog products comprising power management devices consisting of AC-DC and DC-DC converters, USB power switches, and low dropout and linear voltage regulators; linear devices, such as operational amplifiers and comparators, current monitors, voltage references, and reset generators; LED lighting drivers; audio amplifiers; and sensor products, including hall-effect sensors and motor drivers. In addition, the company offers standard logic products comprising low-voltage complementary metal\u2013oxide\u2013semiconductor (CMOS) and high-speed CMOS devices; ultra-low power CMOS logic products and analog switches; multichip products and co-packaged discrete, analog, and mixed-signal silicon in miniature packages; silicon and silicon epitaxial wafers; and crystals and oscillators. It sells its products to the consumer electronics, computing, communications, industrial, and automotive markets through direct sales and marketing personnel, independent sales representatives, and distributors. Diodes Incorporated was founded in 1959 and is headquartered in Plano, Texas.", "industry_name": "Semiconductors and Semiconductor Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2576734680, "total_enterprise": 2511672680, "number_of_employees": 6605, "outstanding_shares": 51206969, "eps": 3.017504, "diluted_eps": 2.96, "earnings_from_cont_operations": 154115000, "gross_profit": 465807000, "cash": 263409000, "total_debt": 151988000, "total_revenue": 1249130000, "cash_from_operations": 229772000, "net_income": 153250000, "ebitda": 287341000, "year_low_stock_price": 30.51, "year_high_stock_price": 59.7, "image_position": [6544, 0, 128, 128]}, {"symbol": "FBM", "name": "Foundation Building Materials, Inc.", "next_earnings_utc": 1589229900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 519488920.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.12625, "eps_up_revisions": 2, "eps_down_revisions": 5, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 9, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "fbmsales.com", "year_founded": 2011, "street_address": "2520 Red Hill Avenue", "city": "Santa Ana", "state": "CA", "zipcode": "92705", "country": "United States", "phone_number": "714 380 3127", "short_description": "Foundation Building Materials, Inc. distributes building products in the United States and Canada.", "long_description": "Foundation Building Materials, Inc. distributes building products in the United States and Canada. It offers wallboard, suspended ceiling system, and metal framing products. The company also provides complementary and other products, tools, and accessories, such as wallboard accessories, stucco and finishing systems, safety accessories, fasteners, insulations, doors, and roofing products. It serves its products to commercial, residential, and other specialty contractors. The company was founded in 2011 and is headquartered in Santa Ana, California. Foundation Building Materials, Inc. is a subsidiary of Lone Star Fund IX (U.S.) L.P.", "industry_name": "Trading Companies and Distributors", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 517116640, "total_enterprise": 1161135640, "number_of_employees": 3500, "outstanding_shares": 43201056, "eps": 0.936334, "diluted_eps": 0.933308, "earnings_from_cont_operations": 41828000, "gross_profit": 656609000, "cash": 17766000, "total_debt": 661785000, "total_revenue": 2154530000, "cash_from_operations": 145718000, "net_income": 40239000, "ebitda": 168744000, "year_low_stock_price": 7.99, "year_high_stock_price": 22.14, "image_position": [6672, 0, 128, 128]}, {"symbol": "UNVR", "name": "Univar Solutions Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 2165844800.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.274, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "univar.com", "year_founded": 1924, "street_address": "3075 Highland Parkway", "city": "Downers Grove", "state": "IL", "zipcode": "60515", "country": "United States", "phone_number": "331 777 6000", "short_description": "Univar Solutions Inc. distributes commodity and specialty chemical products, and related services worldwide.", "long_description": "Univar Solutions Inc. distributes commodity and specialty chemical products, and related services worldwide. It also provides epoxy resins, polyurethanes, titanium dioxide, fumed silica, esters, plasticizers, silicones, and specialty amines; chemicals and service to midstream pipeline and downstream refinery operators; and commodity and specialty products for meat processing, baked goods, dairy, grain mill products, processed foods, carbonated soft drinks, fruit drinks, and alcoholic beverage markets. In addition, the company offers chemical products for use at various stages of production, from sap stain prevention to pulp and paper manufacturing; ingredients for cleaners, detergents, and disinfectant products; base stocks and performance-enhancing additives for lubricants and metalworking fluids; excipients, solvents, reactants, active pharmaceutical ingredients, and intermediates to pharmaceutical ingredient producers; and products for water treatment that includes pH adjusters, flocculants, coagulants, dechlorinators, and disinfectants. Further, it provides transportation and warehousing infrastructure, chemicals and hazardous materials handling, waste management services, inventory management, and blending and repackaging services, as well as industrial cleaning, site remediation, and emergency environmental response services. Univar Solutions Inc. distributes its products through warehouse and direct-to-consumer delivery channels. The company was formerly known as Univar Inc. and changed its name to Univar Solutions Inc. in September 2019. The company was founded in 1924 and is headquartered in Downers Grove, Illinois.", "industry_name": "Trading Companies and Distributors", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2541632245, "total_enterprise": 5111032245, "number_of_employees": 10300, "outstanding_shares": 168879219, "eps": -0.610603, "diluted_eps": -0.610603, "earnings_from_cont_operations": -105600000, "gross_profit": 2153300000, "cash": 330300000, "total_debt": 2899700000, "total_revenue": 9286900000, "cash_from_operations": 363900000, "net_income": -100200000, "ebitda": 581800000, "year_low_stock_price": 6.4, "year_high_stock_price": 24.77, "image_position": [6800, 0, 128, 128]}, {"symbol": "CSOD", "name": "Cornerstone OnDemand, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 147759670.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 0.245, "eps_up_revisions": 0, "eps_down_revisions": 10, "revenue_up_revisions": 0, "revenue_down_revisions": 8, "total_analysts": 11, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 4, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "cornerstoneondemand.com", "year_founded": 1999, "street_address": "1601 Cloverfield Boulevard", "city": "Santa Monica", "state": "CA", "zipcode": "90404", "country": "United States", "phone_number": "310-752-0200", "short_description": "Cornerstone OnDemand, Inc., together with its subsidiaries, provides learning and people development solutions through software-as-a-service model worldwide.", "long_description": "Cornerstone OnDemand, Inc., together with its subsidiaries, provides learning and people development solutions through software-as-a-service model worldwide. Its enterprise people development solution comprises four product suites, such as Recruiting Suite that helps organizations to attract, hire, and onboard the right employees; Learning Suite, which provides robust, a modern learning management software to supports compliance, knowledge sharing, and employee-driven development training; Performance Suite that provides tools to manage goal setting, performance reviews, competency assessments, development plans, continuous feedback, compensation management, and succession planning; and HR Suite, which provides an aggregated view of all employee data with workforce planning, self-service management, and compliance reporting capabilities. The company also offers professional services, including application configuration, system integration, business process re-engineering, change management, and training. Cornerstone OnDemand, Inc. sells its software, content, and services directly through its sales force and indirectly through its domestic and international network of distributors. It serves business services, financial services, healthcare, pharmaceuticals, insurance, manufacturing, retail, and technology industries. Cornerstone OnDemand, Inc. was founded in 1999 and is headquartered in Santa Monica, California.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2343401308, "total_enterprise": 2293519308, "number_of_employees": 2000, "outstanding_shares": 63766022, "eps": -0.067469, "diluted_eps": -0.067469, "earnings_from_cont_operations": -4054000, "gross_profit": 427308000, "cash": 417486000, "total_debt": 367604000, "total_revenue": 576523000, "cash_from_operations": 115549000, "net_income": -4054000, "ebitda": 24908000, "year_low_stock_price": 22.22, "year_high_stock_price": 64.45, "image_position": [6928, 0, 128, 128]}, {"symbol": "NHI", "name": "National Health Investors, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 80766000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.96, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 8, "analysts_sell": 2, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "nhireit.com", "year_founded": 1991, "street_address": "222 Robert Rose Drive", "city": "Murfreesboro", "state": "TN", "zipcode": "37129", "country": "United States", "phone_number": "615-890-9100", "short_description": "Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments.", "long_description": "Incorporated in 1991, National Health Investors, Inc. (NYSE: NHI) is a real estate investment trust specializing in sale-leaseback, joint-venture, mortgage and mezzanine financing of need-driven and discretionary senior housing and medical investments. NHI's portfolio consists of independent, assisted and memory care communities, entrance-fee retirement communities, skilled nursing facilities, medical office buildings and specialty hospitals.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2353055105, "total_enterprise": 3792360105, "number_of_employees": 17, "outstanding_shares": 44650002, "eps": 3.695624, "diluted_eps": 3.669999, "earnings_from_cont_operations": 160449000, "gross_profit": 312343000, "cash": 5215000, "total_debt": 1443899000, "total_revenue": 318081000, "cash_from_operations": 240955000, "net_income": 160456000, "ebitda": 296887000, "year_low_stock_price": 31.37, "year_high_stock_price": 91.12, "image_position": [7008, 0, 80, 80]}, {"symbol": "FATE", "name": "Fate Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 11, "next_earnings_revenue_consensus": 1570450.0, "next_earnings_eps_num_analysts": 12, "next_earnings_eps_consensus": -0.39057, "eps_up_revisions": 3, "eps_down_revisions": 6, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 15, "analysts_sell": 0, "analysts_buy": 11, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "fatetherapeutics.com", "year_founded": 2007, "street_address": "3535 General Atomics Court", "city": "San Diego", "state": "CA", "zipcode": "92121", "country": "United States", "phone_number": "858-875-1800", "short_description": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide.", "long_description": "Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development includes FT516 for the treatment of acute myeloid leukemia (AML) and B-cell lymphoma, FT596 to treat B-cell lymphoma and CLL, FT538 to treat AML and multiple myeloma, FT576 to treat multiple myeloma, FT819 to treat B-cell malignancies, and FT-ONO1 to treat hematologic malignancies; and FT500, FT516, and FT-ONO2 for the treatment of advanced solid tumors. The company's NK- and T-cell immuno-oncology programs under development also includes ProTmune for the treatment of hematologic malignancies; FATE-NK100 for the treatment of recurrent ovarian cancer; and FATE-NK100 for the treatment of advanced solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of two off-the-shelf iPSC-derived CAR T-cell product candidates; strategic research collaboration and license agreement with Juno Therapeutics, Inc. to screen for and identify small molecule modulators that enhance the therapeutic properties of genetically-engineered T-cell immunotherapies; and a collaboration and option agreement with Janssen Biotech, Inc. Fate Therapeutics, Inc. was founded in 2007 and is headquartered in San Diego, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2190034183, "total_enterprise": 1995537183, "number_of_employees": 178, "outstanding_shares": 75937385, "eps": -1.43933, "diluted_eps": -1.43933, "earnings_from_cont_operations": -98149000, "gross_profit": -77090000, "cash": 221427000, "total_debt": 26927000, "total_revenue": 10680000, "cash_from_operations": -83175000, "net_income": -98149000, "ebitda": -98534000, "year_low_stock_price": 12.59, "year_high_stock_price": 32.39, "image_position": [7136, 0, 128, 128]}, {"symbol": "AMN", "name": "AMN Healthcare Services, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 601338890.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.78, "eps_up_revisions": 2, "eps_down_revisions": 6, "revenue_up_revisions": 8, "revenue_down_revisions": 1, "total_analysts": 11, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "amnhealthcare.com", "year_founded": 1985, "street_address": "8840 Cypress Waters Boulevard", "city": "Dallas", "state": "TX", "zipcode": "75019", "country": "United States", "phone_number": "866 871 8519", "short_description": "AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States.", "long_description": "AMN Healthcare Services, Inc. provides healthcare workforce solutions and staffing services to hospitals and healthcare facilities in the United States. It operates through three segments: Nurse and Allied Solutions, Locum Tenens Solutions, and Other Workforce Solutions. It offers travel nurse staffing under the American Mobile, Onward Healthcare, Nurses Rx, Advanced, and O'Grady-Peyton brands; nurse staffing and labor disruption services, a staffing solution under the NurseChoice and HealthSource Global Staffing brands; local, or per diem, staffing for daily shift work under the Nursefinders brand; and locum tenens staffing for specialties, clinicians, and dentists on an independent contractor basis on temporary assignments under the Staff Care and Locum Leaders brands. It also provides allied staffing services, such as skilled nursing facilities, rehabilitation clinics, and retail and mail-order pharmacies under the Med Travelers and Club Staffing brands; physician permanent placement services to hospitals, healthcare facilities, and physician practice groups under the Merritt Hawkins brand, as well as physician executive leadership search services under the B.E. Smith brand; and executive and clinical leadership interim staffing, healthcare executive search, and advisory services. In addition, it offers managed services programs; vendor management systems, including ShiftWise and Medefis technologies; recruitment process outsourcing for permanent hiring needs; workforce optimization services comprising consulting, data analytics, predictive modeling, and SaaS-based scheduling technology under the Smart Square brand; medical coding, clinical documentation improvement, case management, clinical data registry, and auditing and advisory services; digital staffing services; flex pool management; and credentialing software solutions to clinicians and healthcare enterprises. AMN Healthcare Services, Inc. was founded in 1985 and is based in Dallas, Taxas.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2061595536, "total_enterprise": 2700921536, "number_of_employees": 3236, "outstanding_shares": 46854444, "eps": 2.440647, "diluted_eps": 2.4, "earnings_from_cont_operations": 113988000, "gross_profit": 743465000, "cash": 82985000, "total_debt": 722311000, "total_revenue": 2222107000, "cash_from_operations": 224862000, "net_income": 113988000, "ebitda": 242613000, "year_low_stock_price": 41.55, "year_high_stock_price": 89.22, "image_position": [7264, 0, 128, 128]}, {"symbol": "PK", "name": "Park Hotels & Resorts Inc.", "next_earnings_utc": 1589191500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 572020310.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.09, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 16, "analysts_sell": 2, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 7, "analysts_underperform": 2, "webpage": "pkhotelsandresorts.com", "year_founded": null, "street_address": "1775 Tysons  Boulevard", "city": "Tysons", "state": "VA", "zipcode": "22102", "country": "United States", "phone_number": "571-302-5757", "short_description": "Park is the second largest publicly traded lodging REIT with a diverse portfolio of market-leading hotels and resorts with significant underlying real estate value.", "long_description": "Park is the second largest publicly traded lodging REIT with a diverse portfolio of market-leading hotels and resorts with significant underlying real estate value. Park's portfolio currently consists of 60 premium-branded hotels and resorts with over 33,000 rooms primarily located in prime city center and resort locations.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2094410636, "total_enterprise": 5834410636, "number_of_employees": 488, "outstanding_shares": 240184706, "eps": 1.438679, "diluted_eps": 1.438679, "earnings_from_cont_operations": 316000000, "gross_profit": 902000000, "cash": 346000000, "total_debt": 4131000000, "total_revenue": 2830000000, "cash_from_operations": 499000000, "net_income": 306000000, "ebitda": 710000000, "year_low_stock_price": 3.99, "year_high_stock_price": 31.14, "image_position": [7392, 0, 128, 58]}, {"symbol": "NSA", "name": "National Storage Affiliates Trust", "next_earnings_utc": 1589231400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 101652500.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.08, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 0, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "nationalstorageaffiliates.com", "year_founded": null, "street_address": "8400 East Prentice Avenue", "city": "Greenwood Village", "state": "CO", "zipcode": "80111", "country": "United States", "phone_number": "720-630-2600", "short_description": "National Storage Affiliates Trust is a Maryland real estate investment trust focused on the ownership, operation and acquisition of self storage properties located within the top 100 metropolitan statistical areas throughout the United States.", "long_description": "National Storage Affiliates Trust is a Maryland real estate investment trust focused on the ownership, operation and acquisition of self storage properties located within the top 100 metropolitan statistical areas throughout the United States. As of December 31, 2019, the Company held ownership interests in and operated 742 self storage properties located in 35 states and Puerto Rico with approximately 47.1 million rentable square feet. NSA is one of the largest owners and operators of self storage properties among public and private companies in the United States.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 2015562474, "total_enterprise": 4322468474, "number_of_employees": 459, "outstanding_shares": 68001433, "eps": -0.145031, "diluted_eps": -0.15, "earnings_from_cont_operations": 66013000, "gross_profit": 276462000, "cash": 21538000, "total_debt": 1577795000, "total_revenue": 382926000, "cash_from_operations": 196651000, "net_income": 3983000, "ebitda": 225681000, "year_low_stock_price": 19.34, "year_high_stock_price": 38.22, "image_position": [7520, 0, 128, 128]}, {"symbol": "SUN", "name": "Sunoco LP", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 3765003010.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.7225, "eps_up_revisions": 2, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 13, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 3, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "sunocolp.com", "year_founded": 2012, "street_address": "8111 Westchester Drive", "city": "Dallas", "state": "TX", "zipcode": "75225", "country": "United States", "phone_number": "214-981-0700", "short_description": "Sunoco LP, together with its subsidiaries, engages in the distribution and retailing of motor fuels in the United States.", "long_description": "Sunoco LP, together with its subsidiaries, engages in the distribution and retailing of motor fuels in the United States. It operates through two segments, Fuel Distribution and Marketing, and All Other. The Fuel Distribution and Marketing segment purchases motor fuel from independent refiners and major oil companies and supplies it to independently operated dealer stations, distributors and other consumer of motor fuel, and partnership operated stations, as well as to commission agent locations. The All Other segment operates retail stores that offer motor fuel, merchandise, foodservice, and other services that include car washes, lottery, automated teller machines, money orders, prepaid phone cards, and wireless services. It also leases and rents real estate properties. Sunoco GP LLC serves as the general partner of the company. The company was formerly known as Susser Petroleum Partners LP and changed its name to Sunoco LP in October 2014. Sunoco LP was incorporated in 2012 and is headquartered in Dallas, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1979129165, "total_enterprise": 5579129165, "number_of_employees": null, "outstanding_shares": 83017163, "eps": 2.839689, "diluted_eps": 2.82, "earnings_from_cont_operations": 313000000, "gross_profit": 1224000000, "cash": 21000000, "total_debt": 3621000000, "total_revenue": 16596000000, "cash_from_operations": 435000000, "net_income": 313000000, "ebitda": 723000000, "year_low_stock_price": 10.46, "year_high_stock_price": 34.09, "image_position": [7648, 0, 128, 81]}, {"symbol": "ENSG", "name": "The Ensign Group, Inc.", "next_earnings_utc": 1589228400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 582728500.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.6125, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "ensigngroup.net", "year_founded": 1999, "street_address": "29222 Rancho Viejo Road", "city": "San Juan Capistrano", "state": "CA", "zipcode": "92675", "country": "United States", "phone_number": "949 487 9500", "short_description": "The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses.", "long_description": "The Ensign Group, Inc. provides health care services in the post-acute care continuum and other ancillary businesses. The company offers transitional and skilled services, which include short and long-term nursing care services for patients with chronic conditions, prolonged illness, and the elderly. It also provides standard services, such as room and board, special nutritional program, social, recreational, entertainment, and other services. In addition, the company offers senior living, as well as mobile diagnostics services; leases real estate properties; and provides other ancillary services consisting of digital x-ray, ultrasound, electrocardiogram, laboratory, sub-acute, and patient transportation services to people in their homes or at long-term care facilities. As of December 31, 2019, it operated 223 skilled nursing and senior living facilities in Arizona, California, Colorado, Idaho, Iowa, Kansas, Massachusetts, Nebraska, Nevada, South Carolina, Texas, Utah, Washington, and Wisconsin. The Ensign Group, Inc. was founded in 1999 and is based in San Juan Capistrano, California.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 2006562242, "total_enterprise": 3278446242, "number_of_employees": 24500, "outstanding_shares": 53665746, "eps": 2.067911, "diluted_eps": 1.976614, "earnings_from_cont_operations": 92213000, "gross_profit": 291107000, "cash": 76929000, "total_debt": 1346866000, "total_revenue": 2036524000, "cash_from_operations": 192223000, "net_income": 110534000, "ebitda": 178253000, "year_low_stock_price": 24.06, "year_high_stock_price": 58.92, "image_position": [7728, 0, 80, 80]}, {"symbol": "CBT", "name": "Cabot Corporation", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 752325690.0, "next_earnings_eps_num_analysts": 9, "next_earnings_eps_consensus": 0.69474, "eps_up_revisions": 0, "eps_down_revisions": 8, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 10, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "cabotcorp.com", "year_founded": 1882, "street_address": "Two Seaport Lane", "city": "Boston", "state": "MA", "zipcode": "02210-2019", "country": "United States", "phone_number": "617-345-0100", "short_description": "Cabot Corporation operates as a specialty chemicals and performance materials company.", "long_description": "Cabot Corporation operates as a specialty chemicals and performance materials company. The company offers rubber grade carbon blacks used in tires as a rubber reinforcing agent and performance additive, as well as in industrial products, such as hoses, belts, extruded profiles, and molded goods; and compounds of carbon black and rubber. It also provides specialty grades of carbon black used in inks, coatings, plastics, adhesives, toners, batteries, and displays applications; masterbatch and conductive compound products for use in automotive, industrial, packaging, infrastructure, agriculture, consumer products, and electronics industries; inkjet colorants used in the inkjet printing applications; fumed silica used in adhesives, sealants, cosmetics, batteries, inks, toners, silicone elastomers, coatings, polishing slurries, and pharmaceuticals; fumed alumina used in various products, including inkjet media, lighting, coatings, cosmetics, and polishing slurries; and aerogel, a hydrophobic, silica-based particle for use in various thermal insulation and specialty chemical applications. In addition, the company offers activated carbon products used for the purification of water, air, food and beverages, pharmaceuticals, and other liquids and gases; and activated carbon solutions for activated carbon injection in coal-fired utilities, mobile water filter units, and carbon reactivation services. Cabot Corporation sells its products primarily through distributors and sales representatives in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. Cabot Corporation was founded in 1882 and is headquartered in Boston, Massachusetts.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1841520106, "total_enterprise": 3007520106, "number_of_employees": 4500, "outstanding_shares": 56679597, "eps": 2.191544, "diluted_eps": 2.171994, "earnings_from_cont_operations": 155000000, "gross_profit": 667000000, "cash": 173000000, "total_debt": 1214000000, "total_revenue": 3243000000, "cash_from_operations": 507000000, "net_income": 129000000, "ebitda": 485000000, "year_low_stock_price": 20.0, "year_high_stock_price": 50.58, "image_position": [7856, 0, 128, 35]}, {"symbol": "CLF", "name": "Cleveland-Cliffs Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 366230750.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.17329, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 7, "analysts_underperform": 0, "webpage": "clevelandcliffs.com", "year_founded": 1847, "street_address": "200 Public Square", "city": "Cleveland", "state": "OH", "zipcode": "44114", "country": "United States", "phone_number": "216-694-5700", "short_description": "Cleveland-Cliffs Inc. operates as an iron ore mining company in the United States, Canada, and internationally.", "long_description": "Cleveland-Cliffs Inc. operates as an iron ore mining company in the United States, Canada, and internationally. The company operates four iron ore mines, including the Tilden mine in Michigan; and the Northshore, United Taconite, and Hibbing mines in Minnesota. It serves integrated steel companies and steel producers. The company was formerly known as Cliffs Natural Resources Inc. and changed its name to Cleveland-Cliffs Inc. in August 2017. Cleveland-Cliffs Inc. was founded in 1847 and is headquartered in Cleveland, Ohio.", "industry_name": "Metals and Mining", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1921318371, "total_enterprise": 3741318371, "number_of_employees": 2372, "outstanding_shares": 398613770, "eps": 1.057952, "diluted_eps": 1.034024, "earnings_from_cont_operations": 294500000, "gross_profit": 575700000, "cash": 352600000, "total_debt": 2172600000, "total_revenue": 1989900000, "cash_from_operations": 562500000, "net_income": 292800000, "ebitda": 520300000, "year_low_stock_price": 2.63, "year_high_stock_price": 11.61, "image_position": [7984, 0, 128, 128]}, {"symbol": "GDOT", "name": "Green Dot Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 10, "next_earnings_revenue_consensus": 324123380.0, "next_earnings_eps_num_analysts": 12, "next_earnings_eps_consensus": 0.931, "eps_up_revisions": 4, "eps_down_revisions": 5, "revenue_up_revisions": 2, "revenue_down_revisions": 5, "total_analysts": 16, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 2, "analysts_hold": 9, "analysts_underperform": 0, "webpage": "greendot.com", "year_founded": 1999, "street_address": "3465 East Foothill Boulevard", "city": "Pasadena", "state": "CA", "zipcode": "91107", "country": "United States", "phone_number": "626-765-2000", "short_description": "Green Dot Corporation operates as a financial technology and bank holding company in the United States.", "long_description": "Green Dot Corporation operates as a financial technology and bank holding company in the United States. It operates in two segments, Account Services, and Processing and Settlement Services. The company offers deposit account programs, such network-branded reloadable prepaid debit cards under the consumer brand names of GPR cards, consumer and small business checking accounts, network-branded gift cards, secured credit cards, and other financial services. It also provides swipe reload system for crediting cash onto an enabled payment card by swiping the payment card at the point-of-sale through Green Dot Network participating retailer; MoneyPak, a product that allows a consumer to add funds to accounts; and e-cash remittance, a service that allows a consumer to transfer funds to a smartphone, as well as offers disbursement services through Simply Paid platform. In addition, the company offers prepaid cards, debit cards, payroll debit cards, consumer cash processing services, wage disbursements, and tax refund processing services, as well as issuing, settlement, and capital management services. Further, it provides mobile banking, loan disbursement accounts, mobile P2P, money transfer, instant payment, and processing and settlement services. The company markets its products under the brand names of Green Dot, GoBank, MoneyPak, AccountNow, RushCard, and RapidPay. Green Dot Corporation markets and sells its products and services through retail stores, various direct-to-consumer Websites, corporate distribution partnerships, tax preparation companies and individual tax preparers, and apps, as well as distributes through \u2018Banking as a Service\u2019 platform. The company was formerly known as Next Estate Communications, Inc. and changed its name to Green Dot Corporation in October 2005. Green Dot Corporation was incorporated in 1999 and is headquartered in Pasadena, California.", "industry_name": "Consumer Finance", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1666507909, "total_enterprise": 661650909, "number_of_employees": 1200, "outstanding_shares": 52905013, "eps": 1.913918, "diluted_eps": 1.88, "earnings_from_cont_operations": 99897000, "gross_profit": 907921000, "cash": 1073446000, "total_debt": 68589000, "total_revenue": 1108595000, "cash_from_operations": 189914000, "net_income": 99897000, "ebitda": 168635000, "year_low_stock_price": 14.2, "year_high_stock_price": 51.86, "image_position": [8112, 0, 128, 128]}, {"symbol": "INO", "name": "Inovio Pharmaceuticals, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 1912500.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.225, "eps_up_revisions": 2, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "inovio.com", "year_founded": 1979, "street_address": "660 West Germantown Pike", "city": "Plymouth Meeting", "state": "PA", "zipcode": "19462", "country": "United States", "phone_number": "267-440-4200", "short_description": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases.", "long_description": "Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of DNA medicines to treat, cure, and protect people from diseases associated with human papillomavirus (HPV), cancer, and infectious diseases. Its SynCon immunotherapy design has the ability to break the immune system's tolerance of cancerous cells and facilitate cross-strain protection against unmatched and matched pathogens. The company is involved in conducting and planning clinical studies of its DNA medicines for HPV-associated precancers, including cervical, vulvar, and anal dysplasia; HPV-associated cancers, including head and neck, cervical, anal, penile, vulvar, and vaginal; other HPV-associated disorders, such as recurrent respiratory papillomatosis; glioblastoma multiforme; prostate cancer; HIV; Ebola; Middle East Respiratory Syndrome (MERS); Lassa fever; Zika virus; and the COVID-19 virus (coronavirus). Its partners and collaborators include ApolloBio Corp., AstraZeneca PLC or AstraZeneca, Beijing Advaccine Biotechnology Co., The Bill & Melinda Gates Foundation, Coalition for Epidemic Preparedness Innovations (CEPI), Defense Advanced Research Projects Agency (DARPA), GeneOne Life Science, HIV Vaccines Trial Network, the U.S. Defense Threat Reduction Agency's Medical CBRN Defense Consortium (MCDC), National Cancer Institute, National Institutes of Health, National Institute of Allergy and Infectious Diseases, Plumbline Life Sciences, Regeneron Pharmaceuticals, Roche/Genentech, the University of Pennsylvania, the Walter Reed Army Institute of Research, and The Wistar Institute. Inovio Pharmaceuticals, Inc. was founded in 1979 and is headquartered in Plymouth Meeting, Pennsylvania.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1582551622, "total_enterprise": 1594494948, "number_of_employees": 190, "outstanding_shares": 145790108, "eps": -1.209092, "diluted_eps": -1.21, "earnings_from_cont_operations": -120551777, "gross_profit": -82005389, "cash": 89534114, "total_debt": 99507681, "total_revenue": 4111930, "cash_from_operations": -97850136, "net_income": -119359219, "ebitda": -104543863, "year_low_stock_price": 1.92, "year_high_stock_price": 19.36, "image_position": [8240, 0, 128, 128]}, {"symbol": "ERI", "name": "Eldorado Resorts, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 542447670.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.12302, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "eldoradoresorts.com", "year_founded": 1973, "street_address": "100 West Liberty Street", "city": "Reno", "state": "NV", "zipcode": "89501", "country": "United States", "phone_number": "775-328-0100", "short_description": "Eldorado Resorts, Inc. operates as a gaming and hospitality company in the United States.", "long_description": "Eldorado Resorts, Inc. operates as a gaming and hospitality company in the United States. It owns and operates Eldorado Resort Casino Reno, a hotel, casino, and entertainment facility; Silver Legacy Resort Casino, a casino, race, sportsbook, restaurant, an outdoor swimming pool, sundeck, and retail shop; Circus Circus Reno, a circus-themed hotel-casino and entertainment complex; Eldorado Resort Casino Shreveport, a hotel and tri-level riverboat casino; and Eldorado Gaming Scioto Downs, a modern racino. The company also operates Isle Casino Hotel\u00e2\u20ac\u201dBlack Hawk and Lady Luck Casino\u00e2\u20ac\u201dBlack Hawk; Isle Casino Racing Pompano Park, a casino and harness racing track; Isle Casino Bettendorf, a land-based casino; Isle Casino Waterloo, a single-level land-based casino; Isle of Capri Casino Hotel Lake Charles, a dockside casino, dining venue, and entertainment center; Isle of Capri Casino Lula, a two dockside casino; Lady Luck Casino Vicksburg and Isle of Capri Casino Kansas City, a dockside casinos; and Isle of Capri Casino Boonville, a single-level dockside casino. In addition, it operates Tropicana Casino and Resort, Atlantic City; Tropicana Evansville, a casino hotel and entertainment complex; Lumiere Place Casino, Tropicana Laughlin Hotel and Casino, MontBleu Casino Resort & Spa, and Grand Victoria Casino; Trop Casino Greenville, a land-based gaming facility; and Belle of Baton Rouge Casino & Hotel, a dockside riverboat. As of March 17, 2020, the company owned 23 gaming facilities with approximately 23,900 slot machines, video lottery terminals, and e-tables; 660 table games; and 11,300 hotel rooms. Eldorado Resorts, Inc. was founded in 1973 and is based in Reno, Nevada.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1640736431, "total_enterprise": 5137943431, "number_of_employees": 15500, "outstanding_shares": 77796891, "eps": 1.042789, "diluted_eps": 1.03, "earnings_from_cont_operations": 81001000, "gross_profit": 1342100000, "cash": 240951000, "total_debt": 3738158000, "total_revenue": 2528249000, "cash_from_operations": 312526000, "net_income": 81001000, "ebitda": 669980000, "year_low_stock_price": 6.02, "year_high_stock_price": 70.74, "image_position": [8368, 0, 128, 31]}, {"symbol": "PSEC", "name": "Prospect Capital Corporation", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 132870000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.14, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 1, "webpage": "prospectstreet.com", "year_founded": 2004, "street_address": "10 East 40th Street", "city": "New York", "state": "NY", "zipcode": "10016", "country": "United States", "phone_number": "212-448-0702", "short_description": "Prospect Capital Corporation is a business development company.", "long_description": "Prospect Capital Corporation is a business development company. It specializes in middle market, mature, mezzanine finance, later stage, emerging growth, leveraged buyouts, refinancing, acquisitions, recapitalizations, turnaround, growth capital, development, capital expenditures and subordinated debt tranches of collateralized loan obligations, cash flow term loans, market place lending and bridge transactions. It also makes real estate investments particularly in multi-family residential real estate asset class. The fund makes secured debt, senior debt, senior and secured term loans, unitranche debt, first-lien and second lien, private debt, private equity, mezzanine debt, and equity investments in private and microcap public businesses. It focuses on both primary origination and secondary loans/portfolios and invests in situations like debt financings for private equity sponsors, acquisitions, dividend recapitalizations, growth financings, bridge loans, cash flow term loans, real estate financings/investments. It also focuses on investing in small-sized and medium-sized private companies rather than large public companies. The fund typically invests across all industry sectors, with a particular expertise in the energy and industrial sectors. It invests in aerospace and defense, chemicals, conglomerate services, consumer services, ecological, electronics, financial services, machinery, manufacturing, media, pharmaceuticals, retail, software, specialty minerals, textiles and leather, transportation, oil and gas production, coal production, materials, industrials, consumer discretionary, information technology, utilities, pipeline, storage, power generation and distribution, renewable and clean energy, oilfield services, healthcare, food and beverage, education, business services, and other select sectors. It prefers to invest in the United States and Canada. The fund seeks to invest between $10 million to $500 million per transaction in companies with EBITDA between $5 million and $150 million, sales value between $25 million and $500 million, and enterprise value between $5 million and $1000 million. It fund also co-invests for larger deals. The fund seeks control acquisitions by providing multiple levels of the capital structure. The fund focuses on sole, agented, club, or syndicated deals.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 1498858048, "total_enterprise": 3501625048, "number_of_employees": null, "outstanding_shares": 367817926, "eps": 0.367626, "diluted_eps": 0.367626, "earnings_from_cont_operations": 134943000, "gross_profit": 659262000, "cash": 137867000, "total_debt": 2140634000, "total_revenue": 659262000, "cash_from_operations": 714787000, "net_income": 134943000, "ebitda": null, "year_low_stock_price": 3.68, "year_high_stock_price": 6.87, "image_position": [8448, 0, 80, 80]}, {"symbol": "MGLN", "name": "Magellan Health, Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 1780817000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.30333, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "magellanhealth.com", "year_founded": 1969, "street_address": "4801 East Washington Street", "city": "Phoenix", "state": "AZ", "zipcode": "85034", "country": "United States", "phone_number": "800-642-1716", "short_description": "Magellan Health, Inc. provides healthcare management services in the United States.", "long_description": "Magellan Health, Inc. provides healthcare management services in the United States. The company operates in Healthcare and Pharmacy Management segments. The Healthcare segment offers carve-out management services for behavioral health; employee assistance plans (EAP); and other areas of specialty healthcare, including diagnostic imaging, musculoskeletal management, cardiac, and physical medicine. It also contracts with state Medicaid agencies, and the centers for Medicare and Medicaid services to manage care for beneficiaries under Medicaid and Medicare programs, such as healthcare and long-term support services through its network of medical and behavioral health professionals, clinics, hospitals, nursing facilities, home care agencies, and ancillary service providers. The Pharmacy Management segment comprises products and solutions that provide clinical and financial management of pharmaceuticals paid under medical and pharmacy benefit programs. It offers pharmacy benefit management services, such as pharmaceutical dispensing services; pharmacy benefit administration for state Medicaid and other government sponsored programs; clinical and formulary management programs; medical pharmacy management programs; and programs for the integrated management of specialty drugs that treat complex conditions. The company provides services to health plans and other managed care organizations, employers, labor unions, various military and governmental agencies, and third party administrators. Magellan Health, Inc. was founded in 1969 and is based in Phoenix, Arizona.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1552823975, "total_enterprise": 2099248975, "number_of_employees": 10100, "outstanding_shares": 24969030, "eps": 2.305902, "diluted_eps": 2.28, "earnings_from_cont_operations": 55902000, "gross_profit": 227166000, "cash": 194819000, "total_debt": 741244000, "total_revenue": 7159423000, "cash_from_operations": 115846000, "net_income": 55902000, "ebitda": 180466000, "year_low_stock_price": 30.6, "year_high_stock_price": 81.04, "image_position": [8576, 0, 128, 47]}, {"symbol": "GECC", "name": "Great Elm Capital Corporation", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 6904500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.245, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "greatelmcc.com", "year_founded": 2016, "street_address": "200 Clarendon Street", "city": "Boston", "state": "MA", "zipcode": "02116", "country": "United States", "phone_number": "617-375-3000", "short_description": "Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments.", "long_description": "Great Elm Capital Corporation is a business development company which specializes in loan and mezzanine, middle market investments. The fund prefers to invest in media, commercial services and supplies, healthcare, telecommunication services, communications equipment. It typically makes equity investments between $3 million and $10 million in companies with revenues between $3 million and $75 million.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 32200582, "total_enterprise": 147507209, "number_of_employees": null, "outstanding_shares": 10062682, "eps": -0.736322, "diluted_eps": -0.736322, "earnings_from_cont_operations": -7547000, "gross_profit": 27038000, "cash": 4606000, "total_debt": 119812000, "total_revenue": 27038000, "cash_from_operations": -24474000, "net_income": -7547000, "ebitda": null, "year_low_stock_price": 2.25, "year_high_stock_price": 9.05, "image_position": [8704, 0, 128, 128]}, {"symbol": "VRRM", "name": "Verra Mobility Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 102007040.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.01742, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "verramobility.com", "year_founded": null, "street_address": "1150 North Alma School Road", "city": "Mesa", "state": "AZ", "zipcode": "85201", "country": "United States", "phone_number": "480 443 7000", "short_description": "Verra Mobility Corporation provides smart mobility technology solutions and services in the United States, Canada, and Europe.", "long_description": "Verra Mobility Corporation provides smart mobility technology solutions and services in the United States, Canada, and Europe. It operates through two segments, Government Solutions and Commercial Services. The Government Solutions segment offers automated safety solutions, including services and technologies that enable photo enforcement through road safety camera programs, which detects and process traffic violations related to red light, speed, school bus, and city bus lanes. This segment serves municipalities, counties, school districts, and law enforcement agencies. The Commercial Services segment provides automated toll and violations management, and title and registration solutions to rental car companies, fleet management companies, and other large fleet owners. The company is headquartered in Mesa, Arizona.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1463317477, "total_enterprise": 2227727477, "number_of_employees": 779, "outstanding_shares": 161692539, "eps": 0.211178, "diluted_eps": 0.21, "earnings_from_cont_operations": 33343000, "gross_profit": 303617000, "cash": 135155000, "total_debt": 899565000, "total_revenue": 448737000, "cash_from_operations": 133802000, "net_income": 33343000, "ebitda": 216837000, "year_low_stock_price": 5.63, "year_high_stock_price": 17.2, "image_position": [8832, 0, 128, 128]}, {"symbol": "GBDC", "name": "Golub Capital BDC", "next_earnings_utc": 1589200200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 84327750.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.3325, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 3, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "golubcapitalbdc.com", "year_founded": 2009, "street_address": null, "city": "Chicago", "state": "IL", "zipcode": null, "country": "United States", "phone_number": null, "short_description": "Golub Capital BDC, Inc. is a business development company and operates as an externally managed closed-end non-diversified management investment company.", "long_description": "Golub Capital BDC, Inc. is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. The company seeks to invest in the United States. It primarily invests in senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 1445102251, "total_enterprise": 3750902251, "number_of_employees": null, "outstanding_shares": 133805764, "eps": 0.122981, "diluted_eps": 0.122981, "earnings_from_cont_operations": 10030000, "gross_profit": 211494000, "cash": 19426000, "total_debt": 2325226000, "total_revenue": 211494000, "cash_from_operations": -114745000, "net_income": 10030000, "ebitda": null, "year_low_stock_price": 8.94, "year_high_stock_price": 18.85, "image_position": [8960, 0, 128, 128]}, {"symbol": "PTLA", "name": "Portola Pharmaceuticals, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 33878500.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.72014, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "portola.com", "year_founded": 2003, "street_address": "270 East Grand Avenue", "city": "South San Francisco", "state": "CA", "zipcode": "94080", "country": "United States", "phone_number": "650 246 7000", "short_description": "Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States.", "long_description": "Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes novel therapeutics in the areas of thrombosis, and other hematologic disorders and inflammation in Europe and the United States. Its lead product Andexxa, an antidote for the treatment of rivaroxaban and apixaban under the Ondexxya Brand. The company offers Bevyxxa (betrixaban), an oral, once-daily Factor Xa inhibitor for the prevention of venous thromboembolism in adult patients for an acute medical illness. It also develops cerdulatinib, an investigational oral, dual spleen tyrosine kinase, and janus kinases inhibitor for the treatment of hematologic cancers; and Syk inhibitors. Portola Pharmaceuticals, Inc. has collaboration agreements with Bristol-Myers Squibb; Pfizer Inc.; Daiichi Sankyo, Inc.; Bayer Pharma, AG; Takeda, Ora, Inc.; Astellas Pharma Inc.; and Janssen Pharmaceuticals, Inc. The company was founded in 2003 and is headquartered in South San Francisco, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1404874644, "total_enterprise": 1332283644, "number_of_employees": 408, "outstanding_shares": 78484617, "eps": -4.062079, "diluted_eps": -4.062079, "earnings_from_cont_operations": -292876000, "gross_profit": -21763000, "cash": 429283000, "total_debt": 356692000, "total_revenue": 116640000, "cash_from_operations": -237923000, "net_income": -290663000, "ebitda": -237682000, "year_low_stock_price": 5.31, "year_high_stock_price": 32.11, "image_position": [9088, 0, 128, 128]}, {"symbol": "IPAR", "name": "Inter Parfums, Inc.", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 157847500.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.42959, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 6, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "interparfumsinc.com", "year_founded": 1982, "street_address": "551 Fifth Avenue", "city": "New York", "state": "NY", "zipcode": "10176", "country": "United States", "phone_number": "212 983 2640", "short_description": "Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products.", "long_description": "Inter Parfums, Inc., together with its subsidiaries, manufactures, markets, and distributes a range of fragrances and fragrance related products. The company operates in two segments, European Based Operations and United States Based Operations. It offers its fragrance and cosmetic products under the Boucheron, Coach, Jimmy Choo, Karl Lagerfeld, Kate Spade New York, Lanvin, Montblanc, Paul Smith, Repetto, Rochas, S.T. Dupont, Van Cleef & Arpels, Abercrombie & Fitch, Anna Sui, bebe, Dunhill, Hollister, French Connection, Graff, GUESS, Lily Aldridge, MCM, and Oscar de la Renta brand names, as well as under the Intimate and Aziza names. It sells its products to department stores, perfumeries, specialty stores, domestic and international wholesalers, and distributors. The company was formerly known as Jean Philippe Fragrances, Inc. and changed its name to Inter Parfums, Inc. in July 1999. Inter Parfums, Inc. was founded in 1982 and is headquartered in New York, New York.", "industry_name": "Personal Products", "sector_name": "Consumer Staples", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1401886844, "total_enterprise": 1342800844, "number_of_employees": 402, "outstanding_shares": 31531418, "eps": 1.91564, "diluted_eps": 1.9, "earnings_from_cont_operations": 76070000, "gross_profit": 392936000, "cash": 253131000, "total_debt": 53051000, "total_revenue": 713514000, "cash_from_operations": 76452000, "net_income": 60249000, "ebitda": 113456000, "year_low_stock_price": 34.2, "year_high_stock_price": 81.4, "image_position": [9216, 0, 128, 128]}, {"symbol": "UNIT", "name": "Uniti Group Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 265640330.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": -0.17286, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 2, "revenue_down_revisions": 2, "total_analysts": 8, "analysts_sell": 2, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "uniti.com", "year_founded": 2014, "street_address": "Benton Building", "city": "Little Rock", "state": "AR", "zipcode": "72211", "country": "United States", "phone_number": "501-850-0820", "short_description": "Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of wireless infrastructure solutions for the communications industry.", "long_description": "Uniti, an internally managed real estate investment trust, is engaged in the acquisition and construction of mission critical communications infrastructure, and is a leading provider of wireless infrastructure solutions for the communications industry. As of December 31, 2019, Uniti owns 6.3 million fiber strand miles, approximately 670 wireless towers, and other communications real estate throughout the United States.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1436897797, "total_enterprise": 6600019797, "number_of_employees": 899, "outstanding_shares": 194175378, "eps": 0.044748, "diluted_eps": 0.04, "earnings_from_cont_operations": 10908000, "gross_profit": 853879000, "cash": 142813000, "total_debt": 5222231000, "total_revenue": 1057611000, "cash_from_operations": 616982000, "net_income": 10582000, "ebitda": 750979000, "year_low_stock_price": 4.86, "year_high_stock_price": 11.85, "image_position": [9276, 0, 60, 60]}, {"symbol": "CDLX", "name": "Cardlytics, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 42969030.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.222, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 1, "webpage": "cardlytics.com", "year_founded": 2008, "street_address": "675 Ponce de Leon Avenue NE", "city": "Atlanta", "state": "GA", "zipcode": "30308", "country": "United States", "phone_number": "888 798 5802", "short_description": "Cardlytics, Inc. operates an advertising platform within financial institutions digital channels, which include online, mobile, email, and various real-time notifications in the United States and the United Kingdom.", "long_description": "Cardlytics, Inc. operates an advertising platform within financial institutions digital channels, which include online, mobile, email, and various real-time notifications in the United States and the United Kingdom. It operates in two segments, Cardlytics Direct and Other Platform Solutions. The company's platform is the Cardlytics Direct solution, a native bank advertising channel that enables marketers to reach consumers through their trusted and frequently visited online and mobile banking channels. It also provides solutions that enable marketers and marketing service providers to leverage the power of purchase intelligence outside the banking channel. The company was founded in 2008 and is headquartered in Atlanta, Georgia.", "industry_name": "Media", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1365591517, "total_enterprise": 1261170517, "number_of_employees": 432, "outstanding_shares": 26956011, "eps": -0.721974, "diluted_eps": -0.721974, "earnings_from_cont_operations": -17144000, "gross_profit": 79457000, "cash": 104458000, "total_debt": 37000, "total_revenue": 210430000, "cash_from_operations": 11457000, "net_income": -17144000, "ebitda": -12790000, "year_low_stock_price": 16.51, "year_high_stock_price": 107.5, "image_position": [9404, 0, 128, 128]}, {"symbol": "EPRT", "name": "Essential Properties Realty Trust, Inc.", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 41961700.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.16, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 2, "total_analysts": 12, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 2, "webpage": "essentialproperties.com", "year_founded": 2016, "street_address": "902 Carnegie Center Boulevard", "city": "Princeton", "state": "NJ", "zipcode": "08540", "country": "United States", "phone_number": "609-436-0619", "short_description": "Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States.", "long_description": "Essential Properties Realty Trust, Inc., a real estate company, acquires, owns, and manages single-tenant properties in the United States. The company leases its properties to middle-market companies, such as restaurants, car washes, automotive services, medical services, convenience stores, entertainment, early childhood education, and health and fitness on a long-term basis. As of December 31, 2019, it had a portfolio of 1000 properties. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was founded in 2016 and is based in Princeton, New Jersey.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1218209211, "total_enterprise": 1954917211, "number_of_employees": 27, "outstanding_shares": 91457148, "eps": 0.64506, "diluted_eps": 0.631152, "earnings_from_cont_operations": 48025000, "gross_profit": 136287000, "cash": 9399000, "total_debt": 738444000, "total_revenue": 139357000, "cash_from_operations": 88568000, "net_income": 41844000, "ebitda": 117524000, "year_low_stock_price": 6.08, "year_high_stock_price": 29.34, "image_position": [9532, 0, 128, 128]}, {"symbol": "AIMT", "name": "Aimmune Therapeutics, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 10, "next_earnings_revenue_consensus": 1344400.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": -1.1775, "eps_up_revisions": 0, "eps_down_revisions": 6, "revenue_up_revisions": 1, "revenue_down_revisions": 6, "total_analysts": 11, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 3, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "aimmune.com", "year_founded": 2011, "street_address": "8000 Marina Boulevard", "city": "Brisbane", "state": "CA", "zipcode": "94005", "country": "United States", "phone_number": "650-614-5220", "short_description": "Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies.", "long_description": "Aimmune Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and commercializes product candidates for the treatment of peanut and other food allergies. Its lead Characterized Oral Desensitization ImmunoTherapy (CODIT) product candidate is AR101, an investigational biologic, which is in Phase III clinical trial for the treatment of patients with peanut allergy. The company also engages in the research and development of AR201, a CODIT product candidate for the treatment of egg allergy in pediatric and young adult patients; and other CODIT product candidates targeting food allergies, such as cow\u00e2\u20ac\u2122s milk allergy. Aimmune Therapeutics, Inc. has a strategic collaboration with an affiliate of Nestle Health Science US Holdings, Inc. for the advancement of food allergy therapeutics; and clinical collaboration agreement with Regeneron Ireland Unlimited Company and Sanofi Biotechnology SAS to study AR101 with adjunctive dupilumab in peanut-allergic patients in a Phase II trial. The company was formerly known as Allergen Research Corporation and changed its name to Aimmune Therapeutics, Inc. in May 2015. Aimmune Therapeutics, Inc. was founded in 2011 and is headquartered in Brisbane, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1145314422, "total_enterprise": 1055671422, "number_of_employees": 275, "outstanding_shares": 65222917, "eps": -3.972265, "diluted_eps": -3.972265, "earnings_from_cont_operations": -248497000, "gross_profit": null, "cash": 143513000, "total_debt": 53870000, "total_revenue": null, "cash_from_operations": -195408000, "net_income": -248497000, "ebitda": -245718000, "year_low_stock_price": 10.09, "year_high_stock_price": 37.0, "image_position": [9660, 0, 128, 128]}, {"symbol": "AMRX", "name": "Amneal Pharmaceuticals, Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 446122220.0, "next_earnings_eps_num_analysts": 10, "next_earnings_eps_consensus": 0.08961, "eps_up_revisions": 2, "eps_down_revisions": 4, "revenue_up_revisions": 2, "revenue_down_revisions": 0, "total_analysts": 11, "analysts_sell": 1, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 8, "analysts_underperform": 1, "webpage": "amneal.com", "year_founded": 2002, "street_address": "400 Crossing Boulevard", "city": "Bridgewater", "state": "NJ", "zipcode": "08807", "country": "United States", "phone_number": "908 947 3120", "short_description": "Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas.", "long_description": "Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, licenses, manufactures, markets, and distributes generic and specialty pharmaceutical products for various dosage forms and therapeutic areas. The company operates in two segments, Generics and Specialty. The Generics segment develops, manufactures, and commercializes complex oral solids, injectables, ophthalmics, liquids, topicals, softgels, inhalation products, and transdermals across a range of therapeutic categories. The Specialty segment is involved in the development, manufacture, and sale of branded pharmaceutical products primarily for central nervous system disorders, endocrinology, parasitic infections, and other therapeutic areas. It also offers licensed and owned, niche, and mature branded products, as well as Rytary for the treatment of Parkinsons Disease; Zomig for the treatment of migraine headaches; Emverm a chewable tablets for the treatment of pinworm, whipworm, common roundworm, common hookworm, and American hookworm in single or mixed infections; and Unithroid for the treatment of hypothyroidism. The company sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. It has operations in the United States, India, Ireland, and internationally. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is based in Bridgewater, New Jersey.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 522918695, "total_enterprise": 3251443695, "number_of_employees": 5500, "outstanding_shares": 147301041, "eps": -2.739595, "diluted_eps": -2.739595, "earnings_from_cont_operations": -603573000, "gross_profit": 496921000, "cash": 152320000, "total_debt": 2766067000, "total_revenue": 1626373000, "cash_from_operations": 1705000, "net_income": -361917000, "ebitda": 262902000, "year_low_stock_price": 2.27, "year_high_stock_price": 12.05, "image_position": [9740, 0, 80, 80]}, {"symbol": "NVAX", "name": "Novavax, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 1931600.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.71167, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 1, "webpage": "novavax.com", "year_founded": 1987, "street_address": "21 Firstfield Road", "city": "Gaithersburg", "state": "MD", "zipcode": "20878", "country": "United States", "phone_number": "240 268 2000", "short_description": "Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases.", "long_description": "Novavax, Inc., together with its subsidiary, Novavax AB, a late-stage biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases. The company's lead vaccine candidates include ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate that in Phase III clinical trial to protect infants from RSV disease through maternal immunization; and NanoFlu, which is in Phase III clinical trial for treating seasonal influenza in older adults. Its lead adjuvant is Matrix-M that is used to enable a vaccine to enhance the amplitude of the immune response and qualitatively change it, and the immune systems attack against microorganisms, as well as to allow immunization with much lower doses of antigen. The company is also developing RSV F vaccine for older adults (60 years and older) that is in Phase II clinical trial, as well as for healthy children between six months to five years of age that is in Phase I clinical trial. In addition, it develops nanoparticle vaccine candidates for clinic testing against ebola virus that is in Phase I clinical trial; and combination respiratory vaccine to protect against influenza and RSV. Further, the company is developing COVID-19 vaccine for coronavirus that causes pneumonia-like symptoms, which is in preclinical stage. Novavax, Inc. was founded in 1987 and is headquartered in Gaithersburg, Maryland.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 964256080, "total_enterprise": 1217310080, "number_of_employees": 168, "outstanding_shares": 51481905, "eps": -5.505975, "diluted_eps": -5.505975, "earnings_from_cont_operations": -132694000, "gross_profit": -95180000, "cash": 78823000, "total_debt": 331877000, "total_revenue": 18662000, "cash_from_operations": -136623000, "net_income": -132694000, "ebitda": -123921000, "year_low_stock_price": 3.54, "year_high_stock_price": 26.34, "image_position": [9868, 0, 128, 128]}, {"symbol": "VCTR", "name": "Victory Capital Holdings, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 204034680.0, "next_earnings_eps_num_analysts": 12, "next_earnings_eps_consensus": 0.8911, "eps_up_revisions": 0, "eps_down_revisions": 9, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 12, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 5, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "vcm.com", "year_founded": 2013, "street_address": "4900 Tiedeman Road", "city": "Brooklyn", "state": "OH", "zipcode": "44144", "country": "United States", "phone_number": "216-898-2400", "short_description": "Victory Capital Holdings, Inc., together with its subsidiaries, operates as an independent investment management company in the United States.", "long_description": "Victory Capital Holdings, Inc., together with its subsidiaries, operates as an independent investment management company in the United States. It offers investment advisory, fund administration, and distribution services through broker-dealers, retirement platforms, and registered investment advisor networks. As of December 31, 2018, its franchises and solutions platform managed a set of 71 investment strategies for a range of institutional and retail clients. The company was founded in 2013 and is headquartered in Brooklyn, Ohio.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1052406525, "total_enterprise": 1939824525, "number_of_employees": 358, "outstanding_shares": 70726245, "eps": 1.367886, "diluted_eps": 1.26, "earnings_from_cont_operations": 92491000, "gross_profit": 287563000, "cash": 37121000, "total_debt": 924539000, "total_revenue": 612373000, "cash_from_operations": 227384000, "net_income": 92491000, "ebitda": 245244000, "year_low_stock_price": 10.18, "year_high_stock_price": 24.83, "image_position": [9982, 0, 114, 114]}, {"symbol": "SVC", "name": "Service Properties Trust", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 481230500.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.05, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "svcreit.com", "year_founded": 1995, "street_address": "Two Newton Place", "city": "Newton", "state": "MA", "zipcode": "02458", "country": "United States", "phone_number": "617-964-8389", "short_description": "Service Properties Trust is a real estate investment trust, or REIT, which owns a diverse portfolio of hotels and net lease service and necessity-based retail properties across the United States and in Puerto Rico and Canada with 151 distinct brands across 24 industries.", "long_description": "Service Properties Trust is a real estate investment trust, or REIT, which owns a diverse portfolio of hotels and net lease service and necessity-based retail properties across the United States and in Puerto Rico and Canada with 151 distinct brands across 24 industries. SVC's properties are primarily operated under long-term management or lease agreements. SVC is managed by the operating subsidiary of The RMR Group Inc. (Nasdaq: RMR), or RMR Inc., an alternative asset management company that is headquartered in Newton, Massachusetts.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1072972908, "total_enterprise": 7182926908, "number_of_employees": 125, "outstanding_shares": 164566397, "eps": 1.580834, "diluted_eps": 1.58, "earnings_from_cont_operations": 259750000, "gross_profit": 903426000, "cash": 27633000, "total_debt": 6137587000, "total_revenue": 2316148000, "cash_from_operations": 617722000, "net_income": 259750000, "ebitda": 840430000, "year_low_stock_price": 3.59, "year_high_stock_price": 26.64, "image_position": [10110, 0, 128, 128]}, {"symbol": "KAMN", "name": "Kaman Corporation", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 182089670.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.30961, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 1, "webpage": "kaman.com", "year_founded": 1945, "street_address": "1332 Blue Hills Avenue", "city": "Bloomfield", "state": "CT", "zipcode": "06002", "country": "United States", "phone_number": "860 743 7100", "short_description": "Kaman Corporation, together with its subsidiaries, operates in the aerospace, medical, and industrial markets.", "long_description": "Kaman Corporation, together with its subsidiaries, operates in the aerospace, medical, and industrial markets. The company produces and markets aircraft bearings and components; super precision miniature ball bearings; spring energized seals, springs, and contacts; and metallic and composite aero structures for commercial, military, and general aviation fixed and rotary wing aircrafts. It also provides safe and arming solutions for missile and bomb systems for the U.S. and allied militaries; manufactures and supports K-MAX manned and unmanned medium-to-heavy lift helicopters; and restores, modifies, and supports its SH-2G Super Seasprite maritime helicopters. The company operates in North America, Europe, the Middle East, Asia, Oceania, and internationally. Kaman Corporation was founded in 1945 and is headquartered in Bloomfield, Connecticut.", "industry_name": "Trading Companies and Distributors", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1087406320, "total_enterprise": 813411320, "number_of_employees": 2935, "outstanding_shares": 27832258, "eps": 7.51106, "diluted_eps": 7.470024, "earnings_from_cont_operations": 56446000, "gross_profit": 240805000, "cash": 471540000, "total_debt": 206542000, "total_revenue": 761608000, "cash_from_operations": -7800000, "net_income": 209829000, "ebitda": 103858000, "year_low_stock_price": 29.38, "year_high_stock_price": 68.24, "image_position": [10238, 0, 128, 33]}, {"symbol": "DRH", "name": "DiamondRock Hospitality Company", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 156939280.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.07, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 13, "analysts_sell": 3, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 6, "analysts_underperform": 2, "webpage": "drhc.com", "year_founded": 2004, "street_address": "2 Bethesda Metro Center", "city": "Bethesda", "state": "MD", "zipcode": "20814", "country": "United States", "phone_number": "240-744-1150", "short_description": "DiamondRock Hospitality Company is a self-advised real estate investment trust (REIT) that is an owner of a leading portfolio of geographically diversified hotels concentrated in top gateway markets and destination resort locations.", "long_description": "DiamondRock Hospitality Company is a self-advised real estate investment trust (REIT) that is an owner of a leading portfolio of geographically diversified hotels concentrated in top gateway markets and destination resort locations. The Company owns 31 premium quality hotels with over 10,000 rooms. The Company has strategically positioned its hotels to be operated both under leading global brand families as well as unique boutique hotels in the lifestyle segment.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1093007824, "total_enterprise": 2175324824, "number_of_employees": 31, "outstanding_shares": 199818615, "eps": 0.907654, "diluted_eps": 0.9, "earnings_from_cont_operations": 184211000, "gross_profit": 247326000, "cash": 122524000, "total_debt": 1196269000, "total_revenue": 938091000, "cash_from_operations": 193289000, "net_income": 183487000, "ebitda": 217609000, "year_low_stock_price": 1.96, "year_high_stock_price": 11.79, "image_position": [10318, 0, 80, 80]}, {"symbol": "BE", "name": "Bloom Energy Corporation", "next_earnings_utc": 1589228400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 152449800.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.43, "eps_up_revisions": 0, "eps_down_revisions": 4, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 3, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "bloomenergy.com", "year_founded": 2001, "street_address": "4353 North First Street", "city": "San Jose", "state": "CA", "zipcode": "95134", "country": "United States", "phone_number": "408 543 1500", "short_description": "Bloom Energy Corporation designs, manufactures, and sells solid-oxide fuel cell systems for on-site power generation.", "long_description": "Bloom Energy Corporation designs, manufactures, and sells solid-oxide fuel cell systems for on-site power generation. It offers Bloom Energy Server, a stationary power generation platform that converts standard low-pressure natural gas, biogas, or hydrogen into electricity through an electrochemical process without combustion. The company serves banking and financial services, cloud services, technology and data centers, communications and media, consumer packaged goods and consumables, education, government, healthcare, hospitality, logistics, manufacturing, real estate, retail, and utilities industries. It primarily operates in the United States, Japan, China, India, and the Republic of Korea. The company was formerly known as Ion America Corp. and changed its name to Bloom Energy Corporation in September 2006. Bloom Energy Corporation was founded in 2001 and is headquartered in San Jose, California.", "industry_name": "Electrical Equipment", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1038362826, "total_enterprise": 2030484826, "number_of_employees": 1252, "outstanding_shares": 125103955, "eps": -2.665682, "diluted_eps": -2.665682, "earnings_from_cont_operations": -323466000, "gross_profit": 192430000, "cash": 202823000, "total_debt": 1103211000, "total_revenue": 785177000, "cash_from_operations": 163770000, "net_income": -304414000, "ebitda": -83677000, "year_low_stock_price": 2.44, "year_high_stock_price": 14.51, "image_position": [10446, 0, 128, 20]}, {"symbol": "SGMO", "name": "Sangamo Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 24880000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.36, "eps_up_revisions": 3, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 2, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "sangamo.com", "year_founded": 1995, "street_address": "7000 Marina Boulevard", "city": "Brisbane", "state": "CA", "zipcode": "94005", "country": "United States", "phone_number": "510-970-6000", "short_description": "Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation.", "long_description": "Sangamo Therapeutics, Inc., a biotechnology company, focuses on translating science into genomic medicines that transform patients' lives using platform technologies in gene therapy, cell therapy, genome editing, and genome regulation. The company's zinc finger proteins (ZFPs) could be engineered to make zinc finger nucleases (ZFNs), proteins that could be used to modify DNA sequences by adding or knocking out specific genes or genome editing; and ZFP transcription factors (ZFP TFs) proteins that can be used to increase or decrease gene expression. Its therapeutic products that are in Phase I/II clinical trial include SB-525 for the treatment of hemophilia A; ST-920 gene therapy for Fabry disease; ST-101 gene therapy for phenylketonuria; ST-400 and BIVV-003 for the treatment of hemoglobinopathies; SB-913 for the treatment of Mucopolysaccharidosis type II; SB-318 for the treatment of Mucopolysaccharidosis type I; and SB-FIX for the treatment of hemophilia B. The company has collaborative and strategic partnerships with Biogen Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi Genzyme; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; F. Hoffmann-La Roche Ltd and Hoffmann-La Roche Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was founded in 1995 and is headquartered in Brisbane, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1011038788, "total_enterprise": 693155788, "number_of_employees": 354, "outstanding_shares": 116211355, "eps": -0.84901, "diluted_eps": -0.84901, "earnings_from_cont_operations": -95419000, "gross_profit": -43494000, "cash": 362474000, "total_debt": 44406000, "total_revenue": 102428000, "cash_from_operations": -144402000, "net_income": -95186000, "ebitda": -101250000, "year_low_stock_price": 4.81, "year_high_stock_price": 13.33, "image_position": [10574, 0, 128, 32]}, {"symbol": "XHR", "name": "Xenia Hotels & Resorts, Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 217149830.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.09, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 10, "analysts_sell": 1, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "xeniareit.com", "year_founded": null, "street_address": "200 South Orange Avenue", "city": "Orlando", "state": "FL", "zipcode": "32801", "country": "United States", "phone_number": "407-246-8100", "short_description": "Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT that invests primarily in uniquely positioned luxury and upper upscale hotels and resorts, with a focus on the top 25 U.S. lodging markets as well as key leisure destinations in the United States.", "long_description": "Xenia Hotels & Resorts, Inc. is a self-advised and self-administered REIT that invests primarily in uniquely positioned luxury and upper upscale hotels and resorts, with a focus on the top 25 U.S. lodging markets as well as key leisure destinations in the United States. The Company owns 39 hotels comprising 11,245 rooms across 16 states. Xenia's hotels are primarily in the luxury and upper upscale segments, and operated and/or licensed by industry leaders such as Marriott, Hyatt, Kimpton, Fairmont, Loews, and Hilton, as well as leading independent management companies including The Kessler Collection and Sage Hospitality.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 1024060685, "total_enterprise": 2274628685, "number_of_employees": 48, "outstanding_shares": 113406499, "eps": 0.486984, "diluted_eps": 0.486984, "earnings_from_cont_operations": 57243000, "gross_profit": 321643000, "cash": 110841000, "total_debt": 1325272000, "total_revenue": 1149087000, "cash_from_operations": 246570000, "net_income": 55400000, "ebitda": 290836000, "year_low_stock_price": 6.28, "year_high_stock_price": 22.91, "image_position": [10702, 0, 128, 128]}, {"symbol": "TLRY", "name": "Tilray, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 13, "next_earnings_revenue_consensus": 49647000.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.39833, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 8, "total_analysts": 16, "analysts_sell": 1, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 13, "analysts_underperform": 0, "webpage": "tilray.com", "year_founded": 2018, "street_address": "1100 Maughan Road", "city": "Nanaimo", "state": "BC", "zipcode": "V9X IJ2", "country": "Canada", "phone_number": "844-845-7291", "short_description": "Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis.", "long_description": "Tilray, Inc. engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products to patients, physicians, pharmacies, governments, and hospitals; and for researchers for commercial purposes, and compassionate access and clinical research applications. It operates in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, the United Kingdom, the United States, and South Africa. The company was incorporated in 2018 and is headquartered in Nanaimo, Canada.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 969785884, "total_enterprise": 1316660884, "number_of_employees": 1646, "outstanding_shares": 124651142, "eps": -3.197121, "diluted_eps": -3.197121, "earnings_from_cont_operations": -321169000, "gross_profit": -21455000, "cash": 122281000, "total_debt": 469156000, "total_revenue": 153843000, "cash_from_operations": -258065000, "net_income": -321169000, "ebitda": -193743000, "year_low_stock_price": 2.43, "year_high_stock_price": 51.03, "image_position": [10830, 0, 128, 128]}, {"symbol": "RMR", "name": "The RMR Group Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 150530900.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.47465, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "rmrgroup.com", "year_founded": 1986, "street_address": "Two Newton Place", "city": "Newton", "state": "MA", "zipcode": "02458", "country": "United States", "phone_number": "617-796-8390", "short_description": "The RMR Group Inc., through its subsidiary, The RMR Group LLC, provides business and property management services in the United States.", "long_description": "The RMR Group Inc., through its subsidiary, The RMR Group LLC, provides business and property management services in the United States. It provides management services to its four publicly traded real estate investment trusts (REITs) and three real estate operating companies. As of September 30, 2019, the company had approximately 2,200 properties in 48 states under management, which are primarily owned by its Managed Equity REITs. It also provides investment advisory services. The company was formerly known as REIT Management & Research Inc. and changed its name to The RMR Group Inc. in September 2015. The RMR Group Inc. was founded in 1986 and is headquartered in Newton, Massachusetts.", "industry_name": "Real Estate Management and Development", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 505146358, "total_enterprise": 402231358, "number_of_employees": 600, "outstanding_shares": 16300302, "eps": 1.958225, "diluted_eps": 1.952224, "earnings_from_cont_operations": 72588000, "gross_profit": 181096000, "cash": 385695000, "total_debt": 38554000, "total_revenue": 181096000, "cash_from_operations": 186056000, "net_income": 31820000, "ebitda": 93850000, "year_low_stock_price": 21.79, "year_high_stock_price": 56.28, "image_position": [10958, 0, 128, 128]}, {"symbol": "AVYA", "name": "Avaya Holdings Corp.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 624198400.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.53247, "eps_up_revisions": 0, "eps_down_revisions": 6, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 5, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "avaya.com", "year_founded": null, "street_address": "4655 Great America Parkway", "city": "Santa Clara", "state": "CA", "zipcode": "95054", "country": "United States", "phone_number": "908-953-6000", "short_description": "Avaya Holdings Corp., through its subsidiaries, provides digital communications products, solutions, and services for businesses worldwide.", "long_description": "Avaya Holdings Corp., through its subsidiaries, provides digital communications products, solutions, and services for businesses worldwide. The company operates through two segments, Products & Solutions, and Services. The Products & Solutions segment offers unified communications and contact center platforms, applications, and devices. It also provides an open development platform for customers and third parties to create custom applications and automated workflows for their needs; and contact center solutions that enable customers to build a customized portfolio of applications driving customer engagement and customer value. This segments communications solutions include voice, email, chat, social media, video, and performance management. The Services segment provides global support services, enterprise cloud and managed services, and professional services. The company also delivers cloud business communications services and solutions to connect with customers. Avaya Holdings Corp. sells directly through its sales force, as well as indirectly through its network of channel partners, including distributors, service providers, dealers, value-added resellers, system integrators, and business partners. The company has a strategic collaboration with RingCentral, Inc. to accelerate the company's transition to the cloud. The company is based in Santa Clara, California.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 997670647, "total_enterprise": 3527670647, "number_of_employees": 7900, "outstanding_shares": 95288505, "eps": -6.689296, "diluted_eps": -6.691142, "earnings_from_cont_operations": -734000000, "gross_profit": 1736000000, "cash": 766000000, "total_debt": 3170000000, "total_revenue": 2864000000, "cash_from_operations": 167000000, "net_income": -734000000, "ebitda": 409000000, "year_low_stock_price": 6.13, "year_high_stock_price": 16.68, "image_position": [11086, 0, 128, 128]}, {"symbol": "LTHM", "name": "Livent Corporation", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 91767770.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.04165, "eps_up_revisions": 1, "eps_down_revisions": 6, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 13, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 0, "analysts_hold": 8, "analysts_underperform": 1, "webpage": "livent.com", "year_founded": 2018, "street_address": "2929 Walnut Street", "city": "Philadelphia", "state": "PA", "zipcode": "19104", "country": "United States", "phone_number": "215-299-6000", "short_description": "Livent Corporation manufactures and sells performance lithium based batteries, specialty polymer, and chemical synthesis applications in North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific.", "long_description": "Livent Corporation manufactures and sells performance lithium based batteries, specialty polymer, and chemical synthesis applications in North America, Latin America, Europe, the Middle East, Africa, and the Asia Pacific. The company offers lithium compounds for use in applications that have specific performance requirements, including battery-grade lithium hydroxide for use in high performance lithium-ion batteries; and butyllithium, which is used in the production of polymers and pharmaceutical products, as well as a range of specialty lithium compounds, including high purity lithium metal, which is used in the production of lightweight materials for aerospace applications and non-rechargeable batteries. It also provides lithium phosphate, pharmaceutical-grade lithium carbonate, high purity lithium chloride, and specialty organics; and lithium carbonate and lithium chloride for use as feedstock in the process of producing performance lithium compounds. The company was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania. Livent Corporation is a subsidiary of FMC Corporation.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 984532269, "total_enterprise": 1139832269, "number_of_employees": 800, "outstanding_shares": 146073037, "eps": 0.343835, "diluted_eps": 0.34, "earnings_from_cont_operations": 50200000, "gross_profit": 114900000, "cash": 16800000, "total_debt": 172100000, "total_revenue": 388400000, "cash_from_operations": 58100000, "net_income": 50200000, "ebitda": 91100000, "year_low_stock_price": 3.95, "year_high_stock_price": 12.29, "image_position": [11214, 0, 128, 128]}, {"symbol": "EB", "name": "Eventbrite, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 71784670.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.23298, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "eventbrite.com", "year_founded": 2008, "street_address": "155 5th Street", "city": "San Francisco", "state": "CA", "zipcode": "94103", "country": "United States", "phone_number": "415-692-7779", "short_description": "Eventbrite, Inc. operates a ticketing and experience technology platform in the United States and internationally.", "long_description": "Eventbrite, Inc. operates a ticketing and experience technology platform in the United States and internationally. Its platform integrates components needed to plan, promote, and produce live events that allow creators to reduce friction and costs, increase reach, and drive ticket sales. The company was formerly known as Mollyguard Corporation and changed its name to Eventbrite, Inc. in 2009. Eventbrite, Inc. was incorporated in 2008 and is headquartered in San Francisco, California.", "industry_name": "Interactive Media and Services", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 890666252, "total_enterprise": 495931252, "number_of_employees": 1126, "outstanding_shares": 86640686, "eps": -0.838751, "diluted_eps": -0.838751, "earnings_from_cont_operations": -68760000, "gross_profit": 197660000, "cash": 420712000, "total_debt": 25977000, "total_revenue": 326801000, "cash_from_operations": 28658000, "net_income": -68760000, "ebitda": -53189000, "year_low_stock_price": 5.71, "year_high_stock_price": 22.9, "image_position": [11342, 0, 128, 67]}, {"symbol": "OMER", "name": "Omeros Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 30208250.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.34, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 0, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "omeros.com", "year_founded": 1994, "street_address": "The Omeros Building", "city": "Seattle", "state": "WA", "zipcode": "98119", "country": "United States", "phone_number": "206 676 5000", "short_description": "Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases.", "long_description": "Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 872443225, "total_enterprise": 1005690225, "number_of_employees": 258, "outstanding_shares": 54510667, "eps": -1.705979, "diluted_eps": -1.705979, "earnings_from_cont_operations": -84486000, "gross_profit": 39981000, "cash": 60788000, "total_debt": 194035000, "total_revenue": 111805000, "cash_from_operations": -60073000, "net_income": -84486000, "ebitda": -61592000, "year_low_stock_price": 8.5, "year_high_stock_price": 20.92, "image_position": [11402, 0, 60, 60]}, {"symbol": "PASG", "name": "Passage Bio, Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.44364, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "passagebio.com", "year_founded": 2017, "street_address": "2 Commerce Square", "city": "Philadelphia", "state": "PA", "zipcode": "19103", "country": "United States", "phone_number": "267-866-0311", "short_description": "Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases.", "long_description": "Passage Bio, Inc., a genetic medicines company, focuses on developing transformative therapies for rare monogenic central nervous system (CNS) diseases. It has a research, collaboration, and license agreement with the University of Pennsylvania and its gene therapy program. The company was founded in 2017 and is based in Philadelphia, Pennsylvania.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 875727301, "total_enterprise": 947458301, "number_of_employees": 20, "outstanding_shares": 43096816, "eps": -10.772759, "diluted_eps": -10.772759, "earnings_from_cont_operations": -45634000, "gross_profit": null, "cash": 158874000, "total_debt": 0, "total_revenue": null, "cash_from_operations": -39896000, "net_income": -45634000, "ebitda": -36555000, "year_low_stock_price": 8.09, "year_high_stock_price": 23.25, "image_position": [11530, 0, 128, 128]}, {"symbol": "WHF", "name": "WhiteHorse Finance", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 16970710.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.35843, "eps_up_revisions": 2, "eps_down_revisions": 2, "revenue_up_revisions": 3, "revenue_down_revisions": 2, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "whitehorsefinance.com", "year_founded": null, "street_address": null, "city": null, "state": null, "zipcode": null, "country": null, "phone_number": null, "short_description": null, "long_description": null, "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 192927240, "total_enterprise": 487557240, "number_of_employees": null, "outstanding_shares": 20546032, "eps": 1.501068, "diluted_eps": 1.501068, "earnings_from_cont_operations": 30841000, "gross_profit": 67073000, "cash": 4294000, "total_debt": 298924000, "total_revenue": 67073000, "cash_from_operations": -94978000, "net_income": 30841000, "ebitda": null, "year_low_stock_price": 5.51, "year_high_stock_price": 14.79, "image_position": [11658, 0, 128, 128]}, {"symbol": "GSKY", "name": "GreenSky, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 123703600.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.04456, "eps_up_revisions": 1, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 7, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "greensky.com", "year_founded": 2006, "street_address": "5565 Glenridge Connector", "city": "Atlanta", "state": "GA", "zipcode": "30342", "country": "United States", "phone_number": "678-264-6105", "short_description": "GreenSky, Inc., a technology company, provides point-of-sale financing and payment solutions to merchants, consumers, and banks.", "long_description": "GreenSky, Inc., a technology company, provides point-of-sale financing and payment solutions to merchants, consumers, and banks. It offers a proprietary technology infrastructure that support the full transaction lifecycle, including credit application, underwriting, real-time allocation to bank partners, document distribution, funding, settlement, and servicing functions. The company was founded in 2006 and is headquartered in Atlanta, Georgia.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 290023278, "total_enterprise": 414649278, "number_of_employees": 1174, "outstanding_shares": 66366883, "eps": 0.523476, "diluted_eps": 0.489188, "earnings_from_cont_operations": 95973000, "gross_profit": 197014000, "cash": 195760000, "total_debt": 401144000, "total_revenue": 529646000, "cash_from_operations": 153327000, "net_income": 31980000, "ebitda": 146192000, "year_low_stock_price": 3.05, "year_high_stock_price": 13.58, "image_position": [11786, 0, 128, 35]}, {"symbol": "SCM", "name": "Stellus Capital Investment Corporation", "next_earnings_utc": 1589162400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 15266750.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.29667, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "stelluscapital.com", "year_founded": 2012, "street_address": "4400 Post Oak Parkway", "city": "Houston", "state": "TX", "zipcode": "77027", "country": "United States", "phone_number": "713-292-5400", "short_description": "Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies.", "long_description": "Stellus Capital Investment Corporation is a business development company specializing in investments in private middle-market companies. It invests through first lien, second lien, unitranche, and mezzanine debt financing, often with a corresponding equity investment. The fund seeks to invest in companies with an EBITDA between $5 million and $50 million.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "cef", "market_cap": 147030572, "total_enterprise": 496925945, "number_of_employees": null, "outstanding_shares": 19474248, "eps": 1.44663, "diluted_eps": 1.44663, "earnings_from_cont_operations": 26438186, "gross_profit": 58911889, "cash": 16133315, "total_debt": 366028688, "total_revenue": 58911889, "cash_from_operations": -93286104, "net_income": 26438186, "ebitda": null, "year_low_stock_price": 4.1, "year_high_stock_price": 15.04, "image_position": [11914, 0, 128, 128]}, {"symbol": "SALT", "name": "Scorpio Bulkers Inc.", "next_earnings_utc": 1589197500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 43886600.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": -2.29714, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 1, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "scorpiobulkers.com", "year_founded": 2013, "street_address": "Le Millenium", "city": "Monaco", "state": null, "zipcode": "98000", "country": "Monaco", "phone_number": "377 9798 5715", "short_description": "Scorpio Bulkers Inc., a shipping company, owns and operates dry bulk carriers worldwide.", "long_description": "Scorpio Bulkers Inc., a shipping company, owns and operates dry bulk carriers worldwide. Its vessels transport a range of bulk commodities, including ores, coal, grains, and fertilizers. As of December 31, 2019, the company operated a fleet of 58 vessels that consist of 55 owned and finance leased vessels, including 17 Kamsarmax vessels and 35 Ultramax vessels; five time chartered-in Kamsarmax vessels; and one Ultramax vessel. Scorpio Bulkers Inc. was founded in 2013 and is based in Monaco.", "industry_name": "Marine", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 138067162, "total_enterprise": 863066162, "number_of_employees": 7, "outstanding_shares": 6882710, "eps": 6.558373, "diluted_eps": 6.4, "earnings_from_cont_operations": 44654000, "gross_profit": 102034000, "cash": 42530000, "total_debt": 767529000, "total_revenue": 224579000, "cash_from_operations": 33880000, "net_income": 44654000, "ebitda": 70061000, "year_low_stock_price": 16.45, "year_high_stock_price": 72.05, "image_position": [12042, 0, 128, 128]}, {"symbol": "VRS", "name": "Verso Corporation", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 493110000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.3795, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "versoco.com", "year_founded": 2006, "street_address": "8540 Gander Creek Drive", "city": "Miamisburg", "state": "OH", "zipcode": "45342", "country": "United States", "phone_number": "877 855 7243", "short_description": "Verso Corporation produces and sells coated papers in North America.", "long_description": "Verso Corporation produces and sells coated papers in North America. It operates through two segments, Paper and Pulp. The company offers coated freesheet and coated groundwood, specialty, packaging, inkjet and digital, supercalendered, and uncoated freesheet papers; and bleached and unbleached market kraft pulp to manufacture printing, writing, and tissue products. Its paper products are used primarily in media and marketing applications, including catalogs, magazines, and commercial printing applications, such as high-end advertising brochures, annual reports, and direct-mail advertising; and specialty applications comprising flexible packaging, and label and converting. The company was formerly known as Verso Paper Corp. and changed its name to Verso Corporation in January 2015. Verso Corporation was founded in 2006 and is headquartered in Miamisburg, Ohio.", "industry_name": "Paper and Forest Products", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 497136623, "total_enterprise": 476136623, "number_of_employees": 3700, "outstanding_shares": 35183059, "eps": 2.772563, "diluted_eps": 2.74, "earnings_from_cont_operations": 96000000, "gross_profit": 328000000, "cash": 42000000, "total_debt": 21000000, "total_revenue": 2444000000, "cash_from_operations": 125000000, "net_income": 96000000, "ebitda": 223000000, "year_low_stock_price": 9.61, "year_high_stock_price": 22.19, "image_position": [12122, 0, 80, 80]}, {"symbol": "CEVA", "name": "CEVA, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 21520000.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.05333, "eps_up_revisions": 1, "eps_down_revisions": 3, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "ceva-dsp.com", "year_founded": 1999, "street_address": "1174 Castro Street", "city": "Mountain View", "state": "CA", "zipcode": "94040", "country": "United States", "phone_number": "650-417-7900", "short_description": "CEVA, Inc. licenses signal processing platforms and artificial intelligence processors for semiconductor companies and original equipment manufacturers (OEMs) serving the mobile, consumer, automotive, industrial, and Internet-of-Things (IoT) markets worldwide.", "long_description": "CEVA, Inc. licenses signal processing platforms and artificial intelligence processors for semiconductor companies and original equipment manufacturers (OEMs) serving the mobile, consumer, automotive, industrial, and Internet-of-Things (IoT) markets worldwide. The company licenses a family of signal processing intellectual properties (IPs), including platforms for 5G baseband processing in handsets and base station RAN; integrated cellular IoT solutions; digital signal processor (DSP) platforms incorporating voice input algorithms and software for voice enabled devices; and DSP platforms for advanced imaging and computer vision in various camera-enabled devices, as well as a family of self-contained artificial intelligent (AI) processors that address a range of edge applications. The company also provides IPs for Bluetooth and Wi-Fi platforms. Its technologies are licensed to companies, which design, manufacture, market, and sell application-specific integrated circuits and application-specific standard products to wireless, consumer electronics, and automotive companies for incorporation into various end products. The company delivers its DSP cores, platforms, and AI processors in the form of a hardware description language definition; and offers development platforms, software development kits, and software debug tools that facilitate system design, debug, and software development. CEVA, Inc. licenses its technology through a direct sales force. The company was formerly known as ParthusCeva, Inc. and changed its name to CEVA, Inc. in December 2003. CEVA, Inc. was founded in 1999 and is headquartered in Mountain View, California.", "industry_name": "Semiconductors and Semiconductor Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 739927192, "total_enterprise": 606008192, "number_of_employees": 382, "outstanding_shares": 22001998, "eps": 0.001276, "diluted_eps": 0.001254, "earnings_from_cont_operations": 28000, "gross_profit": 77046000, "cash": 144585000, "total_debt": 10666000, "total_revenue": 87152000, "cash_from_operations": 9674000, "net_income": 28000, "ebitda": 3807000, "year_low_stock_price": 20.45, "year_high_stock_price": 36.79, "image_position": [12250, 0, 128, 128]}, {"symbol": "RPAY", "name": "Repay Holdings Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 9, "next_earnings_revenue_consensus": 37734780.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": 0.16014, "eps_up_revisions": 3, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 8, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 7, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "repay.com", "year_founded": 2006, "street_address": "3 West Paces Ferry Road", "city": "Atlanta", "state": "GA", "zipcode": "30305", "country": "United States", "phone_number": "404 504 7472", "short_description": "Repay Holdings Corporation provides integrated payment processing solutions to industry-oriented markets.", "long_description": "Repay Holdings Corporation provides integrated payment processing solutions to industry-oriented markets. Its payment processing solutions enable consumers and businesses to make payments using electronic payment methods. The company offers a range of solutions relating to electronic payment methods, including credit and debit processing, automated clearing house processing, and instant funding. It provide payment processing solutions to customers primarily operating in the personal loans, automotive loans, receivables management, and business-to-business verticals. Repay Holdings Corporation was founded in 2006 and is headquartered in Atlanta, Georgia.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 675548245, "total_enterprise": 1070534989, "number_of_employees": 243, "outstanding_shares": 37655978, "eps": -0.455893, "diluted_eps": -0.455893, "earnings_from_cont_operations": -55303206, "gross_profit": 78730578, "cash": 24617996, "total_debt": 213442705, "total_revenue": 104603387, "cash_from_operations": 21085862, "net_income": -40032163, "ebitda": -18229079, "year_low_stock_price": 10.21, "year_high_stock_price": 19.58, "image_position": [12378, 0, 128, 128]}, {"symbol": "CARA", "name": "Cara Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 4705750.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.6, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 3, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "caratherapeutics.com", "year_founded": 2004, "street_address": "4 Stamford Plaza", "city": "Stamford", "state": "CT", "zipcode": "06902", "country": "United States", "phone_number": "203 406 3700", "short_description": "Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States.", "long_description": "Cara Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. Its lead product candidate includes KORSUVA (CR845/ difelikefalin) injection, which is in Phase III clinical trial for the treatment of patients with moderate-to-severe chronic kidney disease-associated pruritus (CKD-aP) undergoing hemodialysis. The company is also developing Oral KORSUVA (CR845/difelikefalin), which has completed Phase II clinical trial for the treatment of pruritus in stage III-V CKD patients; in Phase II clinical trial for treating pruritus chronic liver disease; and in Phase II clinical trial for the treatment of pruritus associated with atopic dermatitis. In addition, it is developing CR845/difelikefalin Injection, which has completed Phase II/III clinical trial for the treatment of acute post-operative pain. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing CR845/difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing CR845/difelikefalin in South Korea. Cara Therapeutics, Inc. was founded in 2004 and is headquartered in Stamford, Connecticut.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 662131863, "total_enterprise": 511444863, "number_of_employees": 67, "outstanding_shares": 46727725, "eps": -2.492961, "diluted_eps": -2.492961, "earnings_from_cont_operations": -106373000, "gross_profit": -93934000, "cash": 155006000, "total_debt": 4319000, "total_revenue": 19886000, "cash_from_operations": -109225000, "net_income": -106373000, "ebitda": -111481000, "year_low_stock_price": 8.88, "year_high_stock_price": 27.55, "image_position": [12506, 0, 128, 128]}, {"symbol": "RDNT", "name": "RadNet, Inc.", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 242089500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.29, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "radnet.com", "year_founded": 1985, "street_address": "1508, 1510 and 1516 Cotner Avenue", "city": "Los Angeles", "state": "CA", "zipcode": "90025", "country": "United States", "phone_number": "310 478 7808", "short_description": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States.", "long_description": "RadNet, Inc., together with its subsidiaries, provides outpatient diagnostic imaging services in the United States. Its services include magnetic resonance imaging, computed tomography, positron emission tomography, nuclear medicine, mammography, ultrasound, diagnostic radiology, fluoroscopy, and other related procedures, as well as multi-modality imaging services. The company also develops and sells computerized systems for the diagnostic imaging industry, including picture archiving communications systems; and provides teleradiology services for remote interpretation of images on behalf of hospitals and hospital-based radiology groups. As of December 31, 2019, it operated 335 centers in California, Delaware, Florida, Maryland, New Jersey, and New York. The company was founded in 1985 and is headquartered in Los Angeles, California.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 731525026, "total_enterprise": 1953884026, "number_of_employees": 6473, "outstanding_shares": 50694735, "eps": 0.297051, "diluted_eps": 0.29, "earnings_from_cont_operations": 23440000, "gross_profit": 260982000, "cash": 40165000, "total_debt": 1181070000, "total_revenue": 1154179000, "cash_from_operations": 104322000, "net_income": 14756000, "ebitda": 154487000, "year_low_stock_price": 5.81, "year_high_stock_price": 23.45, "image_position": [12634, 0, 128, 64]}, {"symbol": "OYST", "name": "Oyster Point Pharma, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.99437, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "oysterpointrx.com", "year_founded": 2015, "street_address": "202 Carnegie Center", "city": "Princeton", "state": "NJ", "zipcode": "08540", "country": "United States", "phone_number": "609 382 9032", "short_description": "Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States.", "long_description": "Oyster Point Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical therapies to treat ocular surface diseases in the United States. The company's lead product candidate is OC-01, a nicotinic acetylcholine receptor agonist that is in Phase III clinical trials for the treatment of signs and symptoms of dry eye disease. It is also developing OC-01 for neurotrophic keratitis. Oyster Point Pharma, Inc. was founded in 2015 and is headquartered in Princeton, New Jersey.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 722749633, "total_enterprise": 584410633, "number_of_employees": 30, "outstanding_shares": 21370480, "eps": -9.969366, "diluted_eps": -9.969366, "earnings_from_cont_operations": -45711000, "gross_profit": null, "cash": 139147000, "total_debt": 808000, "total_revenue": null, "cash_from_operations": -40815000, "net_income": -45711000, "ebitda": -47282000, "year_low_stock_price": 13.26, "year_high_stock_price": 41.37, "image_position": [12762, 0, 128, 128]}, {"symbol": "RTRX", "name": "Retrophin, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 43427330.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.5175, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 4, "revenue_down_revisions": 0, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 3, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "retrophin.com", "year_founded": 2011, "street_address": "3721 Valley Centre Drive", "city": "San Diego", "state": "CA", "zipcode": "92130", "country": "United States", "phone_number": "886 969 7879", "short_description": "Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases.", "long_description": "Retrophin, Inc., a biopharmaceutical company, focuses on the identification, development, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, as well as for adjunctive treatment of patients with peroxisomal disorders; and Thiola and Thiola EC, a tiopronin tablet for the treatment of cystinuria. The company's product candidates also consist of Sparsentan, which is in Phase III clinical trial for the treatment of focal segmental glomerulosclerosis and immunoglobulin A nephropathy. It has a cooperative research and development agreement with National Institutes of Health's National Center for Advancing Translational Sciences, NGLY1.org, and Alagille Syndrome Alliance for identification of potential small molecule therapeutics for NGLY1 deficiency and Alagille syndrome. Retrophin, Inc. was founded in 2011 and is headquartered in San Diego, California.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 660191282, "total_enterprise": 476535282, "number_of_employees": 221, "outstanding_shares": 43149757, "eps": -3.458364, "diluted_eps": -3.459999, "earnings_from_cont_operations": -146427000, "gross_profit": 170104000, "cash": 398524000, "total_debt": 214868000, "total_revenue": 175338000, "cash_from_operations": -58214000, "net_income": -146427000, "ebitda": -79402000, "year_low_stock_price": 8.98, "year_high_stock_price": 21.95, "image_position": [12890, 0, 128, 128]}, {"symbol": "SCSC", "name": "ScanSource, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 759950000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.42667, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "scansource.com", "year_founded": 1992, "street_address": "6 Logue Court", "city": "Greenville", "state": "SC", "zipcode": "29615", "country": "United States", "phone_number": "864-288-2432", "short_description": "ScanSource, Inc. distributes technology products and solutions in the United States, Canada, Brazil, Latin America, and Europe.", "long_description": "ScanSource, Inc. distributes technology products and solutions in the United States, Canada, Brazil, Latin America, and Europe. It operates in two segments, Worldwide Barcode, Networking & Security; and Worldwide Communications & Services. The Worldwide Barcode, Networking & Security segment offers a portfolio of solutions primarily for enterprise mobile computing, data capture, barcode printing, point of sale (POS), payments, networking, electronic physical security, cyber security, and other technologies. This segment offers data capture and POS solutions to automate the collection, processing, and communication of information for commercial and industrial applications, including retail sales, distribution, shipping, inventory control, materials handling, warehouse management, and health care applications. It also provides electronic physical security products, such as identification, access control, video surveillance, intrusion-related, and wireless and networking infrastructure products; and video conferencing, cloud, POS portal, and other services. The Worldwide Communications & Services segment offers a portfolio of solutions primarily for communications technologies and services comprising voice, video conferencing, wireless, data networking, cyber security, digital networks, cable, unified communications and collaboration, cloud, and technology services, as well as IP networks and other solutions for various vertical markets comprising education, healthcare, and government. The company also provides professional, contact center, and infrastructure services. ScanSource, Inc. was founded in 1992 and is headquartered in Greenville, South Carolina.", "industry_name": "Electronic Equipment, Instruments and Components", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 679520844, "total_enterprise": 1033526844, "number_of_employees": 2700, "outstanding_shares": 25345798, "eps": 1.808818, "diluted_eps": 1.808818, "earnings_from_cont_operations": 46190000, "gross_profit": 445863000, "cash": 42005000, "total_debt": 396011000, "total_revenue": 3850620000, "cash_from_operations": 142703000, "net_income": 46190000, "ebitda": 127921000, "year_low_stock_price": 13.78, "year_high_stock_price": 39.01, "image_position": [13018, 0, 128, 128]}, {"symbol": "MAXR", "name": "Maxar Technologies Inc.", "next_earnings_utc": 1589227800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 419516670.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.685, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 9, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 2, "analysts_hold": 6, "analysts_underperform": 0, "webpage": "maxar.com", "year_founded": 1969, "street_address": "1300 West 120th Avenue", "city": "Westminster", "state": "CO", "zipcode": "80234", "country": "United States", "phone_number": "303 684 7660", "short_description": "Maxar Technologies Inc. provides earth intelligence and space infrastructure solutions in the United States, Asia, South America, Europe, the Middle East, Australia, Canada, and internationally.", "long_description": "Maxar Technologies Inc. provides earth intelligence and space infrastructure solutions in the United States, Asia, South America, Europe, the Middle East, Australia, Canada, and internationally. It operates through Earth Intelligence and Space Infrastructure segments. The Earth Intelligence segment offers Earth imagery and radar data solutions, including orthorectified imagery, mosaic, elevation, and information products; and SecureWatch, a subscription offering that provides online access to imagery and geospatial intelligence platform, as well as geospatial information, applications, and analytic services. This segment serves to the U.S., Canadian, and other international government agencies, such as defense and intelligence, and civil agencies, as well as commercial customers in various markets. The Space Infrastructure segment provides space and ground based infrastructure, robotics, components, and information solutions, including communication and imaging satellites and payloads; space platforms for power, propulsion, and communication; satellite ground systems and support services; space-based and airborne remote sensory solutions; space robotics; and defense systems. This segment serves government agencies and commercial satellite operators. Maxar Technologies Inc. was founded in 1969 and is headquartered in Westminster, Colorado.", "industry_name": "Aerospace and Defense", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 678976309, "total_enterprise": 3843976309, "number_of_employees": 5800, "outstanding_shares": 60139620, "eps": 1.828859, "diluted_eps": 1.811893, "earnings_from_cont_operations": 83000000, "gross_profit": 691000000, "cash": 59000000, "total_debt": 3223000000, "total_revenue": 1666000000, "cash_from_operations": 317000000, "net_income": 109000000, "ebitda": 369000000, "year_low_stock_price": 5.73, "year_high_stock_price": 21.45, "image_position": [13146, 0, 128, 36]}, {"symbol": "GSBD", "name": "Goldman Sachs BDC", "next_earnings_utc": 1589232600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 32030000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.46741, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "goldmansachsbdc.com", "year_founded": 2012, "street_address": "200 West Street", "city": "New York", "state": "NY", "zipcode": "10282", "country": "United States", "phone_number": "212-902-1000", "short_description": "Goldman Sachs BDC, Inc. is a business development company specializing in middle market and mezzanine investment in private companies.", "long_description": "Goldman Sachs BDC, Inc. is a business development company specializing in middle market and mezzanine investment in private companies. It seeks to make capital appreciation through direct originations of secured debt, senior secured debt, junior secured debt, including first lien, first lien/last-out unitranche and second lien debt, unsecured debt, including mezzanine debt and, to a lesser extent, investments in equities. The fund primarily invests in United States. It seeks to invest between $10 million and $75 million in companies with EBITDA between $5 million and $75 million annually.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "cef", "market_cap": 630265537, "total_enterprise": 1390583537, "number_of_employees": null, "outstanding_shares": 40401637, "eps": 0.896668, "diluted_eps": 0.896668, "earnings_from_cont_operations": 36148000, "gross_profit": 147261000, "cash": 9409000, "total_debt": 769727000, "total_revenue": 147261000, "cash_from_operations": -35271000, "net_income": 36148000, "ebitda": null, "year_low_stock_price": 8.0, "year_high_stock_price": 22.5, "image_position": [13274, 0, 128, 128]}, {"symbol": "PRPL", "name": "Purple Innovation, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 104805250.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.0, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "purple.com", "year_founded": 2010, "street_address": "4100 North Chapel Ridge Road", "city": "Lehi", "state": "UT", "zipcode": "84043", "country": "United States", "phone_number": "801 756 2600", "short_description": "Purple Innovation, Inc. designs and manufactures mattresses, pillows, and cushions.", "long_description": "Purple Innovation, Inc. designs and manufactures mattresses, pillows, and cushions. It also offers sheets, mattress protector, bed frames, seat cushions, and weighted blanket and duvets. The company markets and sells its products through direct-to-consumer online channels, retail brick-and-mortar wholesale partners, and third-party online retailers, as well as through its factory outlet and the company owned showrooms. Purple Innovation, Inc. was founded in 2010 and is headquartered in Lehi, Utah.", "industry_name": "Household Durables", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 302364339, "total_enterprise": 302745339, "number_of_employees": 863, "outstanding_shares": 23622214, "eps": -0.402458, "diluted_eps": -0.402458, "earnings_from_cont_operations": -12379000, "gross_profit": 188971000, "cash": 33478000, "total_debt": 36237000, "total_revenue": 428358000, "cash_from_operations": 22915000, "net_income": -4027000, "ebitda": 20522000, "year_low_stock_price": 4.42, "year_high_stock_price": 15.96, "image_position": [13402, 0, 128, 46]}, {"symbol": "TRTX", "name": "TPG RE Finance Trust, Inc.", "next_earnings_utc": 1589157000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": -37400000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.39293, "eps_up_revisions": 1, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "tpgrefinance.com", "year_founded": 2014, "street_address": "888 Seventh Avenue", "city": "New York", "state": "NY", "zipcode": "10106", "country": "United States", "phone_number": "212-601-4700", "short_description": "TPG RE Finance Trust, Inc., a commercial real estate finance company, originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments in North America.", "long_description": "TPG RE Finance Trust, Inc., a commercial real estate finance company, originates, acquires, and manages commercial mortgage loans and other commercial real estate-related debt instruments in North America. It invests in commercial mortgage loans; subordinate mortgage interests, mezzanine loans, secured real estate securities, note financing, preferred equity, and miscellaneous debt instruments; and commercial real estate collateralized loan obligations and commercial mortgage-backed securities secured by properties primarily in the office, mixed use, multifamily, industrial, retail, and hospitality real estate sectors. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. TPG RE Finance Trust, Inc. was founded in 2014 and is based in New York, New York.", "industry_name": "Mortgage Real Estate Investment Trusts (REITs)", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 570055870, "total_enterprise": null, "number_of_employees": null, "outstanding_shares": 76414996, "eps": 1.736217, "diluted_eps": 1.73, "earnings_from_cont_operations": 126313000, "gross_profit": 166727000, "cash": 79182000, "total_debt": 4331556000, "total_revenue": 166727000, "cash_from_operations": 121665000, "net_income": 126313000, "ebitda": null, "year_low_stock_price": 2.45, "year_high_stock_price": 21.3, "image_position": [13530, 0, 128, 128]}, {"symbol": "CSTL", "name": "Castle Biosciences, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 13719000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.1475, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 4, "revenue_down_revisions": 0, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "castlebiosciences.com", "year_founded": 2007, "street_address": "820 South Friendswood Drive", "city": "Friendswood", "state": "TX", "zipcode": "77546", "country": "United States", "phone_number": "866 788 9007", "short_description": "Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers.", "long_description": "Castle Biosciences, Inc., a commercial-stage dermatological cancer, develops and commercializes diagnostic and prognostic tests for cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify stage I and II patients at high risk of metastasis based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; and two late-stage proprietary products in development, which address cutaneous squamous cell carcinoma and suspicious pigmented lesions, which are indications with high clinical need in dermatological cancer. It offers test services through physicians, physician assistants, and nurse practitioners. The company was founded in 2007 and is headquartered in Friendswood, Texas.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 541910124, "total_enterprise": 468187124, "number_of_employees": 134, "outstanding_shares": 17203496, "eps": 0.348438, "diluted_eps": -0.208131, "earnings_from_cont_operations": 5277000, "gross_profit": 44555000, "cash": 98845000, "total_debt": 25122000, "total_revenue": 51865000, "cash_from_operations": 7015000, "net_income": 5277000, "ebitda": 7686000, "year_low_stock_price": 15.26, "year_high_stock_price": 39.77, "image_position": [13658, 0, 128, 128]}, {"symbol": "GRBK", "name": "Green Brick Partners, Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 208550000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.23852, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "greenbrickpartners.com", "year_founded": null, "street_address": "2805 Dallas Parkway", "city": "Plano", "state": "TX", "zipcode": "75093", "country": "United States", "phone_number": "469 573 6755", "short_description": "Green Brick Partners, Inc. operates as a homebuilding and land development company in the United States.", "long_description": "Green Brick Partners, Inc. operates as a homebuilding and land development company in the United States. It operates in three segments: Builder operations Central, Builder operations Southeast, and Land development. The company is involved in the land acquisition and development, entitlements, design, construction, title and mortgage services, marketing, and sale of townhomes, patio homes, single family homes, and luxury homes in residential neighborhoods and master planned communities; development and sale of lots; and land and construction financing business. It owns or controls approximately 9,000 home sites in Dallas, Atlanta, and Vero Beach. The company sells its homes through sales representatives and independent real estate brokers. Green Brick Partners, Inc. is based in Plano, Texas.", "industry_name": "Household Durables", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 455552298, "total_enterprise": 690733298, "number_of_employees": 460, "outstanding_shares": 50616922, "eps": 1.160815, "diluted_eps": 1.16, "earnings_from_cont_operations": 64302000, "gross_profit": 169182000, "cash": 33269000, "total_debt": 241612000, "total_revenue": 791660000, "cash_from_operations": -22063000, "net_income": 58656000, "ebitda": 73602000, "year_low_stock_price": 5.66, "year_high_stock_price": 13.08, "image_position": [13738, 0, 80, 80]}, {"symbol": "SGRY", "name": "Surgery Partners, Inc.", "next_earnings_utc": 1589232300, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 390744000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.40101, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "surgerypartners.com", "year_founded": 2004, "street_address": "310 Seven Springs Way", "city": "Brentwood", "state": "TN", "zipcode": "37027", "country": "United States", "phone_number": "615 234 5900", "short_description": "Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States.", "long_description": "Surgery Partners, Inc., through its subsidiaries, owns and operates a network of surgical facilities and related services in the United States. The company operates through three segments: Surgical Facility Services, Ancillary Services, and Optical Services. Its surgical facilities comprise ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including gastroenterology, general surgery, ophthalmology, orthopedics, and pain management. The company's surgical hospitals also provide ancillary services, such as diagnostic imaging, pharmacy, laboratory, obstetrics, oncology, physical therapy, and wound care; and ancillary services, which consist of a diagnostic laboratory, multi-specialty physician practices, urgent care facilities, anesthesia services, and optical services. It also operates optical laboratory that manufactures eyewear. As of March 31, 2020, the company owned or operated a portfolio of 127 surgical facilities, including 111 ambulatory surgical centers and 16 surgical hospitals in 30 states. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 543934139, "total_enterprise": 4754934139, "number_of_employees": 8250, "outstanding_shares": 49742491, "eps": -2.288732, "diluted_eps": -2.29, "earnings_from_cont_operations": 45100000, "gross_profit": 423800000, "cash": 92700000, "total_debt": 2901100000, "total_revenue": 1831400000, "cash_from_operations": 129500000, "net_income": -74800000, "ebitda": 336600000, "year_low_stock_price": 4.0, "year_high_stock_price": 19.74, "image_position": [13866, 0, 128, 128]}, {"symbol": "GDYN", "name": "Grid Dynamics Holdings, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 31500000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.055, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "griddynamics.com", "year_founded": 2006, "street_address": "5000 Executive Parkway", "city": "San Ramon", "state": "CA", "zipcode": "94583", "country": "United States", "phone_number": "619 736 6855", "short_description": "Grid Dynamics Holdings, Inc. provides enterprise-level digital transformation services for Fortune 1000 corporations in the United States, and Central and Eastern European countries.", "long_description": "Grid Dynamics Holdings, Inc. provides enterprise-level digital transformation services for Fortune 1000 corporations in the United States, and Central and Eastern European countries. It works in collaboration with its clients on digital transformation initiatives that cover strategy consulting, early prototypes, and enterprise-scale delivery of new digital platforms. The company offers focused and complex technical consulting, software design, development, testing, and internet service operations services. It serves customers that operate primarily in the retail, technology and media, and financial services sectors. The company was founded in 2006 and is based in San Ramon, California.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 518938313, "total_enterprise": 485936313, "number_of_employees": 1430, "outstanding_shares": 55147536, "eps": 0.83207, "diluted_eps": 0.83207, "earnings_from_cont_operations": 10807000, "gross_profit": 49262000, "cash": 42189000, "total_debt": 0, "total_revenue": 118326000, "cash_from_operations": 12534000, "net_income": 10807000, "ebitda": 20444000, "year_low_stock_price": 4.61, "year_high_stock_price": 13.51, "image_position": [13994, 0, 128, 128]}, {"symbol": "CPRX", "name": "Catalyst Pharmaceuticals, Inc.", "next_earnings_utc": 1589232300, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 31459170.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.08667, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 3, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "catalystpharma.com", "year_founded": 2002, "street_address": "355 Alhambra Circle", "city": "Coral Gables", "state": "FL", "zipcode": "33134", "country": "United States", "phone_number": "305 420 3200", "short_description": "Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States.", "long_description": "Catalyst Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing therapies for people with rare debilitating, chronic neuromuscular, and neurological diseases in the United States. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with lambert-eaton myasthenic syndrome. The company also develops Firdapse, which is in various clinical trials for the treatment of patients with congenital myasthenic syndrome, anti-MuSK antibody positive myasthenia gravis, and spinal muscular atrophy type 3. Catalyst Pharmaceuticals, Inc. has license agreements with BioMarin Pharmaceutical Inc.; and collaboration and license agreement with Endo Ventures Limited for the development and commercialization of generic Sabril tablets. The company was formerly known as Catalyst Pharmaceutical Partners, Inc. and changed its name to Catalyst Pharmaceuticals, Inc. in May 2015. Catalyst Pharmaceuticals, Inc. was founded in 2002 and is based in Coral Gables, Florida.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 502566277, "total_enterprise": 408995567, "number_of_employees": 76, "outstanding_shares": 103408699, "eps": 0.309636, "diluted_eps": 0.3, "earnings_from_cont_operations": 31875337, "gross_profit": 68704446, "cash": 94518760, "total_debt": 948050, "total_revenue": 102306337, "cash_from_operations": 34611473, "net_income": 31875337, "ebitda": 31877586, "year_low_stock_price": 2.23, "year_high_stock_price": 7.67, "image_position": [14122, 0, 128, 127]}, {"symbol": "CRBP", "name": "Corbus Pharmaceuticals Holdings, Inc.", "next_earnings_utc": 1589195100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 1804500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.48, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 4, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "corbuspharma.com", "year_founded": 2009, "street_address": "500 River Ridge Drive", "city": "Norwood", "state": "MA", "zipcode": "02062", "country": "United States", "phone_number": "617-963-0100", "short_description": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases.", "long_description": "Corbus Pharmaceuticals Holdings, Inc., a clinical-stage pharmaceutical company, focuses on the development and commercialization of various therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Its lead product candidate is lenabasum, a synthetic oral endocannabinoid drug that is in Phase III clinical trials for the treatment of systemic sclerosis and dermatomyositis, and in Phase IIb clinical trials to treat systemic lupus erythematosus and cystic fibrosis. The company is also developing CRB-4001, a peripherally-restricted CB1 inverse agonist, for nonalcoholic steatohepatitis and other fibrotic diseases. It has a licensing agreement with Jenrin Discovery, LLC to develop and commercialize the licensed products, which includes the Jenrin library of approximately 600 compounds and multiple issued and pending patent filings; and strategic collaboration with Kaken Pharmaceutical Co., Ltd. for the development and commercialization of lenabasum in Japan. The company was founded in 2009 and is based in Norwood, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 477349606, "total_enterprise": 455046552, "number_of_employees": 141, "outstanding_shares": 72490449, "eps": -1.118225, "diluted_eps": -1.118225, "earnings_from_cont_operations": -71453718, "gross_profit": -53461222, "cash": 31748686, "total_debt": 9445632, "total_revenue": 36143568, "cash_from_operations": -45720728, "net_income": -71453718, "ebitda": -76365201, "year_low_stock_price": 3.29, "year_high_stock_price": 7.8, "image_position": [14250, 0, 128, 128]}, {"symbol": "RPT", "name": "RPT Realty", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 50148160.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.03168, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 8, "analysts_sell": 1, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 2, "webpage": "rptrealty.com", "year_founded": 1997, "street_address": "19 West 44th Street", "city": "New York", "state": "NY", "zipcode": "10036", "country": "United States", "phone_number": "212-221-1261", "short_description": "RPT Realty owns and operates a national portfolio of open-air shopping destinations principally located in top U.S. markets.", "long_description": "RPT Realty owns and operates a national portfolio of open-air shopping destinations principally located in top U.S. markets. The Company's shopping centers offer diverse, locally-curated consumer experiences that reflect the lifestyles of their surrounding communities and meet the modern expectations of the Company's retail partners. The Company is a fully integrated and self-administered REIT publicly traded on the New York Stock Exchange (the \"NYSE\"). The common shares of the Company, par value $0.01 per share (the \"common shares\") are listed and traded on the NYSE under the ticker symbol \"RPT\". As of December 31, 2019, our property portfolio consisted of 49 shopping centers (including five shopping centers owned through a joint venture) representing 11.9 million square feet of gross leasable area (\"GLA\"). As of December 31, 2019, the Company's pro-rata share of the aggregate portfolio was 94.7% leased.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 502175411, "total_enterprise": 1452411411, "number_of_employees": 104, "outstanding_shares": 80606005, "eps": 1.056076, "diluted_eps": 1.037117, "earnings_from_cont_operations": 93686000, "gross_profit": 173067000, "cash": 112590000, "total_debt": 950384000, "total_revenue": 234284000, "cash_from_operations": 90593000, "net_income": 91511000, "ebitda": 126703000, "year_low_stock_price": 4.62, "year_high_stock_price": 15.18, "image_position": [14378, 0, 128, 128]}, {"symbol": "TCPC", "name": "BlackRock TCP Capital Corp", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 46244570.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": 0.37408, "eps_up_revisions": 0, "eps_down_revisions": 7, "revenue_up_revisions": 1, "revenue_down_revisions": 5, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 2, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "tcpcapital.com", "year_founded": 2012, "street_address": "2951 28th Street", "city": "Santa Monica", "state": "CA", "zipcode": "90405", "country": "United States", "phone_number": "310-566-1000", "short_description": "BlackRock TCP Capital Corp. is a business development company specializing in direct equity and debt investments in middle-market, senior secured loans, junior loans, originated loans, mezzanine, senior debt instruments, bonds, and secondary-market investments.", "long_description": "BlackRock TCP Capital Corp. is a business development company specializing in direct equity and debt investments in middle-market, senior secured loans, junior loans, originated loans, mezzanine, senior debt instruments, bonds, and secondary-market investments. It seeks to invest in the United States. The fund typically invests between $10 million and $35 million in companies with enterprise values between $100 million and $1500 million. It prefers to make equity investments in companies for an ownership stake.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 480616664, "total_enterprise": 1343570512, "number_of_employees": null, "outstanding_shares": 57766426, "eps": 0.520379, "diluted_eps": 0.520379, "earnings_from_cont_operations": 30580789, "gross_profit": 195165915, "cash": 44848539, "total_debt": 907802387, "total_revenue": 195165915, "cash_from_operations": 4693354, "net_income": 30580789, "ebitda": null, "year_low_stock_price": 4.02, "year_high_stock_price": 14.79, "image_position": [14478, 0, 100, 100]}, {"symbol": "RUBY", "name": "Rubius Therapeutics, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.55614, "eps_up_revisions": 2, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 7, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "rubiustx.com", "year_founded": 2013, "street_address": "399 Binney Street", "city": "Cambridge", "state": "MA", "zipcode": "02139", "country": "United States", "phone_number": "617-679-9600", "short_description": "Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases.", "long_description": "Rubius Therapeutics, Inc. focuses on the development of red cell therapeutics (RCTs) for the treatment of patients with severe diseases. The company is developing various RCTs, such as RTX-134 for treatment of phenylketonuria; RTX-Uricase for treatment of chronic refractory gout; RTX-CBS for treatment of homocystinuria; and RTX-OxOx for the treatment of second-line hyperoxaluria. It is also developing RTX-240 and RTX-224 for the treatment of cancer; and RTX-aAPC to treat solid and hematological cancers. In addition, the company is developing RTX-T1D for treating type 1 diabetes; and RTX-PV for treating pemphigus vulgaris. The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 500264666, "total_enterprise": 313980666, "number_of_employees": 223, "outstanding_shares": 80428403, "eps": -2.077269, "diluted_eps": -2.077269, "earnings_from_cont_operations": -163458000, "gross_profit": null, "cash": 283287000, "total_debt": 97003000, "total_revenue": null, "cash_from_operations": -110444000, "net_income": -163458000, "ebitda": -166606000, "year_low_stock_price": 3.35, "year_high_stock_price": 17.17, "image_position": [14606, 0, 128, 128]}, {"symbol": "AVDL", "name": "Avadel Pharmaceuticals plc", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 9520000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.2275, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 1, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 5, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "avadel.com", "year_founded": 2015, "street_address": "Blanchardstown Corporate Park", "city": "Dublin", "state": null, "zipcode": "15", "country": "Ireland", "phone_number": "353 1 485 1200", "short_description": "Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland.", "long_description": "Avadel Pharmaceuticals plc operates as a specialty pharmaceutical company in the United States, France, and Ireland. The company primarily develops FT218, which is in a Phase 3 clinical trial for the treatment of narcolepsy patients suffering from excessive daytime sleepiness (EDS) and cataplexy. It also markets three sterile injectable drugs used in the hospital setting, including Akovaz that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia; Bloxiverz, a cholinesterase inhibitor indicated for the reversal of the effects of non-depolarizing neuromuscular blocking agents after surgery; and Vazculep, a phenylephrine hydrochloride injection indicated for the treatment of clinically important hypotension. The company was formerly known as Flamel Technologies SA and changed its name to Avadel Pharmaceuticals PLC in January 2017. Avadel Pharmaceuticals plc was incorporated in 2015 and is headquartered in Dublin, Ireland.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 543334306, "total_enterprise": 603826306, "number_of_employees": 50, "outstanding_shares": 58048537, "eps": -0.888324, "diluted_eps": -0.89, "earnings_from_cont_operations": -33226000, "gross_profit": 47090000, "cash": 64158000, "total_debt": 124650000, "total_revenue": 59215000, "cash_from_operations": -38325000, "net_income": -33226000, "ebitda": -14340000, "year_low_stock_price": 1.09, "year_high_stock_price": 13.49, "image_position": [14666, 0, 60, 60]}, {"symbol": "DRRX", "name": "DURECT Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 7189000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.034, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 2, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "durect.com", "year_founded": 1998, "street_address": "10260 Bubb Road", "city": "Cupertino", "state": "CA", "zipcode": "95014", "country": "United States", "phone_number": "408-777-1417", "short_description": "DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs.", "long_description": "DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for pharmaceutical and medical device clients for use as raw materials in their products under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase I and II development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company\u00e2\u20ac\u2122s oral and injectable delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; Santen Pharmaceutical Co., Ltd.; Sandoz AG; and Zogenix, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 434898088, "total_enterprise": 397046088, "number_of_employees": 90, "outstanding_shares": 195900040, "eps": -0.115579, "diluted_eps": -0.12, "earnings_from_cont_operations": -20578000, "gross_profit": -5288000, "cash": 64674000, "total_debt": 26822000, "total_revenue": 29564000, "cash_from_operations": 11101000, "net_income": -20578000, "ebitda": -19360000, "year_low_stock_price": 0.5, "year_high_stock_price": 3.95, "image_position": [14794, 0, 128, 31]}, {"symbol": "XENT", "name": "Intersect ENT, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 22692860.0, "next_earnings_eps_num_analysts": 9, "next_earnings_eps_consensus": -0.44174, "eps_up_revisions": 2, "eps_down_revisions": 7, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 10, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "intersectent.com", "year_founded": 2003, "street_address": "1555 Adams Drive", "city": "Menlo Park", "state": "CA", "zipcode": "94025", "country": "United States", "phone_number": "650-641-2100", "short_description": "Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States.", "long_description": "Intersect ENT, Inc., a drug delivery company, researches and develops products for the treatment of patients with ear, nose, and throat conditions in the United States. The company offers PROPEL and PROPEL mini drug releasing implants for patients undergoing sinus surgery to treat chronic sinusitis; and PROPEL Contour, a steroid releasing implant to frontal and maxillary sinus ostia, or openings, of the dependent sinuses. It is also developing SINUVA, a steroid releasing implant for refractory disease for the treatment of patients in the physician office setting. The company was formerly known as Sinexus, Inc. and changed its name to Intersect ENT, Inc. in November 2009. Intersect ENT, Inc. was founded in 2003 and is headquartered in Menlo Park, California.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 438992079, "total_enterprise": 360576079, "number_of_employees": 402, "outstanding_shares": 32542037, "eps": -1.369759, "diluted_eps": -1.369759, "earnings_from_cont_operations": -42994000, "gross_profit": 87369000, "cash": 90638000, "total_debt": 12222000, "total_revenue": 109142000, "cash_from_operations": -27251000, "net_income": -42994000, "ebitda": -42727000, "year_low_stock_price": 5.97, "year_high_stock_price": 31.46, "image_position": [14922, 0, 128, 128]}, {"symbol": "CAMT", "name": "Camtek Ltd.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 30033330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.11, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "camtek.com", "year_founded": 1987, "street_address": "Ramat Gavriel Industrial Zone", "city": "Migdal Haemek", "state": null, "zipcode": "23150", "country": "Israel", "phone_number": "972 4 604 8100", "short_description": "Camtek Ltd. develops, manufactures, and sells metrology and inspection equipment for the advanced interconnect packaging, memory, complementary metal oxide semiconductor image sensors, micro-electro mechanical systems, radio frequency, and other segments of the semiconductor industry.", "long_description": "Camtek Ltd. develops, manufactures, and sells metrology and inspection equipment for the advanced interconnect packaging, memory, complementary metal oxide semiconductor image sensors, micro-electro mechanical systems, radio frequency, and other segments of the semiconductor industry. It provides inspection and metrology systems, including Eagle i, a system that delivers 2D inspection and metrology capabilities; Eagle AP, which addresses the advanced packaging market using software and hardware technologies that deliver superior 2D and 3D inspection and metrology capabilities on the same platform; and Golden Eagle, a panel inspection and metrology system to support the manufacturing of panel wafers used in the manufacturing of fan-out level packaging applications. The company sells its products in the Asia Pacific, the United States, and Europe. Camtek Ltd. was incorporated in 1987 and is headquartered in Migdal HaEmek, Israel.", "industry_name": "Semiconductors and Semiconductor Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 432351003, "total_enterprise": 344406003, "number_of_employees": 322, "outstanding_shares": 38671825, "eps": 0.584329, "diluted_eps": 0.570261, "earnings_from_cont_operations": 20823000, "gross_profit": 64784000, "cash": 89547000, "total_debt": 1602000, "total_revenue": 134019000, "cash_from_operations": 24626000, "net_income": 21986000, "ebitda": 23229000, "year_low_stock_price": 6.27, "year_high_stock_price": 14.24, "image_position": [15050, 0, 128, 128]}, {"symbol": "AVD", "name": "American Vanguard Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 98233330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.00667, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "american-vanguard.com", "year_founded": 1969, "street_address": "4695 MacArthur Court", "city": "Newport Beach", "state": "CA", "zipcode": "92660", "country": "United States", "phone_number": "949 260 1200", "short_description": "American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally.", "long_description": "American Vanguard Corporation, through its subsidiaries, develops, manufactures, and markets specialty chemicals for agricultural, commercial, and consumer uses in the United States and internationally. The company manufactures and formulates chemicals, including insecticides, fungicides, herbicides, molluscicides, growth regulators, and soil fumigants in liquid, powder, and granular forms for crops, turf and ornamental plants, and human and animal health protection. It also markets and distributes end-use chemical and biological products for crop applications; distributes chemicals for greenhouse and nursery production markets; and offers formulations, such as PCNB, chlorothalonil, and propiconazole under the FFII and FFIII names. The company distributes its products through national distribution companies, and buying groups or co-operatives; and through sales offices, sales force executives, sales agents, and wholly owned distributors. American Vanguard Corporation was founded in 1969 and is headquartered in Newport Beach, California.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 414353042, "total_enterprise": 567945042, "number_of_employees": 671, "outstanding_shares": 30178663, "eps": 0.468515, "diluted_eps": 0.46, "earnings_from_cont_operations": 13601000, "gross_profit": 177354000, "cash": 6581000, "total_debt": 160173000, "total_revenue": 468186000, "cash_from_operations": 9403000, "net_income": 13601000, "ebitda": 49071000, "year_low_stock_price": 11.35, "year_high_stock_price": 19.6, "image_position": [15178, 0, 128, 128]}, {"symbol": "EXTR", "name": "Extreme Networks, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 207934330.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.12, "eps_up_revisions": 0, "eps_down_revisions": 5, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "extremenetworks.com", "year_founded": 1996, "street_address": "6480 Via del Oro", "city": "San Jose", "state": "CA", "zipcode": "95119", "country": "United States", "phone_number": "408-579-2800", "short_description": "Extreme Networks, Inc. provides software-driven networking solutions for enterprise, data center, and service provider customers worldwide.", "long_description": "Extreme Networks, Inc. provides software-driven networking solutions for enterprise, data center, and service provider customers worldwide. It designs, develops, and manufactures wired and wireless network infrastructure equipment; and develops the software for network management, policy, analytics, security, and access controls. The company offers edge/access switch portfolio that delivers Ethernet connectivity for the edge of the network; aggregation/core switches designed to address aggregation, top-of-rack, and campus core environments; and wireless access point products. It also provides VDX, MLX, and SLX data center family of switches; ExtremeControl, a network access control solution that allows the enterprises to unify the security of their wired and wireless networks with visibility and control over users, devices, and applications; and ExtremeAnalytics, a network-powered application analytics and optimization solution, which captures, aggregates, analyses, correlates, and reports network data that enables in decision making and enhancing business performance. In addition, the company offers ExtremeGuest and ExtremeLocation, which are cloud services that enable enterprises to incorporate location-based services; and ExtremeCloud, a wired and wireless cloud network management solution, which offers visibility and control over users and applications. It markets and sells its products through distributors, resellers, and field sales organizations. The company serves enterprises and organizations in the education, healthcare, manufacturing, hospitality, transportation, and logistics sectors, as well as government agencies, private cloud data centers, universities, and stadiums; and enterprises and private cloud data centers. Extreme Networks, Inc. was founded in 1996 and is headquartered in San Jose, California.", "industry_name": "Communications Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 399369459, "total_enterprise": 701204459, "number_of_employees": 2713, "outstanding_shares": 118507258, "eps": -0.715464, "diluted_eps": -0.715464, "earnings_from_cont_operations": -85263000, "gross_profit": 571079000, "cash": 140414000, "total_debt": 442249000, "total_revenue": 1026201000, "cash_from_operations": 65245000, "net_income": -85263000, "ebitda": 45399000, "year_low_stock_price": 1.43, "year_high_stock_price": 8.5, "image_position": [15306, 0, 128, 31]}, {"symbol": "ORGO", "name": "Organogenesis Holdings Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 61133330.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.133, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "organogenesis.com", "year_founded": 1985, "street_address": "85 Dan Road", "city": "Canton", "state": "MA", "zipcode": "02021", "country": "United States", "phone_number": "781 575 0775", "short_description": "Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States.", "long_description": "Organogenesis Holdings Inc., a regenerative medicine company, focuses on the development, manufacture, and commercialization of solutions for the advanced wound care, and surgical and sports medicine markets primarily in the United States. The company\u2019s advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for treating DFUs; PuraPly AM to address biofilm across a range of wound types; and Affinity and NuShield to address various wound sizes and types. Its surgical and sports medicine products comprise ReNu for in-office joint and tendon applications; NuCel for bony fusion in the spine and extremities; NuShield and Affinity for surgical applications in targeted soft tissue repairs; and PuraPly AM for the surgical treatment of open wounds. The company\u2019s pipeline products include TransCyte for the treatment of second- and third-degree burns; PuraForce, a bioengineered porcine collagen surgical matrix for use in soft tissue reinforcement applications; Novachor for the treatment of chronic and acute wounds; Gintuit for the treatment of mucogingival conditions in adults; and PuraPly XT and PuraPly MZ for the treatment of chronic and acute wounds, as well as for surgical treatment of open wounds. It serves hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices. The company sells its products through direct sales representatives and independent agencies. Organogenesis Holdings Inc. was founded in 1985 and is headquartered in Canton, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 403517110, "total_enterprise": 443949110, "number_of_employees": 835, "outstanding_shares": 105356948, "eps": -0.442684, "diluted_eps": -0.442684, "earnings_from_cont_operations": -40454000, "gross_profit": 185033000, "cash": 60174000, "total_debt": 100606000, "total_revenue": 260981000, "cash_from_operations": -33528000, "net_income": -40454000, "ebitda": -20028000, "year_low_stock_price": 2.47, "year_high_stock_price": 8.35, "image_position": [15366, 0, 60, 60]}, {"symbol": "APTS", "name": "Preferred Apartment Communities, Inc.", "next_earnings_utc": 1589232000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 123972670.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.76, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "pacapts.com", "year_founded": 2009, "street_address": "3284 Northside Parkway NW", "city": "Atlanta", "state": "GA", "zipcode": "30327", "country": "United States", "phone_number": "770-818-4100", "short_description": "Preferred Apartment Communities, Inc. (NYSE: APTS) is a real estate investment trust engaged primarily in the ownership and operation of Class A multifamily properties, with select investments in grocery anchored shopping centers, Class A office buildings, and student housing properties.", "long_description": "Preferred Apartment Communities, Inc. (NYSE: APTS) is a real estate investment trust engaged primarily in the ownership and operation of Class A multifamily properties, with select investments in grocery anchored shopping centers, Class A office buildings, and student housing properties. Preferred Apartment Communities' investment objective is to generate attractive, stable returns for stockholders by investing in income-producing properties and acquiring or originating real estate loans for multifamily properties. As of December 31, 2019, the Company owned or was invested in 123 properties in 15 states, predominantly in the Southeast region of the United States.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 366337956, "total_enterprise": 2911306956, "number_of_employees": null, "outstanding_shares": 47576358, "eps": -2.734282, "diluted_eps": -2.734282, "earnings_from_cont_operations": -7458000, "gross_profit": 294967000, "cash": 94381000, "total_debt": 2636511000, "total_revenue": 468404000, "cash_from_operations": 145631000, "net_income": -7244000, "ebitda": 278414000, "year_low_stock_price": 5.27, "year_high_stock_price": 16.94, "image_position": [15494, 0, 128, 128]}, {"symbol": "RC", "name": "Ready Capital Corporation", "next_earnings_utc": 1589183100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 64668000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.374, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 3, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "readycapital.com", "year_founded": 2007, "street_address": "1251 Avenue of the Americas", "city": "New York", "state": "NY", "zipcode": "10020", "country": "United States", "phone_number": "212-257-4600", "short_description": "Ready Capital Corporation operates as a real estate finance company in the United States.", "long_description": "Ready Capital Corporation operates as a real estate finance company in the United States. The company originates, acquires, finances, and services small balance commercial (SBC) loans, small business administration (SBA) loans, and residential mortgage loans, as well as mortgage backed securities collateralized primarily by SBC loans, or other real estate-related investments. It operates through four segments: Acquisitions; SBC Originations; SBA Originations, Acquisitions and Servicing; and Residential Mortgage Banking. The Acquisitions segment acquires performing and non-performing SBC loans. The SBC Originations segment originates SBC loans secured by stabilized or transitional investor properties using various loan origination channels; and originates and services multi-family loan products. The SBA Originations, Acquisitions and Servicing segment acquires, originates, and services owner-occupied loans guaranteed by the SBA. The Residential Mortgage Banking segment originates residential mortgage loans through retail, correspondent, and broker channels. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Sutherland Asset Management Corporation and changed its name to Ready Capital Corporation in September 2018. Ready Capital Corporation was founded in 2007 and is headquartered in New York, New York.", "industry_name": "Mortgage Real Estate Investment Trusts (REITs)", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 317886961, "total_enterprise": null, "number_of_employees": 430, "outstanding_shares": 52027326, "eps": 1.721304, "diluted_eps": 1.72, "earnings_from_cont_operations": 75056000, "gross_profit": 154042000, "cash": 163231000, "total_debt": 4033427000, "total_revenue": 223778000, "cash_from_operations": -52397000, "net_income": 72968000, "ebitda": null, "year_low_stock_price": 3.92, "year_high_stock_price": 16.9, "image_position": [15622, 0, 128, 128]}, {"symbol": "CPE", "name": "Callon Petroleum Company", "next_earnings_utc": 1589187600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 302653370.0, "next_earnings_eps_num_analysts": 13, "next_earnings_eps_consensus": 0.1039, "eps_up_revisions": 0, "eps_down_revisions": 12, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 21, "analysts_sell": 1, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 15, "analysts_underperform": 2, "webpage": "callon.com", "year_founded": 1950, "street_address": "One Briarlake Plaza", "city": "Houston", "state": "TX", "zipcode": "77042", "country": "United States", "phone_number": "281 589 5200", "short_description": "Callon Petroleum Company, an independent oil and natural gas company, focuses on the acquisition, exploration, and development of oil and natural gas properties in Permian Basin in West Texas.", "long_description": "Callon Petroleum Company, an independent oil and natural gas company, focuses on the acquisition, exploration, and development of oil and natural gas properties in Permian Basin in West Texas. As of December 31, 2019, its estimated net proved reserves totaled approximately 540 million barrel of oil equivalent, including 346.4 MMBbls oil, 757.1 Bcf of natural gas, and 67.5 MMBbls of natural gas liquids. The company was founded in 1950 and is headquartered in Houston, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 321572054, "total_enterprise": 3574286054, "number_of_employees": 475, "outstanding_shares": 397002537, "eps": 0.238599, "diluted_eps": 0.238599, "earnings_from_cont_operations": 67928000, "gross_profit": 537094000, "cash": 13341000, "total_debt": 3266055000, "total_revenue": 628921000, "cash_from_operations": 476316000, "net_income": 67928000, "ebitda": 430848000, "year_low_stock_price": 0.38, "year_high_stock_price": 8.47, "image_position": [15698, 0, 76, 76]}, {"symbol": "CLDT", "name": "Chatham Lodging Trust", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 62059670.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.22, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "chathamlodgingtrust.com", "year_founded": 2009, "street_address": "222 Lakeview Avenue", "city": "West Palm Beach", "state": "FL", "zipcode": "33401", "country": "United States", "phone_number": "561-802-4477", "short_description": "Chatham Lodging Trust is a self-advised, publicly-traded real estate investment trust focused primarily on investing in upscale, extended-stay hotels and premium-branded, select-service hotels.", "long_description": "Chatham Lodging Trust is a self-advised, publicly-traded real estate investment trust focused primarily on investing in upscale, extended-stay hotels and premium-branded, select-service hotels. The company owns interests in 137 hotels totaling 18,783 rooms/suites, comprised of 42 properties it wholly owns with an aggregate of 6,283 rooms/suites in 15 states and the District of Columbia and a minority investment in two joint ventures that own 95 hotels with an aggregate of 12,500 rooms/suites.", "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 328672092, "total_enterprise": 943881092, "number_of_employees": 39, "outstanding_shares": 46955388, "eps": 0.393384, "diluted_eps": 0.389999, "earnings_from_cont_operations": 18880000, "gross_profit": 150332000, "cash": 6620000, "total_debt": 609182000, "total_revenue": 314614000, "cash_from_operations": 86234000, "net_income": 18703000, "ebitda": 99268000, "year_low_stock_price": 3.44, "year_high_stock_price": 20.2, "image_position": [15826, 0, 128, 128]}, {"symbol": "ICAD", "name": "iCAD, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 7713000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.26333, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "icadmed.com", "year_founded": 1984, "street_address": "98 Spit Brook Road", "city": "Nashua", "state": "NH", "zipcode": "03062", "country": "United States", "phone_number": "603-882-5200", "short_description": "iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally.", "long_description": "iCAD, Inc. provides image analysis, workflow solutions, and radiation therapy for the early identification and treatment of cancer in the United States and internationally. It operates through two segments, Cancer Detection and Cancer Therapy. The company provides electronic brachytherapy (eBX) products, including Axxent eBx systems for the treatment of early stage breast cancer, endometrial cancer, cervical cancer, and skin cancer, as well as for treating other cancers or conditions where radiation therapy is indicated comprising intraoperative radiation therapy. It also offers digital mammography computer-aided detection (CAD) products, which include PowerLook Mammo Detection, which detects and identifies suspicious masses and micro-calcifications; and PowerLook Platform, a server residing on a customer\u00e2\u20ac\u2122s network that receives patient studies from the imaging modality, performs analysis, and sends results to picture archiving and communication system and/or review workstations. In addition, the company offers magnetic resonance imaging products to detect breast and prostate cancer; breast tomosynthesis systems; and advanced image analysis and workflow solutions in computed tomography (CT) colonography, including VeraLook that supports the detection of colonic polyps in conjunction with CT colonography. It serves healthcare centers through direct sales organizations, as well as through various original equipment manufacturer partners, distributors, and resellers. The company was formerly known as Howtek, Inc. and changed its name to iCAD, Inc. in June 2002. iCAD, Inc. was founded in 1984 and is headquartered in Nashua, New Hampshire.", "industry_name": "Health Care Technology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 292238375, "total_enterprise": 299415375, "number_of_employees": 137, "outstanding_shares": 22742286, "eps": -0.737349, "diluted_eps": -0.74, "earnings_from_cont_operations": -13551000, "gross_profit": 24624000, "cash": 15313000, "total_debt": 22490000, "total_revenue": 31340000, "cash_from_operations": -7107000, "net_income": -13551000, "ebitda": -5723000, "year_low_stock_price": 5.24, "year_high_stock_price": 15.31, "image_position": [15954, 0, 128, 128]}, {"symbol": "BXG", "name": "Bluegreen Vacations Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 159682000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.16, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "bluegreenvacations.com", "year_founded": 1966, "street_address": "4960 Conference Way North", "city": "Boca Raton", "state": "FL", "zipcode": "33431", "country": "United States", "phone_number": "561 912 8000", "short_description": "Bluegreen Vacations Corporation operates as a vacation ownership company that markets and sells vacation ownership interests (VOIs) in the United States.", "long_description": "Bluegreen Vacations Corporation operates as a vacation ownership company that markets and sells vacation ownership interests (VOIs) in the United States. It operates through two segments, Sales of VOIs and Financing; and Resort Operations and Club Management. The company offers VOIs in resorts that are developed or acquired by the company, or developed and owned by third parties. Its resort network includes 45 club resorts and 23 club associate resorts. The company also provides management services to the Vacation Club and homeowners' associations; mortgage servicing; VOI title services; reservation services; and financing to VOI purchases, as well as construction, design, and development services. In addition, it offers traveler plus programs; food and beverage, and retail services; rental services to third parties; and management of construction activities. The company was formerly known as Bluegreen Corporation and changed its name to Bluegreen Vacations Corporation in September 2017. Bluegreen Vacations Corporation was founded in 1966 and is headquartered in Boca Raton, Florida. Bluegreen Vacations Corporation is a subsidiary of Woodbridge Holdings, LLC.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 301912533, "total_enterprise": 824617533, "number_of_employees": 5873, "outstanding_shares": 74362693, "eps": 0.468182, "diluted_eps": 0.468182, "earnings_from_cont_operations": 46124000, "gross_profit": 571477000, "cash": 190009000, "total_debt": 663180000, "total_revenue": 680262000, "cash_from_operations": 70558000, "net_income": 34851000, "ebitda": 165347000, "year_low_stock_price": 3.25, "year_high_stock_price": 15.43, "image_position": [16082, 0, 128, 128]}, {"symbol": "AMAG", "name": "AMAG Pharmaceuticals, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 64821430.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.495, "eps_up_revisions": 1, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 2, "analysts_hold": 6, "analysts_underperform": 2, "webpage": "amagpharma.com", "year_founded": 1981, "street_address": "1100 Winter Street", "city": "Waltham", "state": "MA", "zipcode": "02451", "country": "United States", "phone_number": "617 498 3300", "short_description": "AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States.", "long_description": "AMAG Pharmaceuticals, Inc., a pharmaceutical company, develops, manufactures, and commercializes therapeutics for maternal and women's health, and anemia management in the United States. The company markets Feraheme (ferumoxytol), an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia in adult patients who have intolerance to oral iron or have had unsatisfactory response to oral iron, as well as patients who have chronic kidney disease; Makena, a hydroxyprogesterone caproate injection to reduce the risk of preterm birth in women pregnant with a single baby who have a history of singleton spontaneous preterm birth; Intrarosa(prasterone) vaginal insert steroid for the treatment of dyspareunia due to menopause; and Vyleesi (bremelanotide), an auto-injector device for the treatment of hypoactive sexual desire disorder in pre-menopausal women. Its product candidates also include AMAG-423 (ovine), an antibody fragment, which is in Phase 2b/3a trial for the treatment of severe preeclampsia in pregnant women; and Ciraparantag, an anticoagulant reversal agent that is in planned Phase 2b trial for the treatment of novel oral anticoagulants or low molecular weight heparin. The company sells Feraheme to authorized wholesalers and specialty distributors. The company has license agreements with Endoceutics, Inc., Palatin Technologies, Inc., Velo Bio, LLC, Prasco, LLC, Perosphere Pharmaceuticals Inc., and Antares Pharma, Inc. AMAG Pharmaceuticals, Inc. was founded in 1981 and is headquartered in Waltham, Massachusetts.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 316277542, "total_enterprise": 445428542, "number_of_employees": 440, "outstanding_shares": 34266256, "eps": -13.707199, "diluted_eps": -13.71, "earnings_from_cont_operations": -466456000, "gross_profit": 178904000, "cash": 171751000, "total_debt": 300902000, "total_revenue": 327751000, "cash_from_operations": -125696000, "net_income": -466456000, "ebitda": -113105000, "year_low_stock_price": 4.41, "year_high_stock_price": 13.53, "image_position": [16210, 0, 128, 128]}, {"symbol": "ETH", "name": "Ethan Allen Interiors Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q4", "next_earnings_year": 2020, "next_earnings_quarter": 4, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 123906000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.2125, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "ethanallen.com", "year_founded": 1932, "street_address": "25 Lake Avenue Extension", "city": "Danbury", "state": "CT", "zipcode": "06811", "country": "United States", "phone_number": "203-743-8000", "short_description": "Ethan Allen Interiors Inc. operates as an interior design company, and manufacturer and retailer of home furnishings in North America, Asia, the Middle East, and Europe.", "long_description": "Ethan Allen Interiors Inc. operates as an interior design company, and manufacturer and retailer of home furnishings in North America, Asia, the Middle East, and Europe. The company operates through two segments, Wholesale and Retail. Its products include case goods items, such as beds, dressers, armoires, tables, chairs, buffets, entertainment units, home office furniture, and wooden accents; upholstery items comprising sleepers, recliners and other motion furniture, chairs, ottomans, custom pillows, sofas, loveseats, cut fabrics, and leather; and home accents and other items consisting of window treatments and drapery hardware, wall decors, florals, lighting, clocks, mattresses, bedspreads, throws, pillows, decorative accents, area rugs, wall coverings, and home and garden furnishings. The company markets and sells its products under the Ethan Allen brand name through home furnishing retail networks and independent retailers, as well as through ethanallen.com Website. As of July 31, 2019, it operated a network of approximately 300 design centers. Ethan Allen Interiors Inc. was founded in 1932 and is headquartered in Danbury, Connecticut.", "industry_name": "Household Durables", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 299225691, "total_enterprise": 422497691, "number_of_employees": 4700, "outstanding_shares": 25929436, "eps": 0.96709, "diluted_eps": 0.963051, "earnings_from_cont_operations": 25860000, "gross_profit": 397022000, "cash": 28306000, "total_debt": 151541000, "total_revenue": 710242000, "cash_from_operations": 47160000, "net_income": 25860000, "ebitda": 65878000, "year_low_stock_price": 8.38, "year_high_stock_price": 22.99, "image_position": [16290, 0, 80, 80]}, {"symbol": "CLAR", "name": "Clarus Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 54950500.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.12471, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "claruscorp.com", "year_founded": 1991, "street_address": "2084 East 3900 South", "city": "Salt Lake City", "state": "UT", "zipcode": "84124", "country": "United States", "phone_number": "801 278 5552", "short_description": "Clarus Corporation focuses on the outdoor and consumer industries in the United States, Canada, Europe, the Middle East, Asia, Australia, New Zealand, Africa, and South America.", "long_description": "Clarus Corporation focuses on the outdoor and consumer industries in the United States, Canada, Europe, the Middle East, Asia, Australia, New Zealand, Africa, and South America. The company develops, manufactures, and distributes outdoor equipment and lifestyle products focusing on the climb, ski, mountain, sport, and skincare markets. It operates in two segments, Black Diamond and Sierra. The Black Diamond segment offers activity-based apparel, such as shells, insulation, midlayers, pants, and logowear; rock-climbing footwear and equipment, including carabiners, protection devices, harnesses, belay devices, helmets, and ice-climbing gears; technical backpacks and day packs; trekking poles; headlamps and lanterns; gloves and mittens; skincare and other sport-enhancing products; and skis, ski poles, ski skins, and snow safety products, such as avalanche airbag systems, avalanche transceivers, shovels, and probes. This segment offers its products for climbing, mountaineering, trail running, backpacking, skiing, and other outdoor recreation activities under the Black Diamond, PIEPS, and SKINourishment brands. The Sierra segment manufactures bullets and ammunition products for rifles and pistols, which are used for precision target shooting, hunting, and military and law enforcement purposes under the Sierra brand. The company sells its products to mountain, rock, ice, and gym climbers; and winter outdoor enthusiasts, backpackers, competitive shooters, hunters, and outdoor-inspired consumers. It markets and distributes its products through independent specialty stores and specialty chains, sporting goods and outdoor recreation stores, distributors, and original equipment manufacturers; and independent distributors, as well as directly to customers through its websites. The company was formerly known as Black Diamond, Inc. and changed its name to Clarus Corporation in August 2017. Clarus Corporation was incorporated in 1991 and is headquartered in Salt Lake City, Utah.", "industry_name": "Leisure Products", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 297994277, "total_enterprise": 320142277, "number_of_employees": 500, "outstanding_shares": 29829257, "eps": 0.634732, "diluted_eps": 0.6086, "earnings_from_cont_operations": 18972000, "gross_profit": 80291000, "cash": 1703000, "total_debt": 23851000, "total_revenue": 229437000, "cash_from_operations": 9522000, "net_income": 18972000, "ebitda": 19713000, "year_low_stock_price": 7.86, "year_high_stock_price": 15.07, "image_position": [16418, 0, 128, 128]}, {"symbol": "PFLT", "name": "PennantPark Floating Rate Capital", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 24964600.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.28667, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "pennantpark.com", "year_founded": 2010, "street_address": "590 Madison Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "212-905-1000", "short_description": "PennantPark Floating Rate Capital Ltd. is a business development company.", "long_description": "PennantPark Floating Rate Capital Ltd. is a business development company. It seeks to make secondary direct, debt, equity, and loan investments. The fund seeks to invest through floating rate loans in private or thinly traded or small market-cap, public middle market companies. It primarily invests in the United States and to a limited extent non-U.S. companies. The fund typically invests between $2 million and $20 million. The fund also invests in equity securities, such as preferred stock, common stock, warrants or options received in connection with debt investments or through direct investments. It primarily invests between $10 million and $50 million in investments in senior secured loans and mezzanine debt. It seeks to invest in companies not rated by national rating agencies. The companies if rated would be between BB and CCC under the Standard & Poor's system. The fund invests 30% is invested in non-qualifying assets like investments in public companies whose securities are not thinly traded or do not have a market capitalization of less than $250 million, securities of middle-market companies located outside of the United States, high-yield bonds, distressed debt, private equity, securities of public companies that are not thinly traded, and investment companies as defined in the 1940 Act. Under normal conditions, the fund expects atleast 80 percent of its net assets plus any borrowings for investment purposes to be invested in Floating Rate Loans and investments with similar economic characteristics, including cash equivalents invested in money market funds. It expects to represent 65 percent of its portfolio through senior secured loans. In case of floating rate loans, it holds investments for a period of three to ten years.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 264037824, "total_enterprise": 900006308, "number_of_employees": null, "outstanding_shares": 38772074, "eps": 0.422825, "diluted_eps": 0.422825, "earnings_from_cont_operations": 16393805, "gross_profit": 94401624, "cash": 56292541, "total_debt": 692261026, "total_revenue": 94401624, "cash_from_operations": -143922196, "net_income": 16393805, "ebitda": null, "year_low_stock_price": 3.34, "year_high_stock_price": 12.92, "image_position": [16546, 0, 128, 128]}, {"symbol": "WVE", "name": "Wave Life Sciences Ltd.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 5902860.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -1.32167, "eps_up_revisions": 3, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "wavelifesciences.com", "year_founded": 2012, "street_address": "Marina One East Tower", "city": "Singapore", "state": null, "zipcode": "018936", "country": "Singapore", "phone_number": "65 6236 3388", "short_description": "Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform.", "long_description": "Wave Life Sciences Ltd., a clinical stage genetic medicine company, designs, optimizes, and produces of novel stereopure oligonucleotides through PRISM, a discovery and drug developing platform. The company is primarily developing oligonucleotides that target genetic defects to either reduce the expression of disease-promoting proteins or transform the production of dysfunctional mutant proteins into the production of functional proteins. It focuses on programs in neurology in the central nervous system and neuromuscular system. The company has a research, license, and option agreement with Pfizer Inc. and Takeda Pharmaceutical Company Limited for the research, development, and commercialization of stereopure oligonucleotide therapeutics and oligonucleotide therapeutics; and research, development, and develop antisense oligonucleotides. Wave Life Sciences Ltd. was founded in 2012 and is based in Singapore.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 275295994, "total_enterprise": 168555994, "number_of_employees": 301, "outstanding_shares": 34601582, "eps": -5.717687, "diluted_eps": -5.717687, "earnings_from_cont_operations": -193638000, "gross_profit": -159448000, "cash": 147161000, "total_debt": 32547000, "total_revenue": 15983000, "cash_from_operations": -188231000, "net_income": -193638000, "ebitda": -200729000, "year_low_stock_price": 6.61, "year_high_stock_price": 39.98, "image_position": [16674, 0, 128, 128]}, {"symbol": "GPMT", "name": "Granite Point Mortgage Trust Inc.", "next_earnings_utc": 1589230800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 29625500.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.35024, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 2, "analysts_hold": 4, "analysts_underperform": 0, "webpage": "gpmortgagetrust.com", "year_founded": 2015, "street_address": "3 Bryant Park", "city": "New York", "state": "NY", "zipcode": "10036", "country": "United States", "phone_number": "212-364-3200", "short_description": "Granite Point Mortgage Trust Inc. originates, invests in, and manages senior floating-rate commercial mortgage loans, and other debt and debt-like commercial real estate investments in the United States.", "long_description": "Granite Point Mortgage Trust Inc. originates, invests in, and manages senior floating-rate commercial mortgage loans, and other debt and debt-like commercial real estate investments in the United States. As of December 31, 2018, its investment portfolio includes 94 commercial real estate debt investments. The company intends to qualify as a real estate investment trust for federal income tax purposes. Granite Point Mortgage Trust Inc. was founded in 2015 and is headquartered in New York, New York.", "industry_name": "Mortgage Real Estate Investment Trusts (REITs)", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 248115982, "total_enterprise": null, "number_of_employees": null, "outstanding_shares": 55136885, "eps": 1.320727, "diluted_eps": 1.319999, "earnings_from_cont_operations": 70214000, "gross_profit": 106815000, "cash": 80281000, "total_debt": 3393172000, "total_revenue": 110485000, "cash_from_operations": 64182000, "net_income": 70214000, "ebitda": null, "year_low_stock_price": 1.74, "year_high_stock_price": 19.38, "image_position": [16802, 0, 128, 128]}, {"symbol": "PLYA", "name": "Playa Hotels & Resorts N.V.", "next_earnings_utc": 1589230800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 171219230.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.12831, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "playaresorts.com", "year_founded": null, "street_address": "3950 University Drive", "city": "Fairfax", "state": "VA", "zipcode": "22030", "country": "United States", "phone_number": null, "short_description": "Playa Hotels & Resorts N.V. owns, operates, and develops all-inclusive resorts in prime beachfront locations in various vacation destinations in Mexico and the Caribbean.", "long_description": "Playa Hotels & Resorts N.V. owns, operates, and develops all-inclusive resorts in prime beachfront locations in various vacation destinations in Mexico and the Caribbean. The company operates under eight brand names. As of December 12, 2019, it owned a portfolio of 23 resorts comprising 8,690 rooms located in Mexico, Jamaica, and the Dominican Republic. Playa Hotels & Resorts N.V. is headquartered in Fairfax, Virginia.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 264806620, "total_enterprise": 1322673620, "number_of_employees": 12000, "outstanding_shares": 129173961, "eps": -0.033509, "diluted_eps": -0.033509, "earnings_from_cont_operations": -4357000, "gross_profit": 264320000, "cash": 20931000, "total_debt": 1078798000, "total_revenue": 630065000, "cash_from_operations": 72188000, "net_income": -4357000, "ebitda": 133130000, "year_low_stock_price": 1.3, "year_high_stock_price": 8.9, "image_position": [16930, 0, 128, 128]}, {"symbol": "ARA", "name": "American Renal Associates Holdings, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 201725050.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.12, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "americanrenal.com", "year_founded": 1999, "street_address": "500 Cummings Center", "city": "Beverly", "state": "MA", "zipcode": "01915", "country": "United States", "phone_number": "978 922 3080", "short_description": "American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States.", "long_description": "American Renal Associates Holdings, Inc. operates as a dialysis services provider in the United States. It operates dialysis clinics focusing on joint venture partnerships with physicians. The company offers kidney dialysis services to patients suffering from chronic kidney failure or end stage renal disease. As of December 31, 2019, it operated 246 dialysis clinics in partnership with 400 nephrologist partners treating approximately 17,300 patients in 27 states and the District of Columbia. The company was founded in 1999 and is headquartered in Beverly, Massachusetts.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 254074620, "total_enterprise": 1244884620, "number_of_employees": 4977, "outstanding_shares": 32996704, "eps": -0.675113, "diluted_eps": -0.68, "earnings_from_cont_operations": 26145000, "gross_profit": 254505000, "cash": 34637000, "total_debt": 734975000, "total_revenue": 822522000, "cash_from_operations": 38821000, "net_income": -13790000, "ebitda": 121262000, "year_low_stock_price": 5.64, "year_high_stock_price": 13.8, "image_position": [17058, 0, 128, 128]}, {"symbol": "PNNT", "name": "PennantPark Investment", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 28023050.0, "next_earnings_eps_num_analysts": 8, "next_earnings_eps_consensus": -0.19212, "eps_up_revisions": 1, "eps_down_revisions": 4, "revenue_up_revisions": 2, "revenue_down_revisions": 4, "total_analysts": 9, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 6, "analysts_underperform": 1, "webpage": "pennantpark.com", "year_founded": 2007, "street_address": "590 Madison Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "212-905-1000", "short_description": "PennantPark Investment Corporation is a business development company.", "long_description": "PennantPark Investment Corporation is a business development company. It specializes in direct and mezzanine investments in middle market companies. It invests in the form of mezzanine debt, senior secured loans, and equity investments. The fund typically invests in building and real estate, hotels and gaming, electronics, healthcare, education and childcare, financial services, printing and publishing, consumer products, business services, energy and utilities, distribution, oil and gas, media, environmental services, aerospace and defense, manufacturing industries and retail. It invests in equity securities and debt transactions through preferred stock, common stock, warrants, options, subordinated loans, mezzanine loans, and senior secured loans. It seeks to invest in companies based in the United States. The fund seeks to invest between $10 million and $50 million in its portfolio companies. Its mezzanine loans, senior secured loans, and other investments in its portfolio companies are between $15 million and $50 million. The fund may also make non-control equity and debt investments.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 203146668, "total_enterprise": 914026796, "number_of_employees": null, "outstanding_shares": 67045105, "eps": 0.421593, "diluted_eps": 0.421593, "earnings_from_cont_operations": 28349127, "gross_profit": 110730418, "cash": 32107649, "total_debt": 742987777, "total_revenue": 110730418, "cash_from_operations": -113815914, "net_income": 28349127, "ebitda": null, "year_low_stock_price": 1.76, "year_high_stock_price": 6.88, "image_position": [17186, 0, 128, 128]}, {"symbol": "OMP", "name": "Oasis Midstream Partners LP", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 107000000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.9175, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "oasismidstream.com", "year_founded": 2013, "street_address": "1001 Fannin Street", "city": "Houston", "state": "TX", "zipcode": "77002", "country": "United States", "phone_number": "281-404-9500", "short_description": "Oasis Midstream Partners LP provides crude oil, natural gas, and water-related midstream services in North America.", "long_description": "Oasis Midstream Partners LP provides crude oil, natural gas, and water-related midstream services in North America. It offers natural gas gathering, compression, processing, and gas lift services; crude oil gathering, stabilization, blending, and storage services; produced and flowback water gathering and disposal services; freshwater supply and distribution services; and crude oil transportation services from the Wild Basin operating area to Johnson's Corner. OMP GP LLC serves as the general partner of the company. Oasis Midstream Partners LP was founded in 2013 and is based in Houston, Texas. Oasis Midstream Partners LP operates as a subsidiary of OMS Holdings LLC", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 220111992, "total_enterprise": 993505992, "number_of_employees": null, "outstanding_shares": 33811366, "eps": 3.467238, "diluted_eps": 3.467238, "earnings_from_cont_operations": 215231000, "gross_profit": 303343000, "cash": 4168000, "total_debt": 464278000, "total_revenue": 410191000, "cash_from_operations": 252539000, "net_income": 119648000, "ebitda": 269130000, "year_low_stock_price": 2.8, "year_high_stock_price": 22.36, "image_position": [17314, 0, 128, 128]}, {"symbol": "ARLO", "name": "Arlo Technologies, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 63985160.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.35425, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 2, "analysts_underperform": 1, "webpage": "arlo.com", "year_founded": 2018, "street_address": "3030 Orchard Parkway", "city": "San Jose", "state": "CA", "zipcode": "95134", "country": "United States", "phone_number": "408 890 3900", "short_description": "Arlo Technologies, Inc. provides smart connected devices to monitor the environments in real-time with a Wi-Fi or a cellular connection in the Americas, Europe, the Middle-East and Africa, and the Asia Pacific regions.", "long_description": "Arlo Technologies, Inc. provides smart connected devices to monitor the environments in real-time with a Wi-Fi or a cellular connection in the Americas, Europe, the Middle-East and Africa, and the Asia Pacific regions. It offers Arlo Security Camera, a battery-operated Wi-Fi security camera; Arlo Q and Arlo Q Plus, an indoor wired solution that allow users to monitor their surroundings; Arlo Pro, a battery-operated weather-resistant Wi-Fi camera; Arlo Go, a LTE-enabled wire-free camera that provides untethered mobile security; and Arlo Baby, a baby monitor with air quality and temperature sensors, motion and audio detection, and advanced night vision. The company also offers Arlo Pro 2, a battery-operated weather-resistant Wi-Fi camera with advancements in sound and motion detection; Arlo Audio Doorbell, a smart audio doorbell solution to pair with Arlo camera or Arlo Security Light products; Arlo Chime, a product that plugs into standard wall outlet and pairs with the Arlo Audio Doorbell to play various ringtones or act as a siren; and accessories, such as charging accessories, device mounts, and device skins. In addition, it provides Arlo Ultra, an integrated spotlight and crystal-clear two-way audio with advanced noise cancellations camera; Arlo Pro 3, an integrated spotlight with color night vision camera; and Arlo Video Doorbell, a doorbell camera which delivers direct-to-mobile video calls and personalized alerts. Further, the company offers Arlo app for iOS and Android devices that allow users to connect various devices; and prepaid services, including seven-day cloud video storage with the ability to connect up to five cameras and 90 days of customer support. The company offers its products through retail channels, wholesale distribution and wireless carrier channels, and paid subscription services through in-app purchases. Arlo Technologies, Inc. was incorporated in 2018 and is headquartered in San Jose, California.", "industry_name": "Electronic Equipment, Instruments and Components", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 198621329, "total_enterprise": -25135671, "number_of_employees": 349, "outstanding_shares": 76687772, "eps": -1.144883, "diluted_eps": -1.144883, "earnings_from_cont_operations": -85951000, "gross_profit": 35873000, "cash": 256670000, "total_debt": 32913000, "total_revenue": 370007000, "cash_from_operations": 9171000, "net_income": -85951000, "ebitda": -126877000, "year_low_stock_price": 1.2, "year_high_stock_price": 5.13, "image_position": [17442, 0, 128, 38]}, {"symbol": "PRTK", "name": "Paratek Pharmaceuticals, Inc.", "next_earnings_utc": 1589196600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 7464000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.78, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 3, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "paratekpharma.com", "year_founded": 1996, "street_address": "75 Park Plaza", "city": "Boston", "state": "MA", "zipcode": "02116", "country": "United States", "phone_number": "617 807 6600", "short_description": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use.", "long_description": "Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and cooperative research and development agreement with the U.S. Army Medical Research Institute of Infectious Diseases to study omadacycline against pathogenic agents causing infectious diseases. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 197334979, "total_enterprise": 245735979, "number_of_employees": 102, "outstanding_shares": 42437630, "eps": -3.92749, "diluted_eps": -3.92749, "earnings_from_cont_operations": -128790000, "gross_profit": -26494000, "cash": 215379000, "total_debt": 263780000, "total_revenue": 16544000, "cash_from_operations": -134045000, "net_income": -128790000, "ebitda": -102781000, "year_low_stock_price": 2.5, "year_high_stock_price": 5.89, "image_position": [17570, 0, 128, 128]}, {"symbol": "XGN", "name": "Exagen Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 7733330.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.565, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "avisetest.com", "year_founded": 2002, "street_address": "1261 Liberty Way", "city": "Vista", "state": "CA", "zipcode": "92081", "country": "United States", "phone_number": "760-560-1501", "short_description": "Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sj\u00f6gren\u2019s syndrome, and scleroderma, as well as other disorders, including fibromyalgia.", "long_description": "Exagen Inc. operates as a commercial-stage diagnostics company, develops and markets products for the diagnosis, prognosis, and monitoring of patients affected by autoimmune rheumatic diseases (ARDs). Its lead product includes Avise SLE+CT, a proprietary diagnostic test that provides an enhanced solution for patients with a range of ARDs, such as systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), Sj\u00f6gren\u2019s syndrome, and scleroderma, as well as other disorders, including fibromyalgia. The company also offers Avise SLE Prognostic, a blood test that complements Avise SLE+CT; Avise MTX, a therapeutic drug monitoring test to measure levels of methotrexate polyglutamates; and Avise HCQ, a blood test for physicians to monitor blood levels of HCQ. In addition, it is developing Anti-TNF, a blood test to monitor the levels of anti-TNF bioactivity in patients with RA; Avise SLE Monitoring, a multi-analyte panel blood test for physicians to track the disease status of their SLE patients; and Avise RA, a blood test to determine bone damage or joint erosion. The company primarily serves rheumatologists in the United States. It was formerly known as Exagen Diagnostics, Inc. Exagen Inc. was incorporated in 2002 and is headquartered in Vista, California.", "industry_name": "Health Care Providers and Services", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 198777021, "total_enterprise": 153421021, "number_of_employees": 153, "outstanding_shares": 12636810, "eps": -8.460725, "diluted_eps": -8.460725, "earnings_from_cont_operations": -12038000, "gross_profit": 21579000, "cash": 72084000, "total_debt": 26728000, "total_revenue": 40387000, "cash_from_operations": -9711000, "net_income": -12038000, "ebitda": -8708000, "year_low_stock_price": 11.4, "year_high_stock_price": 29.86, "image_position": [17698, 0, 128, 128]}, {"symbol": "OAS", "name": "Oasis Petroleum Inc.", "next_earnings_utc": 1589184000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 301886500.0, "next_earnings_eps_num_analysts": 17, "next_earnings_eps_consensus": -0.17567, "eps_up_revisions": 2, "eps_down_revisions": 14, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 22, "analysts_sell": 5, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 9, "analysts_underperform": 6, "webpage": "oasispetroleum.com", "year_founded": 2007, "street_address": "1001 Fannin Street", "city": "Houston", "state": "TX", "zipcode": "77002", "country": "United States", "phone_number": "281 404 9500", "short_description": "Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of onshore unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin and the Texas region of the Delaware Basin.", "long_description": "Oasis Petroleum Inc., an independent exploration and production company, focuses on the acquisition and development of onshore unconventional oil and natural gas resources in the North Dakota and Montana regions of the Williston Basin and the Texas region of the Delaware Basin. As of December 31, 2019, the company had 408,117 net leasehold acres in the Williston Basin; and 24,995 net leasehold acres in the Delaware Basin, as well as approximately 286.4 million barrels of oil equivalent of estimated net proved reserves. It also operates midstream services business. The company sells its crude oil and natural gas to refiners, marketers, and other purchasers that have access to pipeline and rail facilities. Oasis Petroleum Inc. was founded in 2007 and is headquartered in Houston, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 193361835, "total_enterprise": 3116326835, "number_of_employees": 609, "outstanding_shares": 323726495, "eps": -0.407118, "diluted_eps": -0.41, "earnings_from_cont_operations": -90647000, "gross_profit": 1106875000, "cash": 20019000, "total_debt": 2742041000, "total_revenue": 1959152000, "cash_from_operations": 892853000, "net_income": -128243000, "ebitda": 870397000, "year_low_stock_price": 0.24, "year_high_stock_price": 5.92, "image_position": [17826, 0, 128, 42]}, {"symbol": "EXTN", "name": "Exterran Corporation", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 209850000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.31667, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "exterran.com", "year_founded": 2007, "street_address": "11000 Equity Drive", "city": "Houston", "state": "TX", "zipcode": "77041", "country": "United States", "phone_number": "281 836 7000", "short_description": "Exterran Corporation, a systems and process company, provides various solutions in the oil, gas, water, and power markets worldwide.", "long_description": "Exterran Corporation, a systems and process company, provides various solutions in the oil, gas, water, and power markets worldwide. The company operates through three segments: Contract Operations, Aftermarket Services, and Product Sales. It offers compression, processing, and treating services through the operation of natural gas compression equipment, and crude oil and natural gas production and process equipment; and water treatment and power solutions. The company also sells parts and components; and provides operation, maintenance, overhaul, upgrade, startup and commissioning, and reconfiguration services. In addition, it designs, engineers, manufactures, sells, and installs natural gas compression packages and equipment, such as wellheads, gatherings, residue and high pressure natural gas compression equipment, cryogenic plants, mechanical refrigeration and dew point control plants, condensate stabilizers, water treatment equipment, integrated power generation, and skid-mounted production packages used in treating and processing of crude oil and natural gas. Further, the company sells custom-engineered and built-to-specification natural gas and oil processing and treating equipment; and skid-mounted natural gas compression equipment and pre-engineered compressor units. It serves integrated and national oil and natural gas companies, national energy companies, and independent oil and natural gas producers, as well as oil and natural gas processors, gatherers, and pipeline operators. Exterran Corporation was founded in 2007 and is headquartered in Houston, Texas.", "industry_name": "Energy Equipment and Services", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 184065722, "total_enterprise": 648432722, "number_of_employees": 3600, "outstanding_shares": 33164995, "eps": -2.986232, "diluted_eps": -2.99081, "earnings_from_cont_operations": -108863000, "gross_profit": 363222000, "cash": 16683000, "total_debt": 481050000, "total_revenue": 1317440000, "cash_from_operations": 178726000, "net_income": -102377000, "ebitda": 198908000, "year_low_stock_price": 3.24, "year_high_stock_price": 14.89, "image_position": [17954, 0, 128, 57]}, {"symbol": "VERI", "name": "Veritone, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 12613400.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.298, "eps_up_revisions": 4, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "veritone.com", "year_founded": 2014, "street_address": "575 Anton Boulevard", "city": "Costa Mesa", "state": "CA", "zipcode": "92626", "country": "United States", "phone_number": "888-507-1737", "short_description": "Veritone, Inc. provides artificial intelligence (AI) and computing solutions in the United States and the United Kingdom.", "long_description": "Veritone, Inc. provides artificial intelligence (AI) and computing solutions in the United States and the United Kingdom. It develops and operates aiWARE platform, an AI operating system that integrates and orchestrates a range of cognitive engines to reveal multivariate insights from structured and unstructured data, as well as to conduct cognitive workflows based on these insights. The company also provides media advertising agency services, including media planning and strategy, media buying and placement, campaign messaging, clearance verification and attribution, and custom analytics directly to advertisers through outbound sales networking, and client and partner referrals, as well as indirectly through advertising agencies or marketing consultants. It serves media and entertainment, legal and compliance, and government markets The company was formerly known as Veritone Delaware, Inc. and changed its name to Veritone, Inc. in July 2014. Veritone, Inc. was founded in 2014 and is headquartered in Costa Mesa, California.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 160610325, "total_enterprise": 116545325, "number_of_employees": 277, "outstanding_shares": 27084372, "eps": -2.847913, "diluted_eps": -2.847913, "earnings_from_cont_operations": -62078000, "gross_profit": 32359000, "cash": 44065000, "total_debt": 0, "total_revenue": 49648000, "cash_from_operations": -30117000, "net_income": -62078000, "ebitda": -56106000, "year_low_stock_price": 1.22, "year_high_stock_price": 9.98, "image_position": [18082, 0, 128, 128]}, {"symbol": "CPS", "name": "Cooper-Standard Holdings Inc.", "next_earnings_utc": 1589237100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 730000000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.81, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "cooperstandard.com", "year_founded": 1960, "street_address": "39550 Orchard Hill Place Drive", "city": "Novi", "state": "MI", "zipcode": "48375", "country": "United States", "phone_number": "248 596 5900", "short_description": "Cooper-Standard Holdings Inc., through its subsidiary, Cooper-Standard Automotive Inc., designs, manufactures, and sells sealing, fuel and brake delivery, and fluid transfer systems worldwide.", "long_description": "Cooper-Standard Holdings Inc., through its subsidiary, Cooper-Standard Automotive Inc., designs, manufactures, and sells sealing, fuel and brake delivery, and fluid transfer systems worldwide. The company's sealing systems include obstacle detection sensor system, flush glass systems, dynamic seals, variable extrusion systems, static seals, specialty sealing products, encapsulated glasses, stainless steel trims, and textured surfaces with cloth appearance. Its fuel and brake delivery systems comprise chassis and tank fuel lines and bundles, direct injection and port fuel rails, metallic brake lines and bundles, tube coatings, quick connects, and brake jounce lines. The company's fluid transfer systems consist of heater/coolant hoses, turbo charger hoses, quick connects, charged air cooler ducts/assemblies, DPF and SCR emission lines, secondary air hoses, degas tanks, brake and clutch hoses, air intake and charge systems, and transmission oil cooling hoses. The company's products are primarily used in passenger vehicles and light trucks that are manufactured by automotive original equipment manufacturers and replacement markets. Cooper-Standard Holdings Inc. was founded in 1960 and is headquartered in Novi, Michigan.", "industry_name": "Auto Components", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 196367223, "total_enterprise": 748594223, "number_of_employees": 28000, "outstanding_shares": 16884542, "eps": 3.938441, "diluted_eps": 3.92, "earnings_from_cont_operations": 62213000, "gross_profit": 359122000, "cash": 359536000, "total_debt": 891956000, "total_revenue": 3108400000, "cash_from_operations": 97697000, "net_income": 67529000, "ebitda": 191634000, "year_low_stock_price": 6.64, "year_high_stock_price": 52.61, "image_position": [18162, 0, 80, 80]}, {"symbol": "BBX", "name": "BBX Capital Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 205227000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.005, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "bbxcapital.com", "year_founded": 1980, "street_address": "401 East Las Olas Boulevard", "city": "Fort Lauderdale", "state": "FL", "zipcode": "33301", "country": "United States", "phone_number": "954-940-4900", "short_description": "BBX Capital Corporation, formerly known as BFC Financial Corporation, is a private equity and venture capital firm specializing in investments and acquisitions of middle market companies.", "long_description": "BBX Capital Corporation, formerly known as BFC Financial Corporation, is a private equity and venture capital firm specializing in investments and acquisitions of middle market companies. The firm also invests in mergers and acquisition, add-on acquisitions, divestiture, taking public companies private and private companies public, leveraged buyout, partnership, recapitalization, and restructuring. It typically does not invest in industries or companies whose ultimate returns are event driven. The firm seeks to invest across a broad range of industries ranging from service to manufacturing businesses. The firm prefers to acquire controlling interests in its portfolio companies and can also consider minority investments. BFC Financial Corporation was founded in 1980 and is based in Fort Lauderdale, Florida.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 158564537, "total_enterprise": 768474537, "number_of_employees": 7185, "outstanding_shares": 96573090, "eps": 0.190989, "diluted_eps": 0.19, "earnings_from_cont_operations": 32103000, "gross_profit": 635646000, "cash": 356604000, "total_debt": 872230000, "total_revenue": 869366000, "cash_from_operations": 78242000, "net_income": 17691000, "ebitda": 78392000, "year_low_stock_price": 1.11, "year_high_stock_price": 5.15, "image_position": [18290, 0, 128, 128]}, {"symbol": "EVLO", "name": "Evelo Biosciences, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.705, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "evelobio.com", "year_founded": 2014, "street_address": "620 Memorial Drive", "city": "Cambridge", "state": "MA", "zipcode": "02139", "country": "United States", "phone_number": "617-577-0300", "short_description": "Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer.", "long_description": "Evelo Biosciences, Inc., a biotechnology company, focuses on the development of monocolonal microbials for the treatment of inflammatory diseases and cancer. It is involved in developing EDP1066 and EDP1815, which are in Phase 1b placebo-controlled dose-escalating safety and tolerability clinical study for the treatment of atopic dermatitis, asthma, psoriatic arthritis, rheumatoid arthritis, and inflammatory bowel diseases. The company is also involved in developing EDP150, a monoclonal microbial candidate, which is in Phase 1/2 clinical study for the treatment of colorectal cancer, triple-negative breast cancer, and melanoma, as well as patients who have relapsed on prior PD-1/L1 inhibitor treatment across multiple tumor types. Evelo Biosciences, Inc. was founded in 2014 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 164251822, "total_enterprise": 106052822, "number_of_employees": 98, "outstanding_shares": 32333036, "eps": -2.668343, "diluted_eps": -2.668343, "earnings_from_cont_operations": -85472000, "gross_profit": null, "cash": 77833000, "total_debt": 19634000, "total_revenue": null, "cash_from_operations": -71980000, "net_income": -85472000, "ebitda": -84593000, "year_low_stock_price": 3.01, "year_high_stock_price": 10.09, "image_position": [18418, 0, 128, 128]}, {"symbol": "CEIX", "name": "CONSOL Energy Inc.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 322750000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.55667, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "consolenergy.com", "year_founded": 1864, "street_address": "1000 Consol Energy Drive", "city": "Canonsburg", "state": "PA", "zipcode": "15317", "country": "United States", "phone_number": "724-416-8300", "short_description": "CONSOL Energy Inc. produces and exports bituminous coal.", "long_description": "CONSOL Energy Inc. produces and exports bituminous coal. It owns and operates its mining operations in the Northern Appalachian Basin. The company owns and operates the Pennsylvania Mining Complex (PAMC), which comprises three underground mines, including Bailey, Enlow Fork, and Harvey; and CONSOL Marine Terminal located in the port of Baltimore. As of December 31, 2018, it had 698.5 million tons of proven and probable coal reserves at PAMC. In addition, it owns approximately 1.6 billion tons of Greenfield coal reserves located in the Northern Appalachian, Central Appalachian, and Illinois basins. CONSOL Energy Inc. was founded in 1864 and is headquartered in Canonsburg, Pennsylvania.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 186889670, "total_enterprise": 1031794670, "number_of_employees": 1792, "outstanding_shares": 26029202, "eps": 2.821294, "diluted_eps": 2.809999, "earnings_from_cont_operations": 93558000, "gross_profit": 448185000, "cash": 80293000, "total_debt": 788002000, "total_revenue": 1411864000, "cash_from_operations": 244566000, "net_income": 76001000, "ebitda": 378256000, "year_low_stock_price": 3.35, "year_high_stock_price": 31.76, "image_position": [18546, 0, 128, 19]}, {"symbol": "FLNT", "name": "Fluent, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 68558000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.04, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "fluentco.com", "year_founded": null, "street_address": "300 Vesey Street", "city": "New York", "state": "NY", "zipcode": "10282", "country": "United States", "phone_number": "646 669 7272", "short_description": "Fluent, Inc. provides data-driven digital marketing services primarily in the United States.", "long_description": "Fluent, Inc. provides data-driven digital marketing services primarily in the United States. The company also offers customer acquisition services by operating digital marketing campaigns, through which the company connects its advertiser clients with consumers. It delivers data and performance-based marketing executions to approximately 500 consumer brands, direct marketers, and agencies across a range of industries, including financial products and services, media and entertainment, health and wellness, staffing and recruitment, and retail and consumer Fluent, Inc. is headquartered in New York, New York.", "industry_name": "Media", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 168470439, "total_enterprise": 212923439, "number_of_employees": 190, "outstanding_shares": 76230968, "eps": -0.022009, "diluted_eps": -0.022009, "earnings_from_cont_operations": -1747000, "gross_profit": 87249000, "cash": 18679000, "total_debt": 63132000, "total_revenue": 281684000, "cash_from_operations": 26018000, "net_income": -1747000, "ebitda": 22023000, "year_low_stock_price": 1.02, "year_high_stock_price": 7.44, "image_position": [18674, 0, 128, 128]}, {"symbol": "MBII", "name": "Marrone Bio Innovations, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 10115000.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.034, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 2, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "marronebio.com", "year_founded": 2006, "street_address": "1540 Drew Avenue", "city": "Davis", "state": "CA", "zipcode": "95618", "country": "United States", "phone_number": "530 750 2800", "short_description": "Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally.", "long_description": "Marrone Bio Innovations, Inc. discovers, develops, produces, and promotes biological products for pest management, plant nutrition, and plant health in the United States and internationally. Its products include Regalia, a plant extract-based fungicidal biopesticide for plant disease and plant health; Grandevo, a bioinsecticide for insect and mite control; Venerate, a bioinsecticide, which controls chewing and sucking insects and mites, as well as flies and plant parasitic nematodes; and Majestene, a bionematicide to control soil-dwelling nematodes by preventing and reducing root galls, and reducing adult reproduction and egg hatch, as well as controls soil borne insects. The company also provides Stargus, a biofungicide to control plant diseases, such as Sclerotinia white molds, gray mold/bunch rot, and downy mildews; and Haven, a plant health product that is applied to the leaves of plants to reduce sun stress. In addition, it offers Zequanox, a biomolluscicide that controls invasive mussels, which cause infrastructure and ecological damage primarily to power and industrial companies. Additionally, the company provides Pro Farm products for increasing plant health, yield and quality; and Jet-Ag and Jet-Oxide, peroxyacetic acid-based plant health product lines that stops molds and bacteria on plants and other surfaces. It serves agricultural and water treatment markets. The company provides its products directly through sales force, as well as through distributors. The company formerly known as Marrone Organic Innovations, Inc. Marrone Bio Innovations, Inc. was founded in 2006 and is headquartered in Davis, California.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 145531261, "total_enterprise": 167208261, "number_of_employees": 133, "outstanding_shares": 145531261, "eps": -0.31509, "diluted_eps": -0.31509, "earnings_from_cont_operations": -37175000, "gross_profit": 16113000, "cash": 6252000, "total_debt": 27929000, "total_revenue": 29373000, "cash_from_operations": -21339000, "net_income": -37175000, "ebitda": -19436000, "year_low_stock_price": 0.6101, "year_high_stock_price": 1.92, "image_position": [18802, 0, 128, 128]}, {"symbol": "GNSS", "name": "Genasys Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 8593000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.02, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "genasys.com", "year_founded": null, "street_address": "16262 West Bernardo Drive", "city": "San Diego", "state": "CA", "zipcode": "92127", "country": "United States", "phone_number": "858-676-1112", "short_description": "Genasys Inc. designs, develops, and commercializes directed and multidirectional sound technologies in the Americas, Europe, the Middle East, Africa, and the Asia Pacific.", "long_description": "Genasys Inc. designs, develops, and commercializes directed and multidirectional sound technologies in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It offers voice broadcast products; and location-based mass messaging solutions for emergency warning and workforce management. The company also provides long range acoustic devices, such as acoustic hailing devices and public safety mass notification systems, which are used to project sirens and audible voice messages; and Critical Communications as a Service software solution for sending SMS, text, email, and social media messages to mobile devices. It sells its products directly to governments, militaries, end-users, and defense-related companies. The company was formerly known as LRAD Corporation. Genasys Inc. is based in San Diego, California.", "industry_name": "Communications Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 134058802, "total_enterprise": 120755068, "number_of_employees": 83, "outstanding_shares": 33100939, "eps": 0.072131, "diluted_eps": 0.069958, "earnings_from_cont_operations": 2359379, "gross_profit": 17969354, "cash": 21274112, "total_debt": 7970378, "total_revenue": 35583198, "cash_from_operations": 13167938, "net_income": 2359379, "ebitda": 3375306, "year_low_stock_price": 2.01, "year_high_stock_price": 4.24, "image_position": [18930, 0, 128, 128]}, {"symbol": "NBEV", "name": "New Age Beverages Corporation", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 62916330.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.11, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "newagebev.com", "year_founded": 2010, "street_address": "2420 17th Street", "city": "Denver", "state": "CO", "zipcode": "80202-2507", "country": "United States", "phone_number": "303 566 3030", "short_description": "New Age Beverages Corporation develops, markets, sells, and distributes healthy liquid dietary supplements and ready-to-drink (RTD) beverages.", "long_description": "New Age Beverages Corporation develops, markets, sells, and distributes healthy liquid dietary supplements and ready-to-drink (RTD) beverages. The company offers RTD tea, coffee, kombucha, energy drinks, relaxation drinks, coconut waters, functional waters, and rehydration beverages, as well as functional medical beverages. It provides its products under the Xing Tea, Marley, Bucha Live Kombucha, Coco-Libre, Evian, Volvic, Tahitian Noni Juice, TruAge, Aspen Pure, PediaAde, Coco Libre, BioShield, and NHANCED brands. The company sells its products across 50 states in the United States; and approximately 60 countries internationally through direct-store-delivery systems, brokers and distributors, warehouses, independent product consultants, and e-commerce sites, as well as through grocery retail, natural food retail, specialty outlets, hypermarkets, club stores, pharmacies, convenience stores, gas stations, and individual independent distributors. New Age Beverages Corporation was founded in 2010 and is headquartered in Denver, Colorado.", "industry_name": "Beverages", "sector_name": "Consumer Staples", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 138408014, "total_enterprise": 142862014, "number_of_employees": 920, "outstanding_shares": 85437046, "eps": -1.162882, "diluted_eps": -1.162882, "earnings_from_cont_operations": -89835000, "gross_profit": 150707000, "cash": 60842000, "total_debt": 65296000, "total_revenue": 253708000, "cash_from_operations": -31801000, "net_income": -89835000, "ebitda": -37659000, "year_low_stock_price": 0.981, "year_high_stock_price": 5.65, "image_position": [19058, 0, 128, 128]}, {"symbol": "HCHC", "name": "HC2 Holdings, Inc.", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 461133000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.49, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "hc2.com", "year_founded": 1994, "street_address": "450 Park Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "212 235 2690", "short_description": "HC2 Holdings, Inc. provides construction, marine services, energy, telecommunications, insurance, life sciences, broadcasting, and other services in the United States, the United Kingdom, and internationally.", "long_description": "HC2 Holdings, Inc. provides construction, marine services, energy, telecommunications, insurance, life sciences, broadcasting, and other services in the United States, the United Kingdom, and internationally. The company models, details, fabricates, and erects structural steel for commercial and industrial, and infrastructure construction projects, including building and office complexes, hotels and casinos, convention centers, sports arenas and stadiums, shopping malls, hospitals, dams, bridges, mines, and power plants. It also fabricates trusses and girders; and fabricates and erects water pipes, water storage tanks, pollution control scrubbers, tunnel liners, pressure vessels, strainers, filters, separators, and various customized products. In addition, the company offers subsea cable installation and maintenance services for the telecommunications sector; installation, maintenance, and repair services for fiber optic communication and power infrastructure to offshore oil and gas platforms; and installation services for inter-array power cables for use in offshore wind farms. Further, it distributes natural gas motor fuels; designs, builds, owns, acquires, operates, and maintains compressed natural gas fueling stations for transportation vehicles; and provides voice communication services for national telecommunications, mobile, prepaid, and voice over Internet protocol service operators, as well as wholesale carriers and Internet service providers. Additionally, the company offers long-term care, life, annuity, and other accident and health coverage; focuses on developing products for early osteoarthritis of the knee, as well as skin lightening technology; and operates over-the-air broadcasting stations and Azteca America, a Spanish-language broadcast network. The company was formerly known as PTGi Holding Inc. and changed its name to HC2 Holdings, Inc. in April 2014. HC2 Holdings, Inc. was founded in 1994 and is headquartered in New York, New York.", "industry_name": "Construction and Engineering", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 142444175, "total_enterprise": 933144175, "number_of_employees": 3728, "outstanding_shares": 46550384, "eps": -0.662946, "diluted_eps": -0.662946, "earnings_from_cont_operations": -36100000, "gross_profit": 324800000, "cash": 239000000, "total_debt": 914300000, "total_revenue": 1984100000, "cash_from_operations": 110500000, "net_income": -31500000, "ebitda": 125200000, "year_low_stock_price": 1.29, "year_high_stock_price": 4.33, "image_position": [19118, 0, 60, 60]}, {"symbol": "MTNB", "name": "Matinas BioPharma Holdings, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 26200.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.032, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "matinasbiopharma.com", "year_founded": 2013, "street_address": "1545 Route 206 South", "city": "Bedminster", "state": "NJ", "zipcode": "07921", "country": "United States", "phone_number": "908 443 1860", "short_description": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates.", "long_description": "Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of various product candidates. It develops products using its lipid nano-crystal (LNC) platform technology. The company's LNC delivery technology platform utilizes lipid nano-crystals for the delivery of small molecules, gene therapies, vaccines, proteins, and peptides. Its lead product candidate is MAT9001, a prescription-only omega-3 free fatty acid formulation for the treatment of cardiovascular and metabolic conditions. The company also offers MAT2203, an oral formulation of amphotericin B that has completed Phase II clinical trials for the prevention of invasive fungal infections due to immunosuppressive therapy in patients. In addition, it provides MAT2501, an orally administered formulation of the broad-spectrum aminoglycoside antibiotic amikacin that has completed Phase I clinical trials to treat various types of multidrug-resistant bacteria, including non-tuberculous mycobacterium infections, as well as various multidrug-resistant gram negative and intracellular bacterial infections. Matinas BioPharma Holdings, Inc. has a research collaboration with the National Institute of Neurological Disorders and Stroke (NINDS) for the development of a novel therapy for the treatment of HIV, as well as with ViiV Healthcare to develop and evaluate formulations of antiviral drug candidates; and a feasibility collaboration with Genentech, Inc. for the development of oral formulations. The company was founded in 2013 and is based in Bedminster, New Jersey.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 134444894, "total_enterprise": 114884115, "number_of_employees": 21, "outstanding_shares": 196556863, "eps": -0.126015, "diluted_eps": -0.126015, "earnings_from_cont_operations": -17372651, "gross_profit": -11144736, "cash": 27775072, "total_debt": 4228488, "total_revenue": 89812, "cash_from_operations": -14092066, "net_income": -17372651, "ebitda": -18592274, "year_low_stock_price": 0.49, "year_high_stock_price": 2.49, "image_position": [19246, 0, 128, 128]}, {"symbol": "SNCR", "name": "Synchronoss Technologies, Inc.", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 74410670.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.51863, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "synchronoss.com", "year_founded": 2000, "street_address": "200 Crossing Boulevard", "city": "Bridgewater", "state": "NJ", "zipcode": "08807", "country": "United States", "phone_number": "866 620 3940", "short_description": "Synchronoss Technologies, Inc. provides cloud, digital, messaging, and Internet of Things (IoT) platforms, products, and solutions in North America, Europe, the Middle East, Africa, and the Asia Pacific.", "long_description": "Synchronoss Technologies, Inc. provides cloud, digital, messaging, and Internet of Things (IoT) platforms, products, and solutions in North America, Europe, the Middle East, Africa, and the Asia Pacific. Its platforms, products, and solutions include digital experience management platform as a service, which includes digital journey creation and journey design products that use analytics that power digital advisor products for IT and business channel owners; and cloud sync, backup, storage, device set up, content transfer, and content engagement for user generated content. The company's platforms, products, and solutions also comprise multi-channel messaging peer-to-peer communications and application-to-person commerce solutions; and IoT management technology for smart cities, smart buildings, and others. In addition, it offers software development and customization services. The company markets and sells its services through direct sales force and strategic partners. Synchronoss Technologies, Inc. was founded in 2000 and is headquartered in Bridgewater, New Jersey.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 127799862, "total_enterprise": 371612862, "number_of_employees": 1659, "outstanding_shares": 41225762, "eps": -3.359881, "diluted_eps": -3.36, "earnings_from_cont_operations": -103467000, "gross_profit": 158342000, "cash": 39001000, "total_debt": 69449000, "total_revenue": 308749000, "cash_from_operations": 32583000, "net_income": -104593000, "ebitda": -31986000, "year_low_stock_price": 2.46, "year_high_stock_price": 9.05, "image_position": [19374, 0, 128, 128]}, {"symbol": "CCR", "name": "CONSOL Coal Resources LP", "next_earnings_utc": 1589169600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 72100000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.15333, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "ccrlp.com", "year_founded": 2015, "street_address": "CNX Center", "city": "Canonsburg", "state": "PA", "zipcode": "15317-6506", "country": "United States", "phone_number": "724-416-8300", "short_description": "CONSOL Coal Resources LP produces and sells high- British thermal unit (Btu) coal in the Northern Appalachian Basin and the eastern United States.", "long_description": "CONSOL Coal Resources LP produces and sells high- British thermal unit (Btu) coal in the Northern Appalachian Basin and the eastern United States. It owns a 25% undivided interest in the Pennsylvania mining complex, which consists of three underground mines and related infrastructure that produce high-Btu thermal coal located primarily in southwestern Pennsylvania. The company markets its thermal coal principally to electric utilities. CONSOL Coal Resources GP LLC operates as a general partner of the company. The company was formerly known as CNX Coal Resources LP and changed its name to CONSOL Coal Resources LP in November 2017. CONSOL Coal Resources LP was founded in 2015 and is headquartered in Canonsburg, Pennsylvania.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 134848181, "total_enterprise": 350302181, "number_of_employees": null, "outstanding_shares": 27632824, "eps": 1.621278, "diluted_eps": 1.62, "earnings_from_cont_operations": 45551000, "gross_profit": 108127000, "cash": 543000, "total_debt": 204082000, "total_revenue": 330219000, "cash_from_operations": 81125000, "net_income": 44783000, "ebitda": 98011000, "year_low_stock_price": 4.4, "year_high_stock_price": 17.6, "image_position": [19502, 0, 128, 128]}, {"symbol": "ADES", "name": "Advanced Emissions Solutions, Inc.", "next_earnings_utc": 1589230800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 16539000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.62, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "advancedemissionssolutions.com", "year_founded": 1996, "street_address": "640 Plaza Drive", "city": "Highlands Ranch", "state": "CO", "zipcode": "80129", "country": "United States", "phone_number": "720 598 3500", "short_description": "Advanced Emissions Solutions, Inc., together with its subsidiaries, provides emission reduction technologies and specialty chemicals in the United States.", "long_description": "Advanced Emissions Solutions, Inc., together with its subsidiaries, provides emission reduction technologies and specialty chemicals in the United States. It operates through two segments, Refined Coal; and Power Generation and Industrials. The company offers CyClean technology, a pre-combustion coal treatment process to enhance combustion, as well as to reduce emissions of nitrogen oxide and mercury from coals burned in cyclone boilers; and M-45 and M-45-PC technologies, which are pre-combustion coal treatment technologies used to control emissions from circulating fluidized bed boilers and pulverized coal boilers. It also provides powdered activated carbon, granular activated carbon, coal additives, and scrubber additives, as well as owns an associated lignite mine that supplies the raw material for the powdered activated carbon plant. The company serves customers in the coal-fired power generation and industrial boiler processes, as well as drinking water and wastewater treatment markets. Advanced Emissions Solutions, Inc. was founded in 1996 and is headquartered in Highlands Ranch, Colorado.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 137961137, "total_enterprise": 175439137, "number_of_employees": 133, "outstanding_shares": 18493450, "eps": 1.955106, "diluted_eps": 1.93, "earnings_from_cont_operations": 35537000, "gross_profit": 29543000, "cash": 12080000, "total_debt": 49558000, "total_revenue": 70086000, "cash_from_operations": 62262000, "net_income": 35537000, "ebitda": -2522000, "year_low_stock_price": 4.45, "year_high_stock_price": 15.34, "image_position": [19630, 0, 128, 128]}, {"symbol": "CBAY", "name": "CymaBay Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 8, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.3115, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 7, "analysts_underperform": 0, "webpage": "cymabay.com", "year_founded": 1988, "street_address": "7575 Gateway Boulevard", "city": "Newark", "state": "CA", "zipcode": "94560", "country": "United States", "phone_number": "510 293 8800", "short_description": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases.", "long_description": "CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta, which has completed Phase II clinical study for the treatments of primary biliary cholangitis and sclerosing cholangitis, as well as patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, a selective orally-active G protein-coupled receptor agonist that interacts with bioactive lipids known to stimulate glucose-dependent insulin secretion for the treatment of gut/liver disease. Its preclinical stage product candidate is CB-001, a G protein-coupled receptor for omega-3 fatty acids, such as docosahexaenoic acid for the treatment of gut/liver disease. It has development and licensing agreement with Janssen Pharmaceuticals, Inc. to develop and discover undisclosed metabolic disease target agonists for the treatment of type 2 diabetes and other disorders; and a license agreement with DiaTex, Inc. to develop and commercialize therapeutic products comprising halofenate and its enantiomers, derivatives, and analogs for the treatment of diseases. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 122610777, "total_enterprise": -66184223, "number_of_employees": 36, "outstanding_shares": 68882459, "eps": -1.533691, "diluted_eps": -1.533691, "earnings_from_cont_operations": -102808000, "gross_profit": -64579000, "cash": 190945000, "total_debt": 2150000, "total_revenue": 5207000, "cash_from_operations": -97911000, "net_income": -102808000, "ebitda": -102503000, "year_low_stock_price": 1.21, "year_high_stock_price": 13.32, "image_position": [19758, 0, 128, 128]}, {"symbol": "GPX", "name": "GP Strategies Corporation", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 131945670.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.085, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 2, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "gpstrategies.com", "year_founded": 1959, "street_address": "70 Corporate Center", "city": "Columbia", "state": "MD", "zipcode": "21044", "country": "United States", "phone_number": "443 367 9600", "short_description": "GP Strategies Corporation provides performance improvement and learning solutions worldwide.", "long_description": "GP Strategies Corporation provides performance improvement and learning solutions worldwide. The company operates in two segments, Workforce Excellence and Business Transformation Services. The Workforce Excellence segment offers managed learning services, including strategic learning and development consulting; digital learning content design and development solutions; and a suite of learning operations services, such as managed facilitation and delivery, managed training administration and logistics, help desk support, and event and vendor management. This segment also provides engineering and technical services comprising design, development and delivery of technical work-based learning, plant launch initiatives, engineering design and construction management, fabrication, management, operational excellence consulting, chemical demilitarization, homeland security, emergency management support, and asset management and performance improvement consulting, as well as technical documentation services; EtaPRO performance and condition monitoring system, a suite of real-time digital solutions for facilities and power-generating units; and GPiLEARN+ portal, a web-based off-the-shelf delivery format of technical courses. The Business Transformation Services segment offers custom product sales training and service technical training primarily to automotive manufacturers and service technicians; and organizational development solutions, including strategy, leadership, employee engagement and culture consulting, enterprise technology implementation and adoption, and organization design and business performance consulting. It serves companies in the automotive, financial services and insurance, pharmaceutical, oil and gas, power, chemical, electronics and technology, manufacturing, software, retail, healthcare, education, and food and beverage industries, as well as government agencies. GP Strategies Corporation was founded in 1959 and is headquartered in Columbia, Maryland.", "industry_name": "Professional Services", "sector_name": "Industrials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 112390769, "total_enterprise": 220832769, "number_of_employees": 4856, "outstanding_shares": 17080664, "eps": 0.902656, "diluted_eps": 0.9, "earnings_from_cont_operations": 15189000, "gross_profit": 89213000, "cash": 8159000, "total_debt": 116601000, "total_revenue": 583290000, "cash_from_operations": 13400000, "net_income": 15189000, "ebitda": 26328000, "year_low_stock_price": 5.78, "year_high_stock_price": 16.68, "image_position": [19838, 0, 80, 80]}, {"symbol": "ACRX", "name": "AcelRx Pharmaceuticals, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 400000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.1625, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "acelrx.com", "year_founded": 2005, "street_address": "351 Galveston Drive", "city": "Redwood City", "state": "CA", "zipcode": "94063", "country": "United States", "phone_number": "650 216 3500", "short_description": "AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain.", "long_description": "AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of acute pain. The company's lead product candidate is DSUVIA, a 30 mcg sufentanil sublingual tablet for the treatment of moderate-to-severe acute pain. It also develops ZALVISO, a pre-programmed and patient-controlled analgesia system that allows hospital patients with moderate-to-severe acute pain to self-dose with sufentanil sublingual tablets to manage their pain. The company was formerly known as SuRx Pharmaceuticals, Inc. and changed its name to AcelRx Pharmaceuticals, Inc. in August 2006. AcelRx Pharmaceuticals, Inc. was founded in 2005 and is headquartered in Redwood City, California.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 124644414, "total_enterprise": 88264414, "number_of_employees": 99, "outstanding_shares": 80415751, "eps": -0.672355, "diluted_eps": -0.672355, "earnings_from_cont_operations": -53240000, "gross_profit": -9178000, "cash": 66137000, "total_debt": 29757000, "total_revenue": 2289000, "cash_from_operations": -51180000, "net_income": -53240000, "ebitda": -52537000, "year_low_stock_price": 0.7014, "year_high_stock_price": 3.37, "image_position": [19966, 0, 128, 128]}, {"symbol": "GOGO", "name": "Gogo Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 167436500.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.40333, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 7, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "gogoair.com", "year_founded": 1991, "street_address": "111 North Canal Street", "city": "Chicago", "state": "IL", "zipcode": "60606", "country": "United States", "phone_number": "312-517-5000", "short_description": "Gogo Inc., through its subsidiaries, provides inflight broadband connectivity and wireless entertainment services to the aviation industry in the United States and internationally.", "long_description": "Gogo Inc., through its subsidiaries, provides inflight broadband connectivity and wireless entertainment services to the aviation industry in the United States and internationally. It operates through three segments: Commercial Aviation North America (CA-NA), Commercial Aviation Rest of World (CA-ROW), and Business Aviation (BA). The CA-NA segment offers inflight connectivity and wireless digital entertainment solutions to commercial airline passengers flying routes that generally begin and end within North America. The CA-ROW segment provides inflight connectivity and wireless digital entertainment solutions to passengers flying on foreign-based commercial airlines and flights outside of North America for North American based commercial airlines. The BA segment offers equipment for inflight connectivity, including voice and data services to the business aviation market. Its services include Gogo Biz, an inflight broadband service that utilizes air-to-ground (ATG) network and ATG spectrum; Passenger Entertainment, an inflight entertainment service; and satellite-based voice and data services through strategic alliances with satellite companies. This segment serves aircraft manufacturers, owners, and operators, as well as government and military entities. Gogo Inc. was founded in 1991 and is headquartered in Chicago, Illinois.", "industry_name": "Wireless Telecommunication Services", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 123817818, "total_enterprise": 1146730818, "number_of_employees": 1115, "outstanding_shares": 88441299, "eps": -1.80774, "diluted_eps": -1.80774, "earnings_from_cont_operations": -146004000, "gross_profit": 403150000, "cash": 170016000, "total_debt": 1192929000, "total_revenue": 835726000, "cash_from_operations": 64061000, "net_income": -146004000, "ebitda": 155541000, "year_low_stock_price": 1.33, "year_high_stock_price": 7.23, "image_position": [20094, 0, 128, 128]}, {"symbol": "III", "name": "Information Services Group, Inc.", "next_earnings_utc": 1589228400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 64142750.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": 0.04, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "isg-one.com", "year_founded": 2006, "street_address": "2187 Atlantic Street", "city": "Stamford", "state": "CT", "zipcode": "06902", "country": "United States", "phone_number": "203-517-3100", "short_description": "Information Services Group, Inc. operates as a technology research and advisory company in the Americas, Europe, and the Asia Pacific.", "long_description": "Information Services Group, Inc. operates as a technology research and advisory company in the Americas, Europe, and the Asia Pacific. The company offers digital transformation services, including automation, cloud, and data analytics; sourcing advisory; managed governance and risk; network carrier; technology strategy and operations design; change management; and market intelligence and technology research and analysis services. It supports private and public sector organizations to transform and optimize their operational environments. The company also provides subscription research, and advisory and strategy consulting services for senior business and IT executives, technology and software vendors, and business/IT services providers; and consulting services, such as business advisory services, data and analytics, digital solutions, network advisory services, organizational change management, automation, human resources technology and delivery services, software advisory services, and sourcing solutions. In addition, it offers ISG GovernX third-party management services that assist clients with monitoring and managing their supplier relationships, as well as provides them with real-time market intelligence and insights; and a range of industry conferences. The company serves private sector clients operating in the financial services, telecommunications, healthcare and pharmaceuticals, manufacturing, transportation and travel, and energy and utilities industries; and public sector customers, including state and local governments, airport and transit authorities, and national and provincial government units. Information Services Group, Inc. has a strategic partnership with NICE to expand its automation ecosystem. The company was founded in 2006 and is headquartered in Stamford, Connecticut.", "industry_name": "IT Services", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 123643440, "total_enterprise": 199413440, "number_of_employees": 1287, "outstanding_shares": 47012715, "eps": 0.07121, "diluted_eps": 0.07, "earnings_from_cont_operations": 3341000, "gross_profit": 112584000, "cash": 18153000, "total_debt": 93923000, "total_revenue": 265763000, "cash_from_operations": 20437000, "net_income": 3341000, "ebitda": 20124000, "year_low_stock_price": 1.61, "year_high_stock_price": 3.76, "image_position": [20222, 0, 128, 128]}, {"symbol": "HROW", "name": "Harrow Health, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 11769000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.255, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "harrowinc.com", "year_founded": 1998, "street_address": "12264 El Camino Real", "city": "San Diego", "state": "CA", "zipcode": "92130", "country": "United States", "phone_number": "858-704-4040", "short_description": "Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States.", "long_description": "Harrow Health, Inc., together with its subsidiaries, develops, produces, and sells medications for unmet needs primarily in the United States. The company primarily provides ophthalmology based formulations to physicians and patients; and sterile and non-sterile compounded medications. It also develops and commercializes therapeutics for treating ocular surface diseases; and non-intravenous sedation and anesthesia therapeutics for human medical procedures in hospital, outpatient, and in-office settings. Its products portfolio includes topical eye drop drug candidates, including SURF-100 and SURF-200; SURF-300, an oral capsule for treating patients suffering from ocular surface diseases, and DED signs and symptoms; Klarity drops to protect and rehabilitate the ocular surface pathology for patients with DED; MELT-100, a drug that is administered sublingually for conscious sedation during cataract surgery; MAY-66 that is used for the treatment of symptoms associated with Peyronie\u00e2\u20ac\u2122s disease; MAY-44, a non-estrogen topical analgesic gel; and other drug candidates for rare diseases. In addition, the company engages in the development of MAY-88, an oral anhydrous extend release suspension of pentosan polysulfate sodium for interstitial cystitis. The company was formerly known as Imprimis Pharmaceuticals, Inc. and changed its name to Harrow Health, Inc. in December 2018. Harrow Health, Inc. was founded in 1998 and is headquartered in San Diego, California.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 118615590, "total_enterprise": 109259590, "number_of_employees": 133, "outstanding_shares": 25618918, "eps": 0.006634, "diluted_eps": 0.006634, "earnings_from_cont_operations": -125000, "gross_profit": 34416000, "cash": 30054000, "total_debt": 20991000, "total_revenue": 51165000, "cash_from_operations": 950000, "net_income": 168000, "ebitda": 1430500, "year_low_stock_price": 3.33, "year_high_stock_price": 8.99, "image_position": [20350, 0, 128, 128]}, {"symbol": "CHMI", "name": "Cherry Hill Mortgage Investment Corporation", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 3000000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -2.74, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "chmireit.com", "year_founded": 2012, "street_address": "1451 Route 34", "city": "Farmingdale", "state": "NJ", "zipcode": "07727", "country": "United States", "phone_number": "877-870-7005", "short_description": "Cherry Hill Mortgage Investment Corporation, a residential real estate finance company, acquires, invests in, and manages residential mortgage assets in the United States.", "long_description": "Cherry Hill Mortgage Investment Corporation, a residential real estate finance company, acquires, invests in, and manages residential mortgage assets in the United States. The company operates through Investments in RMBS and Investments in Servicing Related Assets segments. It manages a portfolio of servicing related assets, residential mortgage-backed securities (RMBS), and prime residential mortgage loans, as well as other residential mortgage assets. The company qualifies as a real estate investment trust for federal income tax purposes. It generally would not be subject to federal corporate income taxes if it distributes at least 90% of its taxable income to its stockholders. Cherry Hill Mortgage Investment Corporation was founded in 2012 and is based in Farmingdale, New Jersey.", "industry_name": "Mortgage Real Estate Investment Trusts (REITs)", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 108917042, "total_enterprise": null, "number_of_employees": 4, "outstanding_shares": 16527624, "eps": -3.108533, "diluted_eps": -3.109999, "earnings_from_cont_operations": -43496000, "gross_profit": -47887000, "cash": 42960000, "total_debt": 2516964000, "total_revenue": -30765000, "cash_from_operations": 69684000, "net_income": -42793000, "ebitda": null, "year_low_stock_price": 2.76, "year_high_stock_price": 17.42, "image_position": [20478, 0, 128, 128]}, {"symbol": "SIEN", "name": "Sientra, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 7, "next_earnings_revenue_consensus": 17717710.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.48167, "eps_up_revisions": 1, "eps_down_revisions": 4, "revenue_up_revisions": 0, "revenue_down_revisions": 6, "total_analysts": 8, "analysts_sell": 0, "analysts_buy": 6, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "sientra.com", "year_founded": 2003, "street_address": "420 South Fairview Avenue", "city": "Santa Barbara", "state": "CA", "zipcode": "93117", "country": "United States", "phone_number": "805 562 3500", "short_description": "Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States.", "long_description": "Sientra, Inc., a medical aesthetics company, develops and sells medical aesthetics products to plastic surgeons in the United States. It operates through two segments, Breast Products and miraDry. The company offers silicone gel breast implants for use in breast augmentation and breast reconstruction procedures; breast tissue expanders; and scar management products under the Sientra, AlloX2, OPUS, Dermaspan, Softspan, and BIOCORNEUM brand names. It also provides body contouring products; facial and nasal implants; saline filled breast implant sizers; and miraDry System, a non-surgical device for the permanent reduction of underarm sweat, odor, and hair of all colors. The company was formerly known as Juliet Medical, Inc. and changed its name to Sientra, Inc. in April 2007. Sientra, Inc. was incorporated in 2003 and is headquartered in Santa Barbara, California.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 120080260, "total_enterprise": 84996260, "number_of_employees": 339, "outstanding_shares": 50033442, "eps": -2.627472, "diluted_eps": -2.627472, "earnings_from_cont_operations": -106818000, "gross_profit": 50687000, "cash": 87608000, "total_debt": 52524000, "total_revenue": 83699000, "cash_from_operations": -87033000, "net_income": -106818000, "ebitda": -82642000, "year_low_stock_price": 1.0, "year_high_stock_price": 9.71, "image_position": [20606, 0, 128, 128]}, {"symbol": "GTE", "name": "Gran Tierra Energy Inc.", "next_earnings_utc": 1589164200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.04, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 10, "analysts_sell": 1, "analysts_buy": 2, "analysts_outperform": 3, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "grantierra.com", "year_founded": 2003, "street_address": "520 \u00e2\u20ac\u201c 3rd Avenue SW", "city": "Calgary", "state": "AB", "zipcode": "T2P 0R3", "country": "Canada", "phone_number": "403 265 3221", "short_description": "Gran Tierra Energy Inc., together with its subsidiaries, engages in the exploration and production of oil and gas properties in Colombia and Ecuador.", "long_description": "Gran Tierra Energy Inc., together with its subsidiaries, engages in the exploration and production of oil and gas properties in Colombia and Ecuador. As of December 31, 2019, it had total proved undeveloped reserves of 31.0 million barrels of oil equivalent in Colombia. The company was founded in 2003 and is headquartered in Calgary, Canada.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 108259559, "total_enterprise": 708976559, "number_of_employees": 362, "outstanding_shares": 366981556, "eps": 0.102763, "diluted_eps": 0.099999, "earnings_from_cont_operations": 38690000, "gross_profit": 367379000, "cash": 103042000, "total_debt": 703759000, "total_revenue": 570983000, "cash_from_operations": 177665000, "net_income": 38690000, "ebitda": 332649000, "year_low_stock_price": 0.1775, "year_high_stock_price": 2.22, "image_position": [20734, 0, 128, 128]}, {"symbol": "CRMD", "name": "CorMedix, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 250000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.23, "eps_up_revisions": 2, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "cormedix.com", "year_founded": 2006, "street_address": "400 Connell Drive", "city": "Berkeley Heights", "state": "NJ", "zipcode": "07922", "country": "United States", "phone_number": "908 517 9500", "short_description": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally.", "long_description": "CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. It primarily focuses on the development of its lead product candidate, Neutrolin, an anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, critical/intensive care, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was founded in 2006 and is based in Berkeley Heights, New Jersey.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 105986409, "total_enterprise": 77656257, "number_of_employees": 30, "outstanding_shares": 26105027, "eps": -1.802563, "diluted_eps": -1.802563, "earnings_from_cont_operations": -16433074, "gross_profit": -89968, "cash": 28334394, "total_debt": 4000, "total_revenue": 283266, "cash_from_operations": -15052024, "net_income": -16433074, "ebitda": -20934590, "year_low_stock_price": 2.16, "year_high_stock_price": 9.99, "image_position": [20862, 0, 128, 128]}, {"symbol": "ABUS", "name": "Arbutus Biopharma Corporation", "next_earnings_utc": 1589196600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 1283989.535083205, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.313376987839102, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 2, "revenue_down_revisions": 0, "total_analysts": 6, "analysts_sell": 1, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "arbutusbio.com", "year_founded": null, "street_address": "701 Veterans Circle", "city": "Warminster", "state": "PA", "zipcode": "18974", "country": "United States", "phone_number": "267 469 0914", "short_description": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States.", "long_description": "Arbutus Biopharma Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of a cure for patients suffering from chronic Hepatitis B virus (HBV) infection in the United States. Its HBV product pipeline consists of AB-836, a capsid inhibitor that has the potential to inhibit HBV replication by preventing the assembly of functional viral capsids; and AB-423, which is in pre-clinical studies. The company also develops RNAi drugs, which utilize the RNA interference pathway, allows for a novel approach to treating disease. Its RNAi HBV candidates are designed to reduce hepatitis B surface antigen expression in patients chronically infected with HBV. In addition, it develops AB-729, a second generation RNAi therapeutic targeted to hepatocytes; HBV RNA destabilizer, an orally active agent that cause the destabilization of HBV RNAs, which leads to RNA degradation and to reduction in HBsAg levels. Further, the company engages conducting a Phase 1a/1b clinical trial and several pre-clinical and investigational new drug-enabling studies to evaluate proprietary HBV therapeutic agents, together with standard of care therapies, and in combination with each other. It has strategic alliance, licensing, and research collaboration agreements with Marqibo; Gritstone Oncology, Inc.; and Acuitas Therapeutics, Inc. The company was formerly known as Tekmira Pharmaceuticals Corporation and changed its name to Arbutus Biopharma Corporation in July 2015. Arbutus Biopharma Corporation is headquartered in Warminster, Pennsylvania.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 93097883, "total_enterprise": 142906883, "number_of_employees": 79, "outstanding_shares": 68961395, "eps": -2.887756, "diluted_eps": -2.887756, "earnings_from_cont_operations": -153723000, "gross_profit": -51590000, "cash": 90834000, "total_debt": 3358000, "total_revenue": 6011000, "cash_from_operations": -71006000, "net_income": -153723000, "ebitda": -68217000, "year_low_stock_price": 0.8214, "year_high_stock_price": 3.66, "image_position": [20990, 0, 128, 128]}, {"symbol": "AGFS", "name": "AgroFresh Solutions, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 40217670.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.15138, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "agrofresh.com", "year_founded": null, "street_address": "One Washington Square", "city": "Philadelphia", "state": "PA", "zipcode": "19106", "country": "United States", "phone_number": "267 317 9139", "short_description": "AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and services to enhance the quality and extend the shelf life of fresh produce.", "long_description": "AgroFresh Solutions, Inc. provides science-based solutions, data-driven technologies, and services to enhance the quality and extend the shelf life of fresh produce. It offers solutions in various fresh produce categories, including apples, bananas, cherries, citrus, and pears, as well as avocados, kiwifruits, melons, ornamentals, peaches and nectarines, plums, tomatoes, and others. The company supports growers, packers, and retailers by providing post-harvest solutions across the industry to enhance crop values while conserving planet's resources and reducing food waste. The company's flagship product is the SmartFresh system that regulates the post-harvest ripening effects of ethylene to preserve the texture, firmness, taste, and appearance of produce during storage, transportation, and retail display. It also provides Harvista technology for use in pre-harvest management of pome fruit, apples, pears, cherries, and blueberries. In addition, the company is developing RipeLock, a packaging- based freshness technology solution for fruits and vegetables; FreshCloud, a suite of monitoring and screening solutions; and LandSpring, a 1-Methylcyclopropene technology targeted to transplanted vegetable seedlings. It operates in North America, Europe, the Middle East, and Africa, as well as Latin America and the Asia Pacific. The company was formerly known as Boulevard Acquisition Corp. and changed its name to AgroFresh Solutions, Inc. in July 2015. AgroFresh Solutions, Inc. is headquartered in Philadelphia, Pennsylvania.", "industry_name": "Chemicals", "sector_name": "Materials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 113653124, "total_enterprise": 502521124, "number_of_employees": 292, "outstanding_shares": 51195101, "eps": -1.21364, "diluted_eps": -1.21364, "earnings_from_cont_operations": -61510000, "gross_profit": 125016000, "cash": 29288000, "total_debt": 410571000, "total_revenue": 170065000, "cash_from_operations": 20059000, "net_income": -60832000, "ebitda": 64126000, "year_low_stock_price": 1.0, "year_high_stock_price": 2.96, "image_position": [21118, 0, 128, 128]}, {"symbol": "APYX", "name": "Apyx Medical Corporation", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 5201250.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.25, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "apyxmedical.com", "year_founded": 1982, "street_address": "5115 Ulmerton Road", "city": "Clearwater", "state": "FL", "zipcode": "33760", "country": "United States", "phone_number": "727-384-2323", "short_description": "Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide.", "long_description": "Apyx Medical Corporation, a medical technology company, manufactures and sells medical devices in the cosmetic and surgical markets worldwide. It operates through two segments, Advanced Energy and original equipment manufacturing (OEM). The company develops J-Plasma, a patented plasma-based surgical product for cutting, coagulation, and ablation of soft tissue. It markets and sells Helium Plasma Technology under the Renuvion brand name in the cosmetic surgery market and under the J-Plasma brand name in the hospital surgical market. The company\u00e2\u20ac\u2122s Renuvion cosmetic technology enables plastic surgeons, fascial plastic surgeons, and cosmetic physicians to provide controlled heat to the tissue to achieve their desired results; and the J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminating unintended tissue trauma. It also designs, develops, manufactures, and sells electrosurgical and OEM generators and related accessories for medical device manufacturers. The company was formerly known as Bovie Medical Corporation and changed its name to Apyx Medical Corporation in January 2019. Apyx Medical Corporation was incorporated in 1982 and is based in Clearwater, Florida.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 107911430, "total_enterprise": 50232430, "number_of_employees": 266, "outstanding_shares": 34174314, "eps": -0.578414, "diluted_eps": -0.58, "earnings_from_cont_operations": -19706000, "gross_profit": 19094000, "cash": 58812000, "total_debt": 1133000, "total_revenue": 28235000, "cash_from_operations": -18475000, "net_income": -19706000, "ebitda": -20115000, "year_low_stock_price": 2.81, "year_high_stock_price": 8.59, "image_position": [21246, 0, 128, 128]}, {"symbol": "CLPR", "name": "Clipper Realty Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 31026000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.01, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "clipperrealty.com", "year_founded": null, "street_address": null, "city": null, "state": null, "zipcode": null, "country": null, "phone_number": null, "short_description": null, "long_description": null, "industry_name": "Equity Real Estate Investment Trusts (REITs)", "sector_name": "Real Estate", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 98871429, "total_enterprise": 1138823429, "number_of_employees": 198, "outstanding_shares": 17814672, "eps": -0.111373, "diluted_eps": -0.111373, "earnings_from_cont_operations": -4123000, "gross_profit": 62312000, "cash": 42500000, "total_debt": 997903000, "total_revenue": 116165000, "cash_from_operations": 23772000, "net_income": -1665000, "ebitda": 52720000, "year_low_stock_price": 4.32, "year_high_stock_price": 13.35, "image_position": [21374, 0, 128, 128]}, {"symbol": "SESN", "name": "Sesen Bio, Inc.", "next_earnings_utc": 1589194800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.095, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "sesenbio.com", "year_founded": 2008, "street_address": "245 First Street", "city": "Cambridge", "state": "MA", "zipcode": "02142", "country": "United States", "phone_number": "617-444-8550", "short_description": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer.", "long_description": "Sesen Bio, Inc., a late-stage clinical company, focuses on designing, engineering, developing, and commercializing targeted fusion protein therapeutics (TFPTs) for the treatment of cancer. The company\u2019s lead product candidates include Vicinium, a locally-administered targeted fusion protein that is in Phase III clinical trials for the treatment of high-risk non-muscle invasive bladder cancer (NMIBC); and VB6-845d, a systemically-administered product candidate, which is in Phase I/II clinical trials for use in the treatment of various types of EpCAM-positive solid tumors. It is also developing Vicinium in combination with Durvalumab, which is in Phase I clinical trials for use in the treatment of high-risk NMIBC; and Vicinium in combination with AstraZeneca\u2019s checkpoint inhibitor that is in Phase I/IIa clinical trials for the treatment of squamous cell carcinoma of the head and neck. The company was formerly known as Eleven Biotherapeutics, Inc. and changed its name to Sesen Bio, Inc. in May 2018. Sesen Bio, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 88804931, "total_enterprise": 40795931, "number_of_employees": 25, "outstanding_shares": 109988768, "eps": -1.182241, "diluted_eps": -1.182241, "earnings_from_cont_operations": -107500000, "gross_profit": -24663000, "cash": 48121000, "total_debt": 112000, "total_revenue": 0, "cash_from_operations": -37521000, "net_income": -107500000, "ebitda": -36652000, "year_low_stock_price": 0.37, "year_high_stock_price": 2.6, "image_position": [21502, 0, 128, 128]}, {"symbol": "MWK", "name": "Mohawk Group Holdings, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 25463330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.39667, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "mohawkgp.com", "year_founded": 2014, "street_address": "37 East 18th Street", "city": "New York", "state": "NY", "zipcode": "10003", "country": "United States", "phone_number": "347 676 1681", "short_description": "Mohawk Group Holdings, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in the United States and internationally.", "long_description": "Mohawk Group Holdings, Inc., together with its subsidiaries, operates as a technology-enabled consumer products company in the United States and internationally. The company provides home and kitchen appliances; kitchenware; environmental appliances, such as dehumidifiers and air conditioners; beauty related products; and consumer electronics under the hOmeLabs, Vremi, Xtava, and RIF6 brands. It primarily serves individual online consumers through Amazon and other e-commerce platforms, as well as through its owned and operated websites and other marketplaces. The company was founded in 2014 and is headquartered in New York, New York.", "industry_name": "Household Durables", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 61131497, "total_enterprise": 65902497, "number_of_employees": 61, "outstanding_shares": 15094197, "eps": -4.349314, "diluted_eps": -4.349314, "earnings_from_cont_operations": -58789000, "gross_profit": 45040000, "cash": 30353000, "total_debt": 35124000, "total_revenue": 114451000, "cash_from_operations": -25200000, "net_income": -58789000, "ebitda": -54150000, "year_low_stock_price": 1.42, "year_high_stock_price": 10.74, "image_position": [21630, 0, 128, 128]}, {"symbol": "MCHX", "name": "Marchex, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 23310000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.065, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "marchex.com", "year_founded": 2003, "street_address": "520 Pike Street", "city": "Seattle", "state": "WA", "zipcode": "98101", "country": "United States", "phone_number": "206-331-3300", "short_description": "Marchex, Inc. operates as a call analytics company that helps businesses connect, drive, measure, and convert callers into customers.", "long_description": "Marchex, Inc. operates as a call analytics company that helps businesses connect, drive, measure, and convert callers into customers. Its products include Marchex Call Analytics, an analytics platform for enterprises that depend on inbound phone calls to drive sales, appointments, and reservations; Marchex Speech Analytics that enable actionable insights for enterprise, mid-sized, and small businesses; Text Analytics and Communications, which enable businesses to send and receive text/SMS messages with customers; Call Monitoring; Marchex Omnichannel Analytics Cloud products, such as Marchex Search Analytics, a product for search marketers that drive phone calls from search campaigns, as well as Marchex Display and Video Analytics, a product for marketers that buy digital display advertising; Marchex Site Analytics, a product for marketers that can drive phone calls from Websites; and Marchex Social Analytics, a product for marketers that buy social media advertising. The company also offers Marchex Audience Targeting that leverages call data to automatically build audience segments for display and social media platforms; and Marchex Call Marketplace, a mobile advertising network for businesses that depend on inbound phone calls to drive sales, as well as provides advertisers ad placements across various mobile and online media sources to deliver qualified calls to their businesses. In addition, it provides Local Leads platform, a service advertising solution for small business resellers, such as Yellow Pages providers and vertical marketing service providers to sell call advertising, search marketing, and other lead generation products through their existing sales channels to small business advertisers. Marchex, Inc. was founded in 2003 and is headquartered in Seattle, Washington.", "industry_name": "Media", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 72761848, "total_enterprise": 37399848, "number_of_employees": 291, "outstanding_shares": 42303400, "eps": -0.088913, "diluted_eps": -0.09, "earnings_from_cont_operations": -4042000, "gross_profit": 49595000, "cash": 42526000, "total_debt": 7164000, "total_revenue": 106132000, "cash_from_operations": 5094000, "net_income": -4042000, "ebitda": 1205000, "year_low_stock_price": 1.1, "year_high_stock_price": 5.54, "image_position": [21758, 0, 128, 128]}, {"symbol": "CFMS", "name": "Conformis, Inc.", "next_earnings_utc": 1589233500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 18284500.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.09481, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 1, "webpage": "conformis.com", "year_founded": 2004, "street_address": "600 Technology Park Drive", "city": "Billerica", "state": "MA", "zipcode": "01821", "country": "United States", "phone_number": "781 345 9001", "short_description": "Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants.", "long_description": "Conformis, Inc., a medical technology company, develops, manufactures, and sells joint replacement implants. The company offers personalized knee replacement products, including iTotal CR, a cruciate-retaining product; iTotal PS, a posterior cruciate ligament substituting product; iDuo, a personalized bicompartmental knee replacement system; and iUni, a personalized unicompartmental knee replacement product to treat the medial or lateral compartment of the knee. It also provides Conformis Hip System, a hip replacement product; and iJigs, a customized single-use patient-specific instrumentation. The company markets and sells its products to hospitals and other medical facilities through sales force, independent sales representatives, and distributors in the United States, Germany, the United Kingdom, Austria, Ireland, Switzerland, Singapore, Hong Kong, Malaysia, Monaco, Hungary, Spain, and Australia. Conformis, Inc. was founded in 2004 and is headquartered in Billerica, Massachusetts.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 68080589, "total_enterprise": 67849589, "number_of_employees": 267, "outstanding_shares": 71558324, "eps": -0.444118, "diluted_eps": -0.444118, "earnings_from_cont_operations": -28478000, "gross_profit": 36737000, "cash": 26394000, "total_debt": 26163000, "total_revenue": 77429000, "cash_from_operations": -2838000, "net_income": -28478000, "ebitda": -20823000, "year_low_stock_price": 0.5003, "year_high_stock_price": 4.83, "image_position": [21838, 0, 80, 80]}, {"symbol": "CMLS", "name": "Cumulus Media Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 249167500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.045, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "cumulusmedia.com", "year_founded": 2018, "street_address": "3280 Peachtree Road, NW", "city": "Atlanta", "state": "GA", "zipcode": "30305", "country": "United States", "phone_number": "404-949-0700", "short_description": "Cumulus Media Inc., an audio-first media and entertainment company, owns and operates radio stations in the United States.", "long_description": "Cumulus Media Inc., an audio-first media and entertainment company, owns and operates radio stations in the United States. It operates through two segments, Cumulus Radio Station Group and Westwood One. The company offers content through approximately 428 owned-and-operated stations in 87 United States media markets; and approximately 8,000 broadcast radio stations affiliates and various digital channels. Cumulus Media Inc. was incorporated in 2018 and is based in Atlanta, Georgia.", "industry_name": "Media", "sector_name": "Communication Services", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 64528289, "total_enterprise": 1207155289, "number_of_employees": 3936, "outstanding_shares": 15932911, "eps": 3.042943, "diluted_eps": 3.02, "earnings_from_cont_operations": 61257000, "gross_profit": 704292000, "cash": 15142000, "total_debt": 1157769000, "total_revenue": 1113445000, "cash_from_operations": 104270000, "net_income": 61257000, "ebitda": 203401000, "year_low_stock_price": 3.23, "year_high_stock_price": 19.18, "image_position": [21966, 0, 128, 128]}, {"symbol": "YRCW", "name": "YRC Worldwide Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 1136650000.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.86333, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 0, "webpage": "yrcw.com", "year_founded": 1924, "street_address": "10990 Roe Avenue", "city": "Overland Park", "state": "KS", "zipcode": "66211", "country": "United States", "phone_number": "913 696 6100", "short_description": "YRC Worldwide Inc., through its subsidiaries, provides a range of transportation services primarily in North America.", "long_description": "YRC Worldwide Inc., through its subsidiaries, provides a range of transportation services primarily in North America. The company operates in two segments, YRC Freight and Regional Transportation. The YRC Freight segment offers various services to transport industrial, commercial, and retail goods; and provides specialized services, including guaranteed expedited, time-specific delivery, cross-border, coast-to-coast air delivery, product return, temperature-sensitive shipment protection, and government material shipment. It serves manufacturing, wholesale, retail, and government customers. As of December 31, 2019, this segment had a fleet of approximately 7,700 tractors comprising 5,500 owned and 2,200 leased tractors; and 29,800 trailers consisting of 21,500 owned and 8,300 leased trailers. The Regional Transportation segment offers regional delivery services, which include next-day and second-day delivery, consolidation/distribution, protect-from-freezing and hazardous materials handling, truckload, and other specialized services; guaranteed and expedited delivery services consisting of day-definite, hour-definite, and time definite capabilities; interregional delivery services; and cross-border delivery services, as well as operates hollandregional.com, newpenn.com, and reddawayregional.com e-commerce websites that provide online resources to manage transportation activities. This segment had a fleet of approximately 6,400 tractors, including 4,800 owned and 1,600 leased tractors; and 13,900 trailers comprising 9,800 owned and 4,100 leased trailers. The company was formerly known as Yellow Roadway Corporation and changed its name to YRC Worldwide Inc. in January 2006. YRC Worldwide Inc. was founded in 1924 and is headquartered in Overland Park, Kansas.", "industry_name": "Road and Rail", "sector_name": "Industrials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 56371003, "total_enterprise": 1179971003, "number_of_employees": 29000, "outstanding_shares": 37580669, "eps": -3.127631, "diluted_eps": -3.13, "earnings_from_cont_operations": -104000000, "gross_profit": 401200000, "cash": 109200000, "total_debt": 1232800000, "total_revenue": 4871200000, "cash_from_operations": 21500000, "net_income": -104000000, "ebitda": 160000000, "year_low_stock_price": 1.29, "year_high_stock_price": 6.01, "image_position": [22026, 0, 60, 60]}, {"symbol": "INFI", "name": "Infinity Pharmaceuticals, Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 198250.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.11838, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 1, "webpage": "infi.com", "year_founded": null, "street_address": "1100 Massachusetts Avenue", "city": "Cambridge", "state": "MA", "zipcode": "02138", "country": "United States", "phone_number": "617 453 1000", "short_description": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer.", "long_description": "Infinity Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing novel medicines for people with cancer. It offers IPI-549, an orally administered, clinical-stage, immuno-oncology product candidate that selectively inhibits the enzyme phosphoinositide-3-kinase-gamma Its product candidate is IPI-549, an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma (PI3K-gamma), which is in Phase 1/1b clinical study. The company has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib, as well as duvelisib program for patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with Arcus Biosciences, Inc., F. Hoffmann-La Roche Ltd., and Bristol-Myers Squibb Company. Infinity Pharmaceuticals, Inc. is headquartered in Cambridge, Massachusetts.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 63751293, "total_enterprise": 23614293, "number_of_employees": 25, "outstanding_shares": 57433598, "eps": -0.825798, "diluted_eps": -0.825798, "earnings_from_cont_operations": -47057000, "gross_profit": -31375000, "cash": 42444000, "total_debt": 2307000, "total_revenue": 3049000, "cash_from_operations": -41530000, "net_income": -47057000, "ebitda": -45445000, "year_low_stock_price": 0.6, "year_high_stock_price": 1.8, "image_position": [22154, 0, 128, 128]}, {"symbol": "XOG", "name": "Extraction Oil & Gas, Inc.", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 215340000.0, "next_earnings_eps_num_analysts": 7, "next_earnings_eps_consensus": -0.22989, "eps_up_revisions": 1, "eps_down_revisions": 6, "revenue_up_revisions": 1, "revenue_down_revisions": 3, "total_analysts": 10, "analysts_sell": 3, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 4, "analysts_underperform": 3, "webpage": "extractionog.com", "year_founded": 2012, "street_address": "370 17th Street", "city": "Denver", "state": "CO", "zipcode": "80202", "country": "United States", "phone_number": "720 557 8300", "short_description": "Extraction Oil & Gas, Inc., an independent oil and gas company, focuses on the acquisition, development, and production of oil, natural gas, and natural gas liquid reserves in the Rocky Mountain region, primarily in the Wattenberg Field of the Denver-Julesburg (DJ) Basin of Colorado.", "long_description": "Extraction Oil & Gas, Inc., an independent oil and gas company, focuses on the acquisition, development, and production of oil, natural gas, and natural gas liquid reserves in the Rocky Mountain region, primarily in the Wattenberg Field of the Denver-Julesburg (DJ) Basin of Colorado. The company also engages in the construction and support of midstream assets to gather, process, and produce crude oil and gas. As of December 31, 2019, it had approximately 169,900 net acres of contiguous acreage blocks in the productive areas of the DJ Basin; held approximately 125,500 net acres outside of the Core DJ Basin; had estimated proved reserves of approximately 254.1 MMBoe; and had 1,509 gross producing wells. The company was founded in 2012 and is headquartered in Denver, Colorado.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 58266056, "total_enterprise": 2056218056, "number_of_employees": 323, "outstanding_shares": 138103951, "eps": -9.28729, "diluted_eps": -9.28729, "earnings_from_cont_operations": -1367420000, "gross_profit": 685801000, "cash": 32382000, "total_debt": 1590331000, "total_revenue": 838453000, "cash_from_operations": 557957000, "net_income": -1387412000, "ebitda": 534884000, "year_low_stock_price": 0.2101, "year_high_stock_price": 4.6, "image_position": [22282, 0, 128, 128]}, {"symbol": "REI", "name": "Ring Energy, Inc.", "next_earnings_utc": 1589232300, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 40952750.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": 0.06333, "eps_up_revisions": 0, "eps_down_revisions": 4, "revenue_up_revisions": 0, "revenue_down_revisions": 4, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 5, "analysts_underperform": 0, "webpage": "ringenergy.com", "year_founded": 2004, "street_address": "901 West Wall Street", "city": "Midland", "state": "TX", "zipcode": "79701", "country": "United States", "phone_number": "432 682 7464", "short_description": "Ring Energy, Inc., an exploration and production company, acquires, explores for, develops, and produces oil and natural gas in Texas and New Mexico.", "long_description": "Ring Energy, Inc., an exploration and production company, acquires, explores for, develops, and produces oil and natural gas in Texas and New Mexico. As of December 31, 2019, the company's proved reserves consisted of approximately 81.1 million barrel of oil equivalent. It also had interests in 18,372 net developed acres and 47,427 net undeveloped acres in Andrews and Gaines counties, Texas; 19,138 net developed acres and 860 net undeveloped acres in Culberson and Reeves counties, Texas; and 8,085 net developed acres and 28,514 net undeveloped acres in Gaines, Yoakum, Runnels, and Coke Counties, Texas and Lea County, New Mexico. It primarily sells its oil and natural gas production to end users, marketers, and other purchasers. The company was formerly known as Transglobal Mining Corp. and changed its name to Ring Energy, Inc. in March 2008. Ring Energy, Inc. was founded in 2004 and is headquartered in Midland, Texas.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 52695192, "total_enterprise": 411762710, "number_of_employees": 58, "outstanding_shares": 67993797, "eps": 0.443079, "diluted_eps": 0.439999, "earnings_from_cont_operations": 29496551, "gross_profit": 143769151, "cash": 10004622, "total_debt": 369072140, "total_revenue": 186572452, "cash_from_operations": 106616221, "net_income": 29496551, "ebitda": 118384226, "year_low_stock_price": 0.5182, "year_high_stock_price": 5.54, "image_position": [22410, 0, 128, 128]}, {"symbol": "HZN", "name": "Horizon Global Corporation", "next_earnings_utc": 1589193000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 179802000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.3, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 1, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "horizonglobal.com", "year_founded": 2015, "street_address": "47912 Halyard Drive", "city": "Plymouth", "state": "MI", "zipcode": "48170", "country": "United States", "phone_number": "734 656 3000", "short_description": "Horizon Global Corporation designs, manufactures, and distributes a range of towing, trailering, cargo management, and other related accessory products worldwide.", "long_description": "Horizon Global Corporation designs, manufactures, and distributes a range of towing, trailering, cargo management, and other related accessory products worldwide. It operates through Horizon Americas and Horizon Europe-Africa segments. The company provides towing products, such as hitches, fifth wheels, gooseneck hitches, weight distribution systems, wiring harnesses, draw bars, ball mounts, crossbars, brake controls, security products, and other towing accessories for attaching a trailer, camper, etc. It also offers trailering products, including brake controls, jacks, winches, couplers, interior and exterior vehicle lighting, and brake replacement parts. In addition, the company provides cargo management products, such as bike racks, roof cross bar systems, cargo carriers, luggage boxes, car interior protective products, ropes, tie-downs, tarps, tarp straps, bungee cords, loading ramps, and interior travel organizers. Further, it offers other products comprising tubular push and sports bars, side steps, skid plates, and oil pans. Horizon Global Corporation provides its products under the Reese, Draw-Tite, and Westfalia, as well as Aqua Clear, Bulldog, BTM, DHF, Engetran, Fulton, Kovil, Reese Secure, Reese Explorer, Reese Power Sports, Reese Towpower, ROLA, Tekonsha, Trojan, WesBarg, Best Bars, and Witter Towbar brands. The company serves original equipment manufacturers and servicers, as well as automotive aftermarket and retail sectors in the agricultural, automotive, construction, fleet, horse/livestock, industrial, marine, military, recreational, trailer, utility, mining, and municipality markets; and serves end consumers through independent installers, warehouse distributors, dealers, original equipment channels, retail stores, and online retailers. Horizon Global Corporation was incorporated in 2015 is headquartered in Plymouth, Michigan.", "industry_name": "Auto Components", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 47124002, "total_enterprise": 298924002, "number_of_employees": 3600, "outstanding_shares": 25472434, "eps": 3.192005, "diluted_eps": 3.191626, "earnings_from_cont_operations": -110010000, "gross_profit": 96230000, "cash": 11770000, "total_debt": 267310000, "total_revenue": 690450000, "cash_from_operations": -68480000, "net_income": 80750000, "ebitda": -35560000, "year_low_stock_price": 1.2, "year_high_stock_price": 5.79, "image_position": [22538, 0, 128, 128]}, {"symbol": "GNC", "name": "GNC Holdings, Inc.", "next_earnings_utc": 1589193900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 475500000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.06, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 1, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "gnc.com", "year_founded": 1935, "street_address": "300 Sixth Avenue", "city": "Pittsburgh", "state": "PA", "zipcode": "15222", "country": "United States", "phone_number": "412 288 4600", "short_description": "GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products.", "long_description": "GNC Holdings, Inc., together with its subsidiaries, operates as a specialty retailer of health, wellness, and performance products. It operates in three segments: U.S. and Canada, International, and Manufacturing/Wholesale. The company's products include protein, performance supplements, weight management supplements, vitamins, herbs and greens, wellness supplements, health and beauty products, food and drink products, and other general merchandise. It also provides third-party contract manufacturing services. The company sells its products through company-owned retail stores and its GNC.com Website, e-commerce and wholesale partnerships, and domestic and international franchise activities under the GNC proprietary brands, as well as other third-party brands. As of December 31, 2019, it had 7,532 GNC store locations worldwide. The company has a strategic partnership with Harbin Pharmaceutical Group Holding Co., Ltd. and International Vitamin Corporation. GNC Holdings, Inc. was founded in 1935 and is headquartered in Pittsburgh, Pennsylvania.", "industry_name": "Specialty Retail", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 47381026, "total_enterprise": 1453750026, "number_of_employees": 8400, "outstanding_shares": 84608976, "eps": -0.644075, "diluted_eps": -0.644075, "earnings_from_cont_operations": -35112000, "gross_profit": 741573000, "cash": 117046000, "total_debt": 1312020000, "total_revenue": 2068188000, "cash_from_operations": 96520000, "net_income": -35112000, "ebitda": 183858000, "year_low_stock_price": 0.38, "year_high_stock_price": 3.42, "image_position": [22666, 0, 128, 24]}, {"symbol": "AESE", "name": "Allied Esports Entertainment Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 5868880.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.18667, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "alliedesportsent.com", "year_founded": null, "street_address": "17877 Von Karman Avenue", "city": "Irvine", "state": "CA", "zipcode": "92614", "country": "United States", "phone_number": "949 225 2600", "short_description": "Allied Esports Entertainment Inc. operates as an esports and entertainment company worldwide.", "long_description": "Allied Esports Entertainment Inc. operates as an esports and entertainment company worldwide. The company operates through two segments, Gaming & Entertainment, and E-Sports. It provides infrastructure, transformative live experiences, multiplatform content, and interactive services to audiences under the Allied Esports and World Poker Tour (WPT) brand names. The company operates esports properties designed to connect players and fans through a network of connected arenas; a gaming arena located at the Luxor Hotel in Las Vegas, Nevada; a mobile esports truck that serves as a battleground and content generation hub; and a studio for recording and streaming gaming events. It provides esports, including multiplayer video game competitions. The company also offers televised gaming and entertainment, land-based poker tournaments, and online and mobile poker applications under the WPT brand name. In addition, the company operates ClubWPT.com, an online membership platform that offers inside access to the WPT; and sweepstakes-based poker product that allows members to play for real cash and prizes in 36 states and territories in the United States, and 4 international countries. Further, it engages in the brand and music licensing business. The company is based in Irvine, California. Allied Esports Entertainment Inc. is a subsidiary of Primo Vital Limited.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 45476254, "total_enterprise": 50869297, "number_of_employees": 146, "outstanding_shares": 23934871, "eps": -0.924853, "diluted_eps": -0.924853, "earnings_from_cont_operations": -16738729, "gross_profit": 15610036, "cash": 8440573, "total_debt": 13833616, "total_revenue": 26071995, "cash_from_operations": -10063673, "net_income": -16738729, "ebitda": -7847006, "year_low_stock_price": 0.4, "year_high_stock_price": 10.81, "image_position": [22793, 0, 127, 128]}, {"symbol": "HCFT", "name": "Hunt Companies Finance Trust, Inc.", "next_earnings_utc": 1589230800, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 1906900.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.05, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "huntcompaniesfinancetrust.com", "year_founded": 2012, "street_address": "230 Park Avenue", "city": "New York", "state": "NY", "zipcode": "10169", "country": "United States", "phone_number": "212-521-6323", "short_description": "Hunt Companies Finance Trust, Inc., a real estate investment trust, focuses on investing in, financing, and managing multi-family and other commercial real estate loans.", "long_description": "Hunt Companies Finance Trust, Inc., a real estate investment trust, focuses on investing in, financing, and managing multi-family and other commercial real estate loans. The company is qualified as a real estate investment trust (REIT) under the Internal Revenue Code. As a REIT, it would not be subject to federal income taxes if it distributes at least 90% of its taxable income to its stockholders. The company was formerly known as Five Oaks Investment Corp. and changed its name to Hunt Companies Finance Trust, Inc. in May 2018. Hunt Companies Finance Trust, Inc. was founded in 2012 and is headquartered in New York, New York.", "industry_name": "Mortgage Real Estate Investment Trusts (REITs)", "sector_name": "Financials", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 48132044, "total_enterprise": null, "number_of_employees": null, "outstanding_shares": 24938883, "eps": 0.112467, "diluted_eps": 0.112467, "earnings_from_cont_operations": 6248890, "gross_profit": 16267774, "cash": 10942115, "total_debt": 545314106, "total_revenue": 16267774, "cash_from_operations": 7282343, "net_income": 6248890, "ebitda": null, "year_low_stock_price": 0.86, "year_high_stock_price": 3.51, "image_position": [22921, 0, 128, 128]}, {"symbol": "REED", "name": "Reed's, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 8822900.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.06333, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 2, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "drinkreeds.com", "year_founded": 1987, "street_address": "201 Merritt 7 Corporate Park", "city": "Norwalk", "state": "CT", "zipcode": "06851", "country": "United States", "phone_number": "800 997 3337", "short_description": "Reed's, Inc. develops, manufactures, and sells natural hand-crafted beverages in the craft specialty foods industry in the United States, Canada, Asia, Europe, Australia, and South America.", "long_description": "Reed's, Inc. develops, manufactures, and sells natural hand-crafted beverages in the craft specialty foods industry in the United States, Canada, Asia, Europe, Australia, and South America. Its products include Reed\u2019s craft ginger beers; Virgil\u2019s craft sodas; and Virgil\u2019s zero sugar sodas. Reed's, Inc. sells its products to natural food and gourmet retailers, grocery store chains, mass merchants, club stores, convenience and drug stores, liquor stores, industrial cafeterias, and on-premise bars and restaurants through distributors and independent distributor partners, as well as directly. The company was formerly known as Original Beverage Corporation and changed its name to Reed's, Inc. in 2001. Reed's, Inc. was founded in 1987 and is headquartered in Norwalk, Connecticut.", "industry_name": "Beverages", "sector_name": "Consumer Staples", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 43295820, "total_enterprise": 51128820, "number_of_employees": 28, "outstanding_shares": 60928540, "eps": -0.459723, "diluted_eps": -0.459723, "earnings_from_cont_operations": -16112000, "gross_profit": 7876000, "cash": 913000, "total_debt": 8652000, "total_revenue": 33820000, "cash_from_operations": -18161000, "net_income": -16112000, "ebitda": -14197000, "year_low_stock_price": 0.3612, "year_high_stock_price": 3.93, "image_position": [23049, 0, 128, 128]}, {"symbol": "ICMB", "name": "Investcorp Credit Management BDC, Inc.", "next_earnings_utc": 1589231400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 8417550.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.265, "eps_up_revisions": 2, "eps_down_revisions": 0, "revenue_up_revisions": 1, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "cmfn-inc.com", "year_founded": 2012, "street_address": "399 Park Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "212-257-5180", "short_description": "CM Finance Inc. is a business development company specializing in loan, mezzanine, middle market, growth capital, and recapitalization investments.", "long_description": "CM Finance Inc. is a business development company specializing in loan, mezzanine, middle market, growth capital, and recapitalization investments. The fund typically invests in United States and Europe. Within United States, the fund seeks to invest in Midatlantic, Midwest, Northeast, Southeast, and West Coast regions. The fund primarily invests in cable and satellites; consumer services; healthcare equipment and services; industrials; information technology; telecommunication services; and utilities sectors. The fund seeks to invest in companies with EBITDA more than $15 million. The fund is based in New York, New York.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 47158843, "total_enterprise": 201343237, "number_of_employees": null, "outstanding_shares": 13870248, "eps": -0.332098, "diluted_eps": -0.332098, "earnings_from_cont_operations": -4527083, "gross_profit": 34833891, "cash": 17192788, "total_debt": 171377182, "total_revenue": 34833891, "cash_from_operations": -10317649, "net_income": -4527083, "ebitda": null, "year_low_stock_price": 1.38, "year_high_stock_price": 7.7, "image_position": [23177, 0, 128, 128]}, {"symbol": "QUIK", "name": "QuickLogic Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 2233330.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": -0.29, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "quicklogic.com", "year_founded": 1988, "street_address": "2220 Lundy Avenue", "city": "San Jose", "state": "CA", "zipcode": "95131", "country": "United States", "phone_number": "408-990-4000", "short_description": "QuickLogic Corporation, a semiconductor company, develops semiconductor platforms and intellectual property solutions for smartphones, wearable and hearable devices, tablets, and the Internet-of-Things.", "long_description": "QuickLogic Corporation, a semiconductor company, develops semiconductor platforms and intellectual property solutions for smartphones, wearable and hearable devices, tablets, and the Internet-of-Things. It also provides flexible sensor processing solutions, ultra-low power display bridges, ultra-low field programmable gate arrays (FPGAs), and programming hardware and design software solutions. The company\u00e2\u20ac\u2122s products include pASIC 3, QuickRAM, and QuickPCI. It delivers its solutions through ultra-low power customer programmable System on Chip (SoC) semiconductor solutions, embedded software, and algorithm solutions for always-on voice and sensor processing, and enhanced visual experiences. The company develops its solutions by incorporating various silicon platforms, such as EOS S3, EOS3 LV, EOS S3AI, ArcticLink III S2, ArcticLink III VX and BX, PolarPro 3, PolarPro II, PolarPro, and Eclipse II solution platforms, as well as packaging, IPs, custom logic, software drivers, SensiML analytics, and architecture consulting. In addition, it licenses FPGA technology for use in other semiconductor companies SoCs. The company markets and sells its products to original equipment manufacturers and original design manufacturers through a network of sales managers and distributors in North America, Europe, and Asia. QuickLogic Corporation has a collaboration with Airoha. QuickLogic Corporation was founded in 1988 and is headquartered in San Jose, California.", "industry_name": "Semiconductors and Semiconductor Equipment", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 37705671, "total_enterprise": 33544671, "number_of_employees": 81, "outstanding_shares": 8379038, "eps": -2.015398, "diluted_eps": -2.015398, "earnings_from_cont_operations": -15444000, "gross_profit": 5905000, "cash": 21448000, "total_debt": 17287000, "total_revenue": 10310000, "cash_from_operations": -11594000, "net_income": -15444000, "ebitda": -14155000, "year_low_stock_price": 2.12, "year_high_stock_price": 12.03, "image_position": [23305, 0, 128, 128]}, {"symbol": "NEOS", "name": "Neos Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 4, "next_earnings_revenue_consensus": 14725000.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.0925, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 4, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 1, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "neostx.com", "year_founded": null, "street_address": "2940 North Highway 360", "city": "Grand Prairie", "state": "TX", "zipcode": "75050", "country": "United States", "phone_number": "972-408-1300", "short_description": "Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform.", "long_description": "Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate for treating of ADHD; Adzenys ER amphetamine to treat ADHD; and generic Tussionex hydrocodone and chlorpheniramine for cough and upper respiratory symptoms of a cold. Neos Therapeutics, Inc. is headquartered in Grand Prairie, Texas.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 40541323, "total_enterprise": 64517323, "number_of_employees": 213, "outstanding_shares": 49743955, "eps": -0.339917, "diluted_eps": -0.339917, "earnings_from_cont_operations": -16902000, "gross_profit": 39526000, "cash": 24894000, "total_debt": 48870000, "total_revenue": 64649000, "cash_from_operations": -10783000, "net_income": -16902000, "ebitda": -6619000, "year_low_stock_price": 0.6, "year_high_stock_price": 2.3, "image_position": [23433, 0, 128, 84]}, {"symbol": "USWS", "name": "U.S. Well Services, Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 109900000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.47, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "uswellservices.com", "year_founded": null, "street_address": "1360 Post Oak Boulevard", "city": "Houston", "state": "TX", "zipcode": "77056", "country": "United States", "phone_number": "832 562 3730", "short_description": "U.S. Well Services, Inc. operates as an oilfield service company in the United States.", "long_description": "U.S. Well Services, Inc. operates as an oilfield service company in the United States. It provides hydraulic fracturing services to the oil and natural gas exploration and production companies. The company is headquartered in Houston, Texas.", "industry_name": "Energy Equipment and Services", "sector_name": "Energy", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 29181055, "total_enterprise": 360196055, "number_of_employees": 871, "outstanding_shares": 67878705, "eps": -2.11478, "diluted_eps": -2.11478, "earnings_from_cont_operations": -116082000, "gross_profit": 132930000, "cash": 33794000, "total_debt": 315248000, "total_revenue": 514757000, "cash_from_operations": 74844000, "net_income": -93913000, "ebitda": 98944000, "year_low_stock_price": 0.2487, "year_high_stock_price": 7.99, "image_position": [23561, 0, 128, 128]}, {"symbol": "GARS", "name": "Garrison Capital", "next_earnings_utc": 1589229000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 8542000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.15, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "garrisoncapitalbdc.com", "year_founded": 2010, "street_address": "1290 Avenue of the Americas", "city": "New York", "state": "NY", "zipcode": "10104", "country": "United States", "phone_number": "212-372-9590", "short_description": "Garrison Capital Inc. is a business development company specializing in investments primarily in the debt and equity of middle market companies.", "long_description": "Garrison Capital Inc. is a business development company specializing in investments primarily in the debt and equity of middle market companies. It seeks to invest in  first lien senior secured loans, second lien senior secured loans, \u201cone-stop\u201d senior secured or \u201cunitranche\u201d loans, subordinated or mezzanine loans, unsecured consumer loans and to a lesser extent, selected equity co-investments in middle-market companies, warrants and minority equity securities in United States middle-market companies. The fund focuses on consumer loans, capital market activities, traditional direct lending but at times may purchase loans in the secondary market or make special situation investments. It seeks to invest between $5 million and $25 million in equity and between $10 million and $25 million in debt per transaction primarily in debt securities and loans with annual EBITDA between $5 million and $30 million, annual revenue between $50 million and $200 million. Its investments typically range in maturity from one to six years.", "industry_name": "Capital Markets", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "cef", "market_cap": 26481431, "total_enterprise": 338980430, "number_of_employees": null, "outstanding_shares": 16049352, "eps": -1.176309, "diluted_eps": -1.176309, "earnings_from_cont_operations": -18879000, "gross_profit": 39719000, "cash": 1251000, "total_debt": 313750000, "total_revenue": 39719000, "cash_from_operations": 2272000, "net_income": -18879000, "ebitda": null, "year_low_stock_price": 1.04, "year_high_stock_price": 7.25, "image_position": [23689, 0, 128, 128]}, {"symbol": "IRIX", "name": "IRIDEX Corporation", "next_earnings_utc": 1589227500, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 9508500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.165, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "iridex.com", "year_founded": 1989, "street_address": "1212 Terra Bella Avenue", "city": "Mountain View", "state": "CA", "zipcode": "94043", "country": "United States", "phone_number": "650-940-4700", "short_description": "IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology.", "long_description": "IRIDEX Corporation, an ophthalmic medical technology company, provides therapeutic based laser systems, delivery devices, and consumable instrumentation to treat sight-threatening eye diseases in ophthalmology. The company offers laser consoles, such as Cyclo G6 laser system for use in the treatment of glaucoma; IQ 532 and IQ 577 laser photocoagulation systems, which are used for the treatment of diabetic macular edema and other retinal diseases; and OcuLight TX, OcuLight SL, OcuLight SLx, OcuLight GL, and OcuLight GLx laser photocoagulation systems that are used to treat proliferative diabetic retinopathy, macular holes, retinal tears, and detachments. It also provides delivery devices, including TxCell scanning laser delivery system that allows the physician to perform multi-spot pattern scanning; slit lamp adapter, which allows the physician to utilize a standard slit lamp in diagnosis and treatment procedures; and laser indirect ophthalmoscope for use in procedures to treat peripheral retinal disorders. In addition, the company offers MicroPulse P3 Probe, which is used with its Cylco G6 laser system that delivers laser to treat glaucoma; G-Probe, which is used in procedures to treat uncontrolled glaucoma; G-Probe and G-Probe Illuminate, which are used in procedures to treat refractory glaucoma; and EndoProbe family of products for use in vitrectomy procedures. It serves ophthalmologists, research and teaching hospitals, government installations, surgical centers, hospitals, and office clinics. IRIDEX Corporation markets its products through direct and independent sales force in the United States, as well as through independent distributors internationally. The company was formerly known as IRIS Medical Instruments, Inc. and changed its name to IRIDEX Corporation in November 1995. IRIDEX Corporation was founded in 1989 and is headquartered in Mountain View, California.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 24405965, "total_enterprise": 14961965, "number_of_employees": 94, "outstanding_shares": 13788681, "eps": -0.642956, "diluted_eps": -0.642956, "earnings_from_cont_operations": -8813000, "gross_profit": 17939000, "cash": 12653000, "total_debt": 3209000, "total_revenue": 43447000, "cash_from_operations": -7913000, "net_income": -8813000, "ebitda": -8286000, "year_low_stock_price": 1.22, "year_high_stock_price": 5.69, "image_position": [23817, 0, 128, 128]}, {"symbol": "HNRG", "name": "Hallador Energy Company", "next_earnings_utc": 1589238000, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 59900000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": 0.02, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "halladorenergy.com", "year_founded": 1949, "street_address": "1183 East Canvasback Drive", "city": "Terre Haute", "state": "IN", "zipcode": "47802", "country": "United States", "phone_number": "303-839-5504", "short_description": "Hallador Energy Company, through its subsidiaries, engages in the mining, production, and sale of steam coal for the electric power generation industry in the United States.", "long_description": "Hallador Energy Company, through its subsidiaries, engages in the mining, production, and sale of steam coal for the electric power generation industry in the United States. The company holds interests in the Oaktown 1 mine underground mine located in Knox County, Indiana; the Oaktown 2 mine located in Knox County, Indiana and Lawrence County, Illinois; Carlisle underground coal mine located near the town of Carlisle, Indiana; and Ace in the Hole mine located near Clay City, Indiana. It is also involved in gas exploration activities in Indiana. The company was founded in 1949 and is headquartered in Terre Haute, Indiana.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 21096247, "total_enterprise": 190490247, "number_of_employees": 915, "outstanding_shares": 30419967, "eps": -1.948467, "diluted_eps": -1.948467, "earnings_from_cont_operations": -59854000, "gross_profit": 69570000, "cash": 9044000, "total_debt": 174438000, "total_revenue": 317436000, "cash_from_operations": 38243000, "net_income": -59854000, "ebitda": 59101000, "year_low_stock_price": 0.65, "year_high_stock_price": 6.0, "image_position": [23945, 0, 128, 125]}, {"symbol": "CHAP", "name": "Chaparral Energy, Inc.", "next_earnings_utc": 1589229900, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": null, "next_earnings_revenue_consensus": null, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.14, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "chaparralenergy.com", "year_founded": 1988, "street_address": "701 Cedar Lake Boulevard", "city": "Oklahoma City", "state": "OK", "zipcode": "73114", "country": "United States", "phone_number": "405 478 8770", "short_description": "Chaparral Energy, Inc. engages in the acquisition, exploration, development, production, and operation of oil and natural gas properties primarily in Oklahoma, the United States.", "long_description": "Chaparral Energy, Inc. engages in the acquisition, exploration, development, production, and operation of oil and natural gas properties primarily in Oklahoma, the United States. The company sells crude oil, natural gas, and natural gas liquids primarily to refineries and gas processing plant. Its 210,000 net surface acres are located in the Mid-Continent region, approximately 122,000 net acres are located in the STACK play primarily in Canadian, Kingfisher, and Garfield counties. As of December 31, 2019, the company's estimated proved oil and natural gas reserves were 96.6 million barrels of crude oil equivalent; and had an interest in 2,782 gross producing wells, including 866 gross company operated wells. Chaparral Energy, Inc. was founded in 1988 and is headquartered in Oklahoma City, Oklahoma.", "industry_name": "Oil, Gas and Consumable Fuels", "sector_name": "Energy", "is_defunct": false, "exchange": "NYSE", "equity_type": "stocks", "market_cap": 18700759, "total_enterprise": 420267759, "number_of_employees": 121, "outstanding_shares": 47938374, "eps": -10.275533, "diluted_eps": -10.28, "earnings_from_cont_operations": -468948000, "gross_profit": 173450000, "cash": 22595000, "total_debt": 424162000, "total_revenue": 223055000, "cash_from_operations": 113657000, "net_income": -468948000, "ebitda": 112501000, "year_low_stock_price": 0.211, "year_high_stock_price": 6.38, "image_position": [24073, 0, 128, 128]}, {"symbol": "ELGX", "name": "Endologix, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 29700000.0, "next_earnings_eps_num_analysts": 6, "next_earnings_eps_consensus": -0.605, "eps_up_revisions": 0, "eps_down_revisions": 3, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 7, "analysts_sell": 0, "analysts_buy": 1, "analysts_outperform": 0, "analysts_hold": 5, "analysts_underperform": 1, "webpage": "endologix.com", "year_founded": 1992, "street_address": "2 Musick", "city": "Irvine", "state": "CA", "zipcode": "92618", "country": "United States", "phone_number": "949-595-7200", "short_description": "Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally.", "long_description": "Endologix, Inc. develops, manufactures, markets, and sells medical devices for the treatment of abdominal aortic aneurysms in the United States and internationally. The company offers minimally-invasive endovascular aneurysm repair (EVAR), including AFX (Anatomical Fixation) endovascular AAA system, which is a minimally invasive delivery system; VELA Proximal Endograft, which is designed for the treatment of proximal aortic neck anatomies with AFX; and the Ovation abdominal stent graft system. It also provides endovascular aneurysm sealing system (EVAS) product that is based on the Nellix EVAS system to seal the aneurysm, and provides blood flow to the legs through two blood lumens. In addition, the company offers proximal aortic extensions and limb extensions, which allow physicians to customize the implant to fit the patient's anatomy; and accessories to facilitate the delivery of its EVAR and EVAS products, including compatible guidewires, inflation devices, and snares. It sells its products through direct sales force, and a network of third party distributors and agents. The company was formerly known as Radiance Medical Systems, Inc. and changed its name to Endologix, Inc. in May 2002. Endologix, Inc. was founded in 1992 and is headquartered in Irvine, California.", "industry_name": "Health Care Equipment and Supplies", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 16746603, "total_enterprise": 171273603, "number_of_employees": 488, "outstanding_shares": 19097506, "eps": -3.843145, "diluted_eps": -3.843145, "earnings_from_cont_operations": -64757000, "gross_profit": 91086000, "cash": 41560000, "total_debt": 196087000, "total_revenue": 143370000, "cash_from_operations": -29570000, "net_income": -64757000, "ebitda": -34821000, "year_low_stock_price": 0.6, "year_high_stock_price": 8.14, "image_position": [24201, 0, 128, 128]}, {"symbol": "STAF", "name": "Staffing 360 Solutions, Inc.", "next_earnings_utc": 1589228100, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 72472500.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.13, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "staffing360solutions.com", "year_founded": 2009, "street_address": "641 Lexington Avenue", "city": "New York", "state": "NY", "zipcode": "10022", "country": "United States", "phone_number": "646-507-5710", "short_description": "Staffing 360 Solutions, Inc., a staffing company, engages in the acquisition of staffing companies in the United States and the United Kingdom.", "long_description": "Staffing 360 Solutions, Inc., a staffing company, engages in the acquisition of staffing companies in the United States and the United Kingdom. The company operates through three segments: Commercial - US, Professional - US, and Professional - UK. It focuses primarily on the staffing companies supporting accounting and finance, information technology, engineering, administration, and commercial disciplines. The company, through its subsidiaries, offers temporary contractors; and permanent placement services. The company was formerly known as Golden Fork Corporation and changed its name to Staffing 360 Solutions, Inc. in April 2012. Staffing 360 Solutions, Inc. was founded in 2009 and is headquartered in New York, New York.", "industry_name": "Professional Services", "sector_name": "Industrials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 4487636, "total_enterprise": 64600636, "number_of_employees": 270, "outstanding_shares": 8680148, "eps": -0.823292, "diluted_eps": -0.823292, "earnings_from_cont_operations": -3756000, "gross_profit": 49040000, "cash": 1797000, "total_debt": 61897000, "total_revenue": 288735000, "cash_from_operations": -12179000, "net_income": -3756000, "ebitda": 6364000, "year_low_stock_price": 0.28, "year_high_stock_price": 1.83, "image_position": [24329, 0, 128, 128]}, {"symbol": "RAIL", "name": "FreightCar America, Inc.", "next_earnings_utc": 1589191200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 28500000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.74, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 2, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "freightcaramerica.com", "year_founded": 1901, "street_address": "125 South Wacker Drive", "city": "Chicago", "state": "IL", "zipcode": "60606", "country": "United States", "phone_number": "312 928 0850", "short_description": "FreightCar America, Inc., through its subsidiaries, designs, manufactures, and sells railcars and railcar components for the transportation of bulk commodities and containerized freight products primarily in North America.", "long_description": "FreightCar America, Inc., through its subsidiaries, designs, manufactures, and sells railcars and railcar components for the transportation of bulk commodities and containerized freight products primarily in North America. It operates through two segments, Manufacturing and Parts. The company offers a range of freight cars, including covered hopper cars; open top hoppers; coil gondolas; triple hoppers and hybrid aluminum/stainless steel railcars; ore hopper and gondola railcars; ballast hopper cars; aggregate hopper cars; intermodal flat cars; and non-intermodal flat cars. It also provides coal cars, bulk commodity cars, coil steel cars, and boxcars; and woodchip hoppers, aluminum vehicle carriers, intermodal doublestack railcars, and articulated bulk container railcars. In addition, the company sells used railcars; leases and rebuilds railcars; and sells forged, cast, and fabricated parts for various railcars. It also exports its manufactured railcars to Latin America and the Middle East. The company's customers primarily include railroads, shippers, and financial institutions. FreightCar America, Inc. was founded in 1901 and is headquartered in Chicago, Illinois.", "industry_name": "Machinery", "sector_name": "Industrials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 17643217, "total_enterprise": 30257217, "number_of_employees": 496, "outstanding_shares": 13166580, "eps": -6.086636, "diluted_eps": -6.086636, "earnings_from_cont_operations": -75238000, "gross_profit": -14300000, "cash": 66257000, "total_debt": 78926000, "total_revenue": 229958000, "cash_from_operations": -18979000, "net_income": -75183000, "ebitda": -40166000, "year_low_stock_price": 0.73, "year_high_stock_price": 6.56, "image_position": [24457, 0, 128, 128]}, {"symbol": "SGMS", "name": "Scientific Games Corporation", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 454843730.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.79, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 3, "total_analysts": 11, "analysts_sell": 0, "analysts_buy": 4, "analysts_outperform": 0, "analysts_hold": 6, "analysts_underperform": 1, "webpage": "scientificgames.com", "year_founded": 1984, "street_address": "6601 Bermuda Road", "city": "Las Vegas", "state": "NV", "zipcode": "89119", "country": "United States", "phone_number": "702 897 7150", "short_description": "Scientific Games Corporation develops technology-based products and services, and related content for the gaming, lottery, social and digital gaming industries in the United States and internationally.", "long_description": "Scientific Games Corporation develops technology-based products and services, and related content for the gaming, lottery, social and digital gaming industries in the United States and internationally. The company's Gaming segment sells new and used gaming machines, electronic table systems, video lottery terminals, conversion game kits, and spare parts; slot, casino, and table-management systems; table products, including shufflers; and perpetual licenses to proprietary table games. It also leases gaming machines; provides gaming operations and licensing arrangements; and installs and supports casino management systems, such as ongoing hardware and software maintenance and upgrade services of customer casino management systems. The company's Lottery segment designs, prints, and sells instant lottery products; designs and manufactures instant games tickets; offers instant products planning, monitoring, management system, warehousing, inventory management, distribution, marketing, and game support functions; supplies player loyalty programs, merchandising services, and interactive marketing campaigns; and sublicenses brands for lottery products and lottery-related promotional products. It also provides software, hardware, and related services for lottery operations; and lottery systems software maintenance and support services. The company's SciPlay segment sells virtual coins, chips, or bingo cards; and third-party branded games and original content through mobile and web platforms. Its Digital segment provides digital gaming and sports wagering solutions and services, including digital RMG and sports wagering solutions, distribution platforms, content, products, and services; software design, development, licensing, maintenance, and support services; Open Platform Systems; and content aggregation platforms. The company was founded in 1984 and is headquartered in Las Vegas, Nevada.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 1242235474, "total_enterprise": 9888235474, "number_of_employees": 9800, "outstanding_shares": 94466576, "eps": -1.397849, "diluted_eps": -1.4, "earnings_from_cont_operations": -118000000, "gross_profit": 2116000000, "cash": 313000000, "total_debt": 8855000000, "total_revenue": 3400000000, "cash_from_operations": 546000000, "net_income": -130000000, "ebitda": 1097000000, "year_low_stock_price": 3.76, "year_high_stock_price": 31.63, "image_position": [24585, 0, 128, 61]}, {"symbol": "MSGS", "name": "Madison Square Garden Sports Corp.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q3", "next_earnings_year": 2020, "next_earnings_quarter": 3, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 470406970.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": 0.39736, "eps_up_revisions": null, "eps_down_revisions": null, "revenue_up_revisions": null, "revenue_down_revisions": null, "total_analysts": 10, "analysts_sell": 0, "analysts_buy": 8, "analysts_outperform": 0, "analysts_hold": 2, "analysts_underperform": 0, "webpage": "msgsports.com", "year_founded": null, "street_address": null, "city": null, "state": null, "zipcode": null, "country": null, "phone_number": null, "short_description": null, "long_description": null, "industry_name": null, "sector_name": null, "is_defunct": false, "exchange": "Pending", "equity_type": "stocks", "market_cap": 4141755234, "total_enterprise": 3392352234, "number_of_employees": null, "outstanding_shares": null, "eps": null, "diluted_eps": null, "earnings_from_cont_operations": null, "gross_profit": null, "cash": null, "total_debt": 277136000, "total_revenue": 1624333000, "cash_from_operations": 243906000, "net_income": -23800000, "ebitda": 62988000, "year_low_stock_price": null, "year_high_stock_price": null, "image_position": [24713, 0, 128, 128]}, {"symbol": "EZPW", "name": "EZCORP, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 226336670.0, "next_earnings_eps_num_analysts": 3, "next_earnings_eps_consensus": 0.16667, "eps_up_revisions": 0, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "ezcorp.com", "year_founded": 1989, "street_address": "Building One", "city": "Austin", "state": "TX", "zipcode": "78746", "country": "United States", "phone_number": "512-314-3400", "short_description": "EZCORP, Inc. provides pawn loans.", "long_description": "EZCORP, Inc. provides pawn loans. It operates through three segments: U.S. Pawn, Latin America Pawn, and Other International. The company offers pawn loans, which are non-recourse loans collateralized by tangible personal property, including jewelry, consumer electronics, power tools, sporting goods, and musical instruments; and sells merchandise, such as collateral forfeited from pawn lending operations and used merchandise purchased from customers. It also provides payday and installment loan products through its financial services stores. As of September 30, 2019, the company owned and operated 512 pawn stores in the United States; 357 pawn stores in Latin America; 123 pawn stores in Guatemala, El Salvador, Honduras, and Peru; and 22 financial services stores in Canada. EZCORP, Inc. was founded in 1989 and is headquartered in Austin, Texas.", "industry_name": "Consumer Finance", "sector_name": "Financials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 307029901, "total_enterprise": 639716901, "number_of_employees": 6800, "outstanding_shares": 55621359, "eps": 0.128739, "diluted_eps": 0.123136, "earnings_from_cont_operations": 6693000, "gross_profit": 494468000, "cash": 143141000, "total_debt": 475828000, "total_revenue": 853969000, "cash_from_operations": 69218000, "net_income": 7145000, "ebitda": 76129000, "year_low_stock_price": 3.41, "year_high_stock_price": 10.23, "image_position": [24841, 0, 128, 128]}, {"symbol": "KLR", "name": "Kaleyra, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 3, "next_earnings_revenue_consensus": 36207000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": 0.01, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 3, "analysts_outperform": 0, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "kaleyra.com", "year_founded": 1999, "street_address": "Via Marco D\u00e2\u20ac\u2122Aviano, 2", "city": "Milan", "state": "MI", "zipcode": "20131", "country": "Italy", "phone_number": "39 022 885841", "short_description": "Kaleyra, Inc. provides mobile communication services to financial institutions and enterprises of various sizes worldwide.", "long_description": "Kaleyra, Inc. provides mobile communication services to financial institutions and enterprises of various sizes worldwide. It manages multi-channel integrated communication services that includes messages, push notifications, e-mail, instant messaging, voice services, and chatbots. The company was formerly known as GigCapital, Inc. and changed its name to Kaleyra, Inc. in November 2019. Kaleyra, Inc. was founded in 1999 and is headquartered in Milan, Italy.", "industry_name": "Software", "sector_name": "Information Technology", "is_defunct": false, "exchange": "NYSEMKT", "equity_type": "stocks", "market_cap": 143017630, "total_enterprise": 170473630, "number_of_employees": 267, "outstanding_shares": 22173276, "eps": -0.475033, "diluted_eps": -0.475033, "earnings_from_cont_operations": -5512000, "gross_profit": 26353000, "cash": 21227000, "total_debt": 48683000, "total_revenue": 129558000, "cash_from_operations": 6453000, "net_income": -5512000, "ebitda": 7574000, "year_low_stock_price": 5.88, "year_high_stock_price": 7.35, "image_position": [24969, 0, 128, 128]}, {"symbol": "ASRT", "name": "Assertio Therapeutics, Inc.", "next_earnings_utc": 1589198400, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 1, "next_earnings_revenue_consensus": 11297000.0, "next_earnings_eps_num_analysts": 1, "next_earnings_eps_consensus": -0.08, "eps_up_revisions": 0, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 1, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "assertiotx.com", "year_founded": 1995, "street_address": "100 South Saunders Road", "city": "Lake Forest", "state": "IL", "zipcode": "60045", "country": "United States", "phone_number": "224-419-7106", "short_description": "Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States.", "long_description": "Assertio Therapeutics, Inc., a specialty pharmaceutical company, provides medicines in neurology, orphan, and specialty areas in the United States. The company offers Gralise (gabapentin), a once daily product for the management of postherpetic neuralgia; CAMBIA (diclofenac potassium for oral solution), a non-steroidal anti-inflammatory drug for the acute treatment of migraine attacks; and Zipsor (diclofenac potassium liquid filled capsules), a non-steroidal anti-inflammatory drug for treating mild to moderate acute pain. It also provides NUCYNTA ER (tapentadol extended release tablet), a product for the management of pain severe enough to require daily, around-the-clock, and long term opioid treatment, including neuropathic pain related to diabetic peripheral neuropathy in adults; and NUCYNTA IR (tapentadol), a product for the management of moderate to severe acute pain in adults. In addition, the company offers long-acting cosyntropin, an alcohol-free formulation of synthetic adrenocorticotropic hormone. Assertio Therapeutics, Inc. has a collaboration and license agreement with Ironwood Pharmaceuticals, Inc. The company was formerly known as Depomed Inc. and changed its name to Assertio Therapeutics, Inc. in August 2018. Assertio Therapeutics, Inc. was founded in 1995 and is headquartered in Lake Forest, Illinois.", "industry_name": "Pharmaceuticals", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 64899719, "total_enterprise": 380964719, "number_of_employees": 125, "outstanding_shares": 81297406, "eps": -3.071454, "diluted_eps": -3.071454, "earnings_from_cont_operations": -217201000, "gross_profit": 220021000, "cash": 42107000, "total_debt": 358172000, "total_revenue": 229526000, "cash_from_operations": 90475000, "net_income": -217201000, "ebitda": 99220000, "year_low_stock_price": 0.55, "year_high_stock_price": 4.92, "image_position": [25097, 0, 128, 128]}, {"symbol": "MESA", "name": "Mesa Air Group, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 6, "next_earnings_revenue_consensus": 170026080.0, "next_earnings_eps_num_analysts": 5, "next_earnings_eps_consensus": -0.00677, "eps_up_revisions": 0, "eps_down_revisions": 5, "revenue_up_revisions": 0, "revenue_down_revisions": 5, "total_analysts": 6, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 3, "analysts_underperform": 1, "webpage": "mesa-air.com", "year_founded": 1982, "street_address": "410 North 44th Street", "city": "Phoenix", "state": "AZ", "zipcode": "85008", "country": "United States", "phone_number": "602-685-4000", "short_description": "Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc., which provides regional air carrier services under capacity purchase agreements with the American Airlines and the United Airlines.", "long_description": "Mesa Air Group, Inc. operates as the holding company for Mesa Airlines, Inc., which provides regional air carrier services under capacity purchase agreements with the American Airlines and the United Airlines. As of December 31, 2019, it operated a fleet of 145 aircraft with approximately 742 daily departures to 144 cities in the United States, Canada, Mexico, Cuba, and the Bahamas. The company was founded in 1982 and is headquartered in Phoenix, Arizona.", "industry_name": "Airlines", "sector_name": "Industrials", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 132486895, "total_enterprise": 1015495895, "number_of_employees": 3576, "outstanding_shares": 33039126, "eps": 1.125938, "diluted_eps": 1.125938, "earnings_from_cont_operations": 39284000, "gross_profit": 249998000, "cash": 57763000, "total_debt": 940772000, "total_revenue": 729237000, "cash_from_operations": 145761000, "net_income": 39284000, "ebitda": 194498000, "year_low_stock_price": 2.05, "year_high_stock_price": 11.08, "image_position": [25225, 0, 128, 128]}, {"symbol": "MRKR", "name": "Marker Therapeutics, Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 5, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 4, "next_earnings_eps_consensus": -0.1075, "eps_up_revisions": 1, "eps_down_revisions": 1, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 5, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 3, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "markertherapeutics.com", "year_founded": null, "street_address": "Phoenix Tower", "city": "Houston", "state": "TX", "zipcode": "77027", "country": "United States", "phone_number": "713-400-6400", "short_description": "Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications.", "long_description": "Marker Therapeutics, Inc., a clinical stage immuno-oncology company, engages in the development and commercialization of various T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. Its MultiTAA T cell technology is based on the expansion of non-engineered tumor-specific T cells that recognize tumor associated antigens and kill tumor cells expressing those targets. The company\u00e2\u20ac\u2122s MultiTAA T cell therapies include autologous T cells for the treatment of lymphoma, multiple myeloma, and various solid tumors; and allogeneic T cells for the treatment of acute myeloid leukemia and acute lymphoblastic leukemia. It is also developing TPIV100/110, which is in Phase II clinical trial to treat breast cancer; and TPIV200 that is in Phase II clinical trial for the treatment of breast and ovarian cancers. In addition, the company is developing PolyStart, a proprietary nucleic acid-based antigen expression technology to enhance the ability of the immune system to recognize and destroy diseased cells. Marker Therapeutics, Inc. is headquartered in Houston, Texas.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 111910715, "total_enterprise": 68491145, "number_of_employees": 28, "outstanding_shares": 46532522, "eps": -0.470037, "diluted_eps": -0.470037, "earnings_from_cont_operations": -21427964, "gross_profit": -12551610, "cash": 43903949, "total_debt": 484379, "total_revenue": 213194, "cash_from_operations": -18284293, "net_income": -21427964, "ebitda": -22423683, "year_low_stock_price": 1.33, "year_high_stock_price": 9.17, "image_position": [25353, 0, 128, 128]}, {"symbol": "STKS", "name": "The ONE Group Hospitality, Inc.", "next_earnings_utc": 1589169600, "next_earnings_has_time": true, "next_earnings_name": "2020 Q2", "next_earnings_year": 2020, "next_earnings_quarter": 2, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 16792000.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.16, "eps_up_revisions": 0, "eps_down_revisions": 2, "revenue_up_revisions": 0, "revenue_down_revisions": 2, "total_analysts": 3, "analysts_sell": 0, "analysts_buy": 2, "analysts_outperform": 0, "analysts_hold": 1, "analysts_underperform": 0, "webpage": "togrp.com", "year_founded": 2004, "street_address": "1624 Market Street", "city": "Denver", "state": "CO", "zipcode": "80202", "country": "United States", "phone_number": "646 624 2400", "short_description": "The ONE Group Hospitality, Inc., a hospitality company, develops, owns, and operates restaurants and lounges worldwide.", "long_description": "The ONE Group Hospitality, Inc., a hospitality company, develops, owns, and operates restaurants and lounges worldwide. It operates through STK, Kona Grill, and ONE Hospitality segments. The company also provides turn-key food and beverage services for hospitality venues, including hotels, casinos, and other locations. Its hospitality food and beverage solutions include developing, managing, and operating restaurants, bars, rooftops, pools, banqueting, catering, private dining rooms, room service, and mini bars. The company operates restaurants primarily under the STK and Kona Grill brands. As of December 31, 2019, the Company owned, operated, managed, or licensed 55 venues, including 20 STKs and 24 Kona Grills in North America, Europe, and the Middle East. The company was founded in 2004 and is headquartered in Denver, Colorado.", "industry_name": "Hotels, Restaurants and Leisure", "sector_name": "Consumer Discretionary", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 44725992, "total_enterprise": 180629992, "number_of_employees": 3400, "outstanding_shares": 29042852, "eps": 0.732084, "diluted_eps": 0.699999, "earnings_from_cont_operations": 21133000, "gross_profit": 24793000, "cash": 12344000, "total_debt": 148650000, "total_revenue": 120681000, "cash_from_operations": 8360000, "net_income": 20831000, "ebitda": 13202000, "year_low_stock_price": 0.73, "year_high_stock_price": 4.68, "image_position": [25481, 0, 128, 128]}, {"symbol": "DFFN", "name": "Diffusion Pharmaceuticals Inc.", "next_earnings_utc": 1589227200, "next_earnings_has_time": true, "next_earnings_name": "2020 Q1", "next_earnings_year": 2020, "next_earnings_quarter": 1, "next_earnings_revenue_num_analysts": 2, "next_earnings_revenue_consensus": 0.0, "next_earnings_eps_num_analysts": 2, "next_earnings_eps_consensus": -0.085, "eps_up_revisions": 1, "eps_down_revisions": 0, "revenue_up_revisions": 0, "revenue_down_revisions": 0, "total_analysts": 1, "analysts_sell": 0, "analysts_buy": 0, "analysts_outperform": 1, "analysts_hold": 0, "analysts_underperform": 0, "webpage": "diffusionpharma.com", "year_founded": 2001, "street_address": "1317 Carlton Avenue", "city": "Charlottesville", "state": "VA", "zipcode": "22902", "country": "United States", "phone_number": "434 220 0718", "short_description": "Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions.", "long_description": "Diffusion Pharmaceuticals Inc., a clinical stage biotechnology company, develops treatments for life-threatening medical conditions. Its lead product candidate is transcrocetinate sodium, which is in Phase III trials for the treatment of glioblastoma multiforme (GBM); Phase II clinical trials for the treatment of metastatic brain cancer; and Phase II trial for the treatment of acute stroke. The company is also developing RES-529, a PI3K/Akt/mTOR pathway inhibitor, which has completed two Phase I clinical trials for the treatment of age-related macular degeneration; and is in pre-clinical development stage for the treatment of oncology primarily GBM. Diffusion Pharmaceuticals Inc. has a cooperative research agreement with the University of Virginia Health and the Integrated Translational Research Institute of Virginia to evaluate the transcrocetinate sodium in patients with acute respiratory distress syndrome associated with COVID-19 infection. The company was founded in 2001 and is headquartered in Charlottesville, Virginia.", "industry_name": "Biotechnology", "sector_name": "Health Care", "is_defunct": false, "exchange": "NASDAQ", "equity_type": "stocks", "market_cap": 23852006, "total_enterprise": 9921700, "number_of_employees": 10, "outstanding_shares": 39114475, "eps": -1.759392, "diluted_eps": -1.759392, "earnings_from_cont_operations": -11799379, "gross_profit": null, "cash": 14177349, "total_debt": 247043, "total_revenue": null, "cash_from_operations": -9858375, "net_income": -11799379, "ebitda": -11453881, "year_low_stock_price": 0.211, "year_high_stock_price": 5.47, "image_position": [25609, 0, 128, 128]}]}